0001193125-23-277097.txt : 20231114 0001193125-23-277097.hdr.sgml : 20231114 20231114160651 ACCESSION NUMBER: 0001193125-23-277097 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ESGEN Acquisition Corp CENTRAL INDEX KEY: 0001865506 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 981601409 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40927 FILM NUMBER: 231406042 BUSINESS ADDRESS: STREET 1: 5956 SHERRY LANE, SUITE 1400 CITY: DALLAS STATE: TX ZIP: 75225 BUSINESS PHONE: 214-987-6100 MAIL ADDRESS: STREET 1: 5956 SHERRY LANE, SUITE 1400 CITY: DALLAS STATE: TX ZIP: 75225 10-Q 1 d500566d10q.htm 10-Q 10-Q
Table of Contents
false0001865506--12-31Q3false 0001865506 2022-12-31 0001865506 2023-09-30 0001865506 2022-01-01 2022-09-30 0001865506 2023-01-01 2023-09-30 0001865506 2021-10-22 0001865506 2023-07-01 2023-09-30 0001865506 2022-07-01 2022-09-30 0001865506 2022-04-01 2022-06-30 0001865506 2022-01-01 2022-03-31 0001865506 2023-04-01 2023-06-30 0001865506 2023-01-01 2023-03-31 0001865506 2023-01-18 0001865506 2022-01-01 2022-12-31 0001865506 2023-01-18 2023-01-18 0001865506 2021-12-31 0001865506 2022-09-30 0001865506 2022-06-30 0001865506 2022-03-31 0001865506 2023-06-30 0001865506 2023-03-31 0001865506 us-gaap:CommonClassAMember 2023-09-30 0001865506 us-gaap:CommonClassBMember 2023-09-30 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 us-gaap:IPOMember 2023-09-30 0001865506 us-gaap:IPOMember esac:PublicWarrantsMember 2023-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member 2023-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member 2023-09-30 0001865506 esac:WorkingCapitalLoansWarrantMember 2023-09-30 0001865506 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:RelatedPartyMember 2023-09-30 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2023-09-30 0001865506 us-gaap:CommonClassAMember esac:PublicWarrantsMember 2023-09-30 0001865506 us-gaap:RelatedPartyMember 2023-09-30 0001865506 esac:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember 2023-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0001865506 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member esac:PrivatePlacementWarrantsMember 2023-09-30 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PrivatePlacementWarrantsMember 2023-09-30 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 esac:UnsecuredPromissoryNoteMember 2023-09-30 0001865506 us-gaap:CommonClassAMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:CommonClassBMember 2022-12-31 0001865506 esac:WorkingCapitalLoansWarrantMember 2022-12-31 0001865506 us-gaap:RelatedPartyMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-12-31 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2022-12-31 0001865506 esac:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember 2022-12-31 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PrivatePlacementWarrantsMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassBMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001865506 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001865506 esac:SponsorMember us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001865506 us-gaap:CommonClassBMember 2023-01-01 2023-09-30 0001865506 us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001865506 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member 2023-01-01 2023-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member 2023-01-01 2023-09-30 0001865506 us-gaap:PrivatePlacementMember esac:PrivatePlacementWarrantsMember 2023-01-01 2023-09-30 0001865506 esac:SponsorMember 2023-01-01 2023-09-30 0001865506 esac:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember 2023-01-01 2023-09-30 0001865506 esac:UnitsEachConsistingOfOneShareOfClassCommonStockAndOneHalfOfOneWarrantMember 2023-01-01 2023-09-30 0001865506 us-gaap:WarrantMember esac:NewPubcoCommonClassAMember 2023-01-01 2023-09-30 0001865506 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-07-01 2023-09-30 0001865506 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001865506 us-gaap:CommonClassBMember 2023-07-01 2023-09-30 0001865506 us-gaap:CommonClassAMember 2023-07-01 2023-09-30 0001865506 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001865506 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001865506 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-04-01 2022-06-30 0001865506 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-01-01 2022-03-31 0001865506 us-gaap:IPOMember 2021-10-22 2021-10-22 0001865506 esac:PublicWarrantsMember 2021-10-22 0001865506 esac:PrivateWarrantsMember 2021-10-22 0001865506 us-gaap:IPOMember 2021-10-22 0001865506 us-gaap:IPOMember esac:PrivatePlacementWarrantsMember 2021-10-22 0001865506 us-gaap:OverAllotmentOptionMember 2021-10-22 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2021-04-27 0001865506 us-gaap:RelatedPartyMember 2021-04-27 0001865506 esac:RestatedNoteMember 2023-04-05 0001865506 esac:UnsecuredPromissoryNoteMember 2023-04-05 0001865506 esac:NewPubcoCommonClassAMember 2023-04-19 0001865506 esac:EsgenCommonClassAMember esac:BusinessCombinationAgreementMember 2023-04-19 0001865506 esac:NewPubcoCommonClassAMember us-gaap:WarrantMember 2023-04-19 0001865506 esac:BusinessCombinationAgreementMember 2023-04-19 0001865506 esac:SponsorMember us-gaap:CommonClassAMember esac:InitialSubscriptionAgreementMember 2023-04-19 0001865506 esac:NewPubcoCommonClassAMember 2023-04-19 2023-04-19 0001865506 us-gaap:WarrantMember esac:NewPubcoCommonClassAMember 2023-04-19 2023-04-19 0001865506 esac:BusinessCombinationAgreementMember 2023-04-19 2023-04-19 0001865506 esac:SponsorMember us-gaap:CommonClassAMember esac:InitialSubscriptionAgreementMember 2023-04-19 2023-04-19 0001865506 us-gaap:SubsequentEventMember 2023-10-20 0001865506 us-gaap:SubsequentEventMember us-gaap:CommonClassBMember 2023-10-20 0001865506 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember 2023-10-20 0001865506 esac:EsgenCommonClassAMember esac:WarrantAgreementMember us-gaap:SubsequentEventMember 2023-10-20 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:SubsequentEventMember us-gaap:IPOMember 2023-10-20 0001865506 us-gaap:SubsequentEventMember esac:RestatedNoteMember 2023-10-17 0001865506 us-gaap:SubsequentEventMember esac:UnsecuredPromissoryNoteMember esac:SponsorMember srt:RestatementAdjustmentMember 2023-10-17 0001865506 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2023-10-20 2023-10-20 0001865506 us-gaap:SubsequentEventMember 2023-10-20 2023-10-20 0001865506 us-gaap:SubsequentEventMember us-gaap:CommonClassBMember 2023-10-20 2023-10-20 0001865506 us-gaap:CommonClassAMember 2023-01-18 2023-01-18 0001865506 us-gaap:CommonClassAMember 2023-11-14 0001865506 us-gaap:CommonClassBMember 2023-11-14 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-09-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2023-09-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-09-30 0001865506 us-gaap:RetainedEarningsMember 2023-06-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-06-30 0001865506 us-gaap:RetainedEarningsMember 2022-12-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-12-31 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-12-31 0001865506 us-gaap:RetainedEarningsMember 2023-03-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-03-31 0001865506 us-gaap:RetainedEarningsMember 2022-06-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-06-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001865506 us-gaap:RetainedEarningsMember 2021-12-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001865506 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-12-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001865506 us-gaap:RetainedEarningsMember 2022-03-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 iso4217:USD xbrli:shares xbrli:pure utr:Day utr:Year utr:Month iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 10-Q
 
 
Quarterly Report
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended September 30, 2023
 
 
ESGEN Acquisition Corporation
(Exact name of registrant as specified in its charter)
 
 
 
Cayman Islands
  
001-40927
  
98-1601409
(State or other jurisdiction of
incorporation or organization)
  
(Commission
File Number)
  
(I.R.S. Employer
Identification Number)
5956 Sherry Lane
Suite 1400
Dallas, Texas 75225
(Address of principal executive offices, including zip code)
(214)987-6100
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Units, each consisting of one Class A ordinary share, $0.0001 par value, and
one-half
of one redeemable warrant
  
ESACU
  
The Nasdaq Stock Market LLC
Class A ordinary shares included as part of the units
  
ESAC
  
The Nasdaq Stock Market LLC
Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
  
ESACW
  
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer   ☐    Accelerated filer   ☐
Non-accelerated
filer		   ☒    Smaller reporting company   ☒
     Emerging growth company   ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):    Yes  ☒    No  ☐
As of November
1
4
, 2023, 7,027,632 Class A ordinary shares, par value $0.0001, and 1,280,923 Class B ordinary shares, par value $0.0001, were issued and outstanding.
 
 
 

Table of Contents

ESGEN ACQUISITION CORPORATION

FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2023

TABLE OF CONTENTS

 

     Page  

PART 1 – FINANCIAL INFORMATION

   

Item 1. Financial Statements (Unaudited)

      1  

Condensed Balance Sheets as of September 30, 2023 and December 31, 2022

      1  

Condensed Statements of Operations for the three and nine months ended September 30, 2023 and 2022

      2  

Condensed Statements of Changes in Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit for the three and nine months ended September 30, 2023 and 2022

      3  

Condensed Statements of Cash Flows for the nine months ended September 30, 2023 and 2022

      4  

Notes to Condensed Financial Statements

      5  

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

      21  

Item 3. Quantitative and Qualitative Disclosures about Market Risk

      26  

Item 4. Control and Procedures

      27  

PART II – OTHER INFORMATION

      27  

Item 1. Legal Proceedings

      27  

Item 1A. Risk Factors

      27  

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

      28  

Item 3. Defaults Upon Senior Securities

      28  

Item 4. Mine Safety Disclosures

      28  

Item 5. Other Information

      28  

Item 6. Exhibits

      29  

SIGNATURES

      30  

i

 

Table of Contents
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
ESGEN ACQUISITION CORPORATION
CONDENSED BALANCE SHEETS
(UNAUDITED)
 
    
September 30,
2023
    
December 31, 2022
  
Assets
     
Current assets:
     
Cash
    $ 267,058     $ 614,767  
Prepaid expenses
      4,261       31,110  
  
 
 
    
 
 
  
Total current assets
      271,319       645,877  
Non-current
assets:
     
Marketable securities held in Trust Account
      32,393,380       285,506,568  
  
 
 
    
 
 
  
Total assets
    $ 32,664,699     $ 286,152,445  
  
 
 
    
 
 
  
Liabilities, Redeemable Ordinary Shares and Shareholders’ Deficit
     
Current liabilities:
     
Accounts payable and accrued expenses
    $ 5,296,038     $ 1,866,992  
Due to related party
      309,193       144,193  
Promissory note—related party
      1,409,795       171,346  
  
 
 
    
 
 
  
Total current liabilities
      7,015,026       2,182,531  
Non-current
liabilities:
     
Warrant liabilities
      1,002,240       796,224  
Deferred underwriters fee
      —         9,660,000  
  
 
 
    
 
 
  
Total liabilities
    $ 8,017,266     $ 12,638,755  
  
 
 
    
 
 
  
Commitments and Contingencies
     
Class A ordinary shares subject to possible redemption, $0.0001 par value; 2,896,555 and 27,600,000 shares at redemption value as of September 30, 2023 and December 31, 2022, respectively
      32,393,380       285,506,568  
Shareholders’ Deficit:
     
Preferred shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding
   
 
—  
 
  
 
—  
 
Class A shares, $0.0001 par value; 250,000,000 shares authorized; none issued or outstanding (excluding 2,896,555 and 27,600,000 shares subject to possible redemption) as of September 30, 2023 and December 31, 2022, respectively
   
 
—  
 
  
 
—  
 
Class B shares, $0.0001 par value; 25,000,000 shares authorized; 6,900,000 shares issued and outstanding
      690       690  
Accumulated deficit
      (7,746,637 )      (11,993,568 ) 
  
 
 
    
 
 
  
Total shareholders’ deficit
      (7,745,947 )      (11,992,878 ) 
  
 
 
    
 
 
  
Total Liabilities, Redeemable Ordinary Shares and Shareholders’ Deficit
    $ 32,664,699     $ 286,152,445  
  
 
 
    
 
 
  
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
1
ESGEN ACQUISITION CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
    
For the Three Months Ended

September 30,
    
For the Nine Months Ended

September 30,
  
    
2023
    
2022
    
2023
    
2022
  
Legal and professional fees
    $ 707,780     $ 145,588     $ 3,752,583     $ 937,110  
Insurance
      2,913       133,302       25,479       395,559  
Other operating costs
      88,307       20,385       296,231       181,339  
Operating cost—related party
      30,000       30,000       90,000       90,000  
  
 
 
    
 
 
    
 
 
    
 
 
  
Loss from operations
      (829,000 )      (329,275 )      (4,164,293 )      (1,604,008 ) 
Other income (expense):
         
Dividends earned on marketable securities held in Trust Account
      413,940       1,245,745       1,719,810       1,632,690  
Recovery of offering costs related to the IPO allocated to warrants
      —         —         425,040       —    
Change in fair value of warrant liabilities
      1,046,784       3,345,600       (206,016 )      11,608,560  
  
 
 
    
 
 
    
 
 
    
 
 
  
Total other income, net
      1,460,724       4,591,345       1,938,834       13,241,250  
  
 
 
    
 
 
    
 
 
    
 
 
  
Net income (loss)
    $ 631,724     $ 4,262,070     $ (2,225,459 )    $ 11,637,242  
  
 
 
    
 
 
    
 
 
    
 
 
  
Basic and diluted weighted average shares outstanding of Class A ordinary shares
      2,896,555       27,600,000       4,615,842       27,600,000  
  
 
 
    
 
 
    
 
 
    
 
 
  
Basic and diluted net income (loss) per share, Class A
    $ 0.25     $ 0.13     $ (1.03 )    $ 0.35  
  
 
 
    
 
 
    
 
 
    
 
 
  
Basic and diluted weighted average shares outstanding of Class B ordinary shares
      6,900,000       6,900,000       6,900,000       6,900,000  
  
 
 
    
 
 
    
 
 
    
 
 
  
Basic and diluted net income (loss) per share, Class B
    $ (0.01 )    $ 0.09     $ 0.37     $ 0.29  
  
 
 
    
 
 
    
 
 
    
 
 
  
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
2
ESGEN ACQUISITION CORPORATION
CONDENSED STATEMENTS OF CHANGES IN ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT
(UNAUDITED)
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023
 
    
Class A

ordinary shares subject to

possible redemption
           
Class B

ordinary shares
     
Additional

Paid-in

Capital
     
Accumulated

Deficit
    
Total

Shareholders’

Deficit
  
    
Shares
           
Amount
           
Shares
     
Amount
                      
Balance as of December 31, 2022
      27,600,000        $ 285,506,568          6,900,000      $ 690      $ —      $ (11,993,568 )    $ (11,992,878 ) 
Accretion of ordinary shares subject to possible redemption
      —            1,288,233          —          —          —          (1,288,233 )      (1,288,233 ) 
Redemption of Class A ordinary shares subject to possible redemption
      (24,703,445 )         (255,875,758 )         —          —          —          —         —    
Net loss
      —            —            —          —          —          (1,446,111 )      (1,446,111 ) 
  
 
 
       
 
 
       
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
Balance as of March 31, 2023
      2,896,555          30,919,043          6,900,000        690        —          (14,727,912 )      (14,727,222 ) 
Accretion of ordinary shares subject to possible redemption
      —            712,810          —          —          —          (712,810 )     (712,810 ) 
Waiver of deferred underwriters fee
      —            —            —          —          —          9,234,960     9,234,960  
Net loss
      —            —            —          —          —          (1,411,072 )      (1,411,072 ) 
  
 
 
       
 
 
       
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
Balance as of June 30, 2023
      2,896,555          31,631,853          6,900,000        690        —          (7,616,834 )      (7,616,144 ) 
Accretion of ordinary shares subject to possible redemption
      —            761,527          —          —          —          (761,527 )      (761,527 ) 
Net income
      —            —            —          —          —          631,724       631,724  
  
 
 
       
 
 
       
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
Balance as of September 30, 2023
      2,896,555        $ 32,393,380          6,900,000      $ 690      $ —      $ (7,746,637 )    $ (7,745,947 ) 
  
 
 
       
 
 
       
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022
 
    
Class A

ordinary shares subject to

possible redemption
     
Class B

ordinary shares
     
Additional

Paid-in

Capital
     
Accumulated

Deficit
    
Total

Shareholders’

Deficit
  
    
Shares
     
Amount
     
Shares
     
Amount
                      
Balance as of December 31, 2021
      27,600,000      $ 281,520,000        6,900,000      $ 690      $ —      $ (22,341,250 )    $ (22,340,560 ) 
Accretion of ordinary shares subject to possible redemption
      —          20,308        —          —          —          (20,308 )      (20,308 ) 
Net income
      —          —          —          —          —          5,880,541       5,880,541  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
Balance as of March 31, 2022
      27,600,000        281,540,308        6,900,000        690      $ —        (16,481,017 )      (16,480,327 ) 
Accretion of ordinary shares subject to possible redemption
      —          368,774        —          —          —          (368,774 )      (368,774 ) 
Net income
      —          —          —          —          —          1,494,631       1,494,631  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
Balance as of June 30, 2022
      27,600,000        281,909,082        6,900,000        690        —          (15,355,160 )      (15,354,470 ) 
Accretion of ordinary shares subject to possible redemption
      —          1,245,745        —          —          —          (1,245,745 )      (1,245,745 ) 
Net income
      —          —          —          —          —          4,262,070       4,262,070  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
Balance as of September 30, 2022
      27,600,000      $ 283,154,827        6,900,000      $ 690      $ —      $ (12,338,835 )    $ (12,338,145 ) 
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
3
ESGEN ACQUISITION CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 
    
For the Nine Months Ended

September 30,
  
    
2023
    
2022
  
Cash flows from operating activities:
     
Net (loss) income
    $ (2,225,459 )    $ 11,637,242  
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
     
Dividends earned on marketable securities held in Trust Account
      —         (1,632,690 ) 
Recovery of offering costs related to the IPO allocated to warrants
      (425,040 )      —    
Change in fair value of warrant liabilities
      206,016       (11,608,560 ) 
Changes in current assets and liabilities:
     
Prepaid expenses
      26,849       402,258  
Accounts payable and accrued expenses
      3,429,046       678,120  
Due to related party
      165,000       90,000  
  
 
 
    
 
 
  
Net cash provided by (used in) operating activities
      1,176,412       (433,630 ) 
  
 
 
    
 
 
  
Cash flows from investing activities:
     
Reinvestment of marketable securities held in Trust Account
      (1,719,810 )      —    
Extension funding of Trust Account
      (1,042,760 )      —    
Cash withdrawn from Trust Account in connection with redemption
      255,875,758       —    
  
 
 
    
 
 
  
Net cash provided by investing activities
      253,113,188       —    
  
 
 
    
 
 
  
Cash flows from financing activities:
     
Redemption of Class A ordinary shares subject to possible redemption
      (255,875,758 )      —    
Proceeds from note payable-related party
      1,238,449       —    
  
 
 
    
 
 
  
Net cash used in financing activities
      (254,637,309 )      —    
  
 
 
    
 
 
  
Net change in cash
      (347,709 )      (433,630 ) 
Cash, beginning of the period
      614,767       1,323,903  
  
 
 
    
 
 
  
Cash, end of the period
    $ 267,058     $ 890,273  
  
 
 
    
 
 
  
Supplemental disclosure of cash flow information:
     
Change in value of Class A ordinary shares subject to possible redemption
    $ 2,762,570     $ 1,634,827  
Impact of the waiver of deferred underwriters fee
    $ 9,234,960     $ —    
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
4
ESGEN ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Note 1 — Organization and Business Operation
ESGEN Acquisition Corporation (the “Company”) was incorporated as a Cayman Islands exempted company on April 19, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company.
As of September 30, 2023, the Company had not commenced any operations. All activity for the period from April 19, 2021 (inception) through September 30, 2023, relates to the Company’s formation and the initial public offering (“Public Offering” or “IPO”) described below and since the closing of the IPO, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate
non-operating
income in the form of interest or dividend income on cash and cash equivalents from the proceeds derived from the Public Offering (as defined below).
The Company’s sponsor is ESGEN LLC, a Delaware limited liability company (the “Sponsor”).
The registration statement for the Company’s IPO was declared effective on October 19, 2021. On October 22, 2021, the Company consummated its IPO of 27,600,000 units (the “Units” and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”) at $10.00 per Unit and the sale of 14,040,000 warrants (the “Private Placement Warrants”) each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor that closed simultaneously with the Public Offering.
The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred
underwriters fee
 
and taxes payable on the interest or dividends earned on the Trust Account) at the time of signing a definitive agreement in connection with the initial Business Combination. However, the Company will complete the initial Business Combination only if the post-Business Combination company in which its public shareholders own shares will own or acquire 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act (the “Investment Company Act”). There is no assurance that the Company will be able to complete a Business Combination successfully.
Following the closing of the IPO on October 22, 2021, $281,520,000 ($10.20 per Unit) from the net proceeds sold in the IPO, including proceeds of the sale of the Private Placement Warrants, was deposited in a trust account (“Trust Account”) and, until October 16, 2023, was only invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. To mitigate the risk of being deemed to have been operating as an unregistered investment company under the Investment Company Act, on October 16, 2023, the Company instructed the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in demand deposits (i.e., in one or more bank accounts) until the earliest of ESGEN’s completion of an initial business combination or J
anuary 22, 2024 (unless extended as described below), as applicable.
Except with respect to interest or other income earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the amended and restated memorandum and articles of association, as discussed below and subject to the requirements of law and regulation, will provide that the proceeds from the Public Offering and the sale of the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the public shareholders, until the earliest of (a) the completion of the initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, subject to the limitations described herein, (b) the redemption of any public shares properly
 
5
tendered in connection with a shareholder vote to amend the amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company did not complete its initial Business Combination within 15 months (which was extended pursuant to shareholder approval of the Charter Amendment (as defined below)) from the closing of this offering (the “Combination Period”) or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares, and (c) the redemption of the public shares if the Company has not consummated the Business Combination within Combination Period, subject to applicable law. Public shareholders who redeem their Class A ordinary shares in connection with a shareholder vote described in clause (b) in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within Combination Period, with respect to such Class A ordinary shares so redeemed.
The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek shareholder approval under applicable law or stock exchange listing requirement.
The Company will provide its public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of its initial Business Combination at a
per-share
price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest or dividends earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then-outstanding public shares, subject to the limitations described herein. The amount in the Trust Account is initially $10.20 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred
underwriters fee
 
the Company will pay to the underwriters.
The ordinary shares subject to redemption were recorded at redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.
The Company has until
January 22, 2024 (unless extended as described below),
as
 described in Note 10, to consummate the initial Business Combination. If the Company has not consummated the initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at
a per-share
price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest or dividends earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest or dividends to pay winding up and dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
 
6
On January 18, 2023, the Company held an extraordinary general meeting of shareholders to consider and vote upon, among other things, a proposal to amend the Company’s amended and restated memorandum and articles of association (the “First Extension Charter Amendment”) to (i) extend the date by which the Company must consummate its initial Business Combination (the “Termination Date”) from January 22, 2023 to April 22, 2023 and (ii) in the event that the Company has not consummated an initial business combination by April 22, 2023, to allow the Company, by resolution of the Company’s board of directors (the “Board”) and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to each Additional Extension, to extend the Termination Date up to six times (with each such extension being upon five days’ advance notice), each by one additional month (for a total of up to six additional months to complete a business combination) (each, an “Additional Extension” and such date, the “Additional Extension Date”), provided that the Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (a) $140,000 or (b) $0.04 for each Public Share that is then-outstanding, in exchange for one or more non-interest bearing, unsecured promissory notes issued by the Company to the Sponsor or the Sponsor’s affiliates or permitted designees (the “Lenders” and each a “Lender”). In connection with the vote to approve the First Extension Charter Amendment, the holders of 24,703,445 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.35 per share, for an aggregate redemption amount of approximately $255,875,758.
The Sponsor and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares; (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem
100
% of the public shares if the Company did not complete its initial Business Combination within
15
months from the closing of the Public Offering (which was extended pursuant to shareholder approval of the Charter Amendment) or (B) with respect to any other provision relating to the rights of holders of the Company’s Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an initial Business Combination within Combination Period.
The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company’s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per public share due to reductions in the value of the Trust Account, in each case net of the interest or dividends that may be withdrawn to pay the Company’s income tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.
On October 20, 2023, at the Company’s extraordinary general meeting, the shareholders approved, among other proposals, (i) (a) the extension (such proposal, the “Extension Proposal”) of the time period the Company has to complete an initial Business Combination from October 22, 2023 to January 22, 2024 (the “Charter Amendment”) and (b) in the event that the Company has not consummated an initial Business Combination by January 22, 2024, to allow the Company, by resolution of the Board and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to each Additional Extension, to complete six Additional Extensions, provided that the Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (x) $35,000 or (y) $0.0175 for each Public Share that is then-outstanding, in exchange for one or more non-interest bearing, unsecured promissory notes issued by a Lender, and (ii) the amendment of the Company’s amended and restated memorandum and articles of association to change certain provisions which restrict the Class B ordinary shares, par value $0.0001, of the Company (the “Class B ordinary shares”) from converting to Class A ordinary shares, par value $0.0001 (the “Class A ordinary shares”) prior to the consummation of an initial
Business Combination (such proposal, the “Conversion Proposal”).
 
7
Founder Shares
Founder Shares refers to the Class B ordinary shares (the “Founder Shares”) acquired by the initial shareholders prior to the Company’s IPO.
The initial shareholders and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of the Business Combination; (ii) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with a shareholder vote to approve an amendment to the amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the Business Combination or to redeem 100% of the Company’s public shares if it does not complete the Business Combination by the Termination Date or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an Business Combination by the Termination Date (although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the Business Combination within the prescribed time frame). If the Company seeks shareholder approval, it will complete the Business Combination only if it is approved by an ordinary resolution or such higher approval threshold as may be required by Cayman Islands law and pursuant to the amended and restated memorandum and articles of association. In such case, the initial shareholders and each member of the management team have agreed to vote their Founder Shares and Public Shares in favor of the Business Combination.
In connection with the approval of the Conversion Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor converted all of its 5,619,077 Class B ordinary shares into Class A ordinary shares (the “Sponsor Share Conversion”). As a result of the Sponsor Share Conversion and redemptions made in connection with the Extension Proposal and Conversion Proposal, 7,027,632 Class A ordinary shares remain outstanding. Notwithstanding the Sponsor Share Conversion, the Sponsor will be not entitled to receive any funds held in the Trust Account with respect to any Class A ordinary shares issued to the Sponsor as a result of the Sponsor Share Conversion and no additional amounts will be deposited into the Trust Account in respect of shares of Class A ordinary shares held by the Sponsor in connection with the extension of the Termination Date to the Extended Date or any Additional Extension Dates.
Risks and Uncertainties
The credit and financial markets have experienced extreme volatility and disruptions due to the current conflict between Ukraine and Russia. The conflict is expected to have further global economic consequences, including but not limited to the possibility of severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in inflation rates and uncertainty about economic and political stability. In addition, the United States and other countries have imposed sanctions on Russia which increases the risk that Russia, as a retaliatory action, may launch cyberattacks against the United States, its government, infrastructure and businesses. Any of the foregoing consequences, including those we cannot yet predict, may cause our business, financial condition, results of operations and the price of our ordinary shares to be adversely affected.
Going Concern
As of September 30, 2023, the Company had $267,058 in cash held outside of the Trust Account and owes $5,296,038 in accounts payable and accrued expenses and $1,718,988 to related parties. The Company anticipates that the cash held outside of the Trust Account as of September 30, 2023 will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans.
In connection with the Company’s assessment of going concern considerations in accordance with ASC Subtopic
205-40,
“Presentation of Financial Statements – Going Concern”, the Company has until January 22, 2024 to consummate a Business Combination. If a Business Combination is not consummated by this date and an Additional Extension not obtained, there will be a mandatory liquidation and subsequent dissolution of the Company. It is uncertain whether the Company will be able to consummate a Business Combination by this time. Management has determined that the mandatory liquidation, should a Business Combination not occur, and an extension is not obtained, as well as the potential for us to have insufficient funds available to operate our business prior to a Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern.
 
8
Note 2 — Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and Article 8 of Regulation
S-X
of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on
Form 10-K,
which contains the initial audited financial statements and notes thereto for the period ended December 31, 2022, as filed with the SEC on March 31, 2023. The interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the period ending December 31, 2023 or for any future interim periods.
The breakout of loss from operations on the condensed statement of operations for the three and nine months ended September 30, 2022, has been revised to conform to the current presentation. This presentation did not impact any other financial statement line items.
Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
 
9
Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of September 30, 2023 and December 31, 2022, respectively.
Marketable Securities Held in Trust Account
Substantially all of the assets held in the Trust Account were held in U.S. Money Market Funds. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in investment income on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information.
Fair Value Measurement
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the balance sheet, primarily due to its short-term nature.
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level 1, Level 2 or Level 3. These tiers include:
 
  •
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
  •
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
  •
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheets as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Warrant Liabilities
The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC Topic
815-40
and ASC Topic 480. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. These liabilities are subject to
re-measurement
at each balance sheet date. With each such
re-measurement,
the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations.
 
10
Net Income (Loss) Per Ordinary Share
The Company has two classes of shares, which are referred to as redeemable Class A ordinary shares and
non-redeemable
Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. With respect to the accretion of Class A ordinary shares subject to possible redemption, the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share.
The earnings per share presented in the statement of operations is based on the following:
 
    
For the Three Months Ended

September 30,
     
For the Nine Months Ended

September 30,
  
    
2023
     
2022
     
2023
     
2022
  
                             
Net income (loss)
    $    631,724      $ 4,262,070      $ (2,225,459 )     $ 11,637,242  
Accretion of temporary equity to redemption value
      (761,527 )       (1,245,745 )       6,472,390        (1,632,690 ) 
  
 
 
     
 
 
     
 
 
     
 
 
  
Net income including accretion of temporary equity to redemption value
    $ (129,803 )     $     3,016,325      $ 4,246,931      $ 10,004,552  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
    
For the Three Months Ended

September 30,
  
    
2023
     
2022
  
    
Redeemable
Class A
     
Non-redeemable

Class B
     
Redeemable
Class A
     
Non-redeemable

Class B
  
                             
Basic and diluted net income (loss) per share:
            
Numerator:
            
Allocation of net income including accretion of temporary equity
    $ (38,941 )     $ (90,861 )     $ 2,413,060      $ 603,265  
Allocation of accretion of temporary equity to redemption value
      761,527        —          1,245,745        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
Allocation of net income (loss)
    $ 722,586      $ (90,861 )     $ 3,658,805      $ 603,265  
  
 
 
     
 
 
     
 
 
     
 
 
  
Denominator:
            
Weighted-average shares outstanding
      2,896,555        6,900,000        27,600,000        6,900,000  
Basic and diluted net income (loss) per share
    $ 0.25      $ (0.01 )     $ 0.13      $ 0.09  
 
    
For the Nine Months Ended

September 30,
  
    
2023
     
2022
  
    
Redeemable
Class A
     
Non-redeemable

Class B
     
Redeemable
Class A
     
Non-redeemable

Class B
  
                             
Basic and diluted net (loss) income per share:
            
Numerator:
            
Allocation of net income including accretion of temporary equity
    $ 1,698,772      $ 2,548,159      $ 8,003,642      $ 2,000,910  
Allocation of accretion of temporary equity to redemption value
      (6,472,390 )       —          1,632,690        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
Allocation of net (loss) income
    $ (4,773,618 )     $ 2,548,159      $ 9,636,332      $ 2,000,910  
  
 
 
     
 
 
     
 
 
     
 
 
  
Denominator:
            
Weighted-average shares outstanding
      4,615,842        6,900,000        27,600,000        6,900,000  
Basic and diluted net (loss) income per share
    $ (1.03 )     $ 0.37      $ 0.35      $ 0.29  
 
11
Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding during the period. The Company has not considered the effect of the 27,840,000 ordinary shares issuable upon exercise of the Public Warrants and Private Placement Warrants in the calculation of diluted income (loss) per share, since
th
e exercise of such warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares sold in the IPO feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events.
The Company has made a policy election in accordance with
ASC 480-10-S99-3A
and recognizes changes in redemption value in additional
paid-in
capital (or accumulated deficit in the absence of additional
paid-in
capital) immediately as they occur. The Company recorded accretion of $761,527 and $2,762,570 in accumulated deficit for three and nine months ended September 30, 2023, respectively, and $1,245,745 and $1,634,827 in accumulated deficit for the three and nine months ended September 30, 2022, respectively. For the period ended September 30, 2023, the Company recorded redemption of $255,875,758 and $1,042,760 was deposited in the Trust Account for extension funding.
Income Taxes
The Company accounts for income taxes under ASC Topic 740, “Income Taxes” (“ASC 740”).
ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2023 and December 31, 2022.
The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s unaudited condensed financial statements. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September 30, 2023 and December 31, 2022, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
Recent Accounting Pronouncements
Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements.
 
12
Note 3 — Related Party Transactions
Promissory Notes — Related Party
On April 27, 2021, the Sponsor agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the Public Offering. The Company borrowed a total of $262,268. This loan was
non-interest
bearing, unsecured and due at the earlier of December 31, 2021 or the closing of the Public Offering. The loan was to be repaid upon the closing of the Public Offering out of the offering proceeds not held in the Trust Account. In connection with the closing of the Public Offering, the Company paid down $90,922 of the outstanding balance. As of September 30, 2023 and December 31, 2022, the Company had $171,346 outstanding under the promissory note and as is included on the balance sheet as promissory note
—
related party. The Sponsor has agreed to defer repayment of the loan until the close of the Business Combination.
On April 5, 2023, the Company issued an unsecured promissory note (the “Note”) in the principal amount of up to $1,500,000 to the Sponsor, which may be drawn down by the Company from time to time prior to the consummation of the Company’s Business Combination. The Note does not bear interest, matures on the date of consummation of the Business Combination and is subject to customary events of default. As of September 30, 2023, the Company had $1,238,449 outstanding under the Note and is included on the balance sheet as promissory note
—
related party.
In addition, on October 17, 2023, the Company issued an amended and restated promissory note (the “Restated Note”) in the principal amount of up to $2,500,000 to the Sponsor. The Restated Note amends, restates, replaces and supersedes
 
the Note
 dated April 5, 2023, in the principal amount of $1,500,000. The Restated Note may be drawn down by the Company from time to time prior to the consummation of the Company’s initial Business Combination. The Restated Note does not bear interest, matures on the date of consummation the Business Combination and is subject to customary events of default. The Restated Note will be repaid only to the extent that the Company has funds available to it outside of its Trust Account (see Note 10).
Working Capital Loans
In order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. As of September 30, 2023 and December 31, 2022, the Company had no borrowings under the Working Capital Loans.
Office Space, Secretarial and Administrative Services
Through the earlier of consummation of the initial Business Combination and the liquidation, the Company incurs $10,000 per month for office space, utilities, secretarial support and administrative services provided by the Sponsor. For the three and nine months ended September 30, 2023, the Company has incurred $30,000 and $90,000, respectively. No amounts have been paid for these services. For the three and nine months ended September 30, 2022, the Company incurred $30,000 and $90,000, respectively. No amounts have been paid for these services. As of September 30, 2023 and December 31, 2022, the Company reported on the balance sheets $165,000 and $120,000, respectively, pursuant to this agreement, in “Due to related party”.
Note 4 — Prepaid Expenses
The Company’s prepaid expenses as of September 30, 2023 and December 31, 2022 primarily consisted of the following:
 
    
September 30, 2023
     
December 31, 2022
  
               
Prepaid insurance
    $ 602      $ 26,081  
Other prepaid expenses
      3,659        5,029  
  
 
 
     
 
 
  
   $ 4,261      $ 31,110  
  
 
 
     
 
 
  
 
13
Note 5 — Accounts Payable and Accrued Expense
The Company’s accounts payable and accrued expenses as of September 30, 2023 and December 31, 2022 primarily consisted of legal accruals.
 
    
September 30, 2023
     
December 31, 2022
  
               
Legal accrual
    $ 5,041,722      $ 1,705,049  
Other payables and expenses
      254,316        161,943  
  
 
 
     
 
 
  
   $ 5,296,038      $ 1,866,992  
  
 
 
     
 
 
  
Note 6 — Commitments & Contingencies
Registration and Shareholder Rights
The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable
lock-up
period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the private placement warrants and the respective Class A ordinary shares issuable upon exercise of the private placement warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Working Capital Loans and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company’s register such securities.
In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Except as described herein, the Sponsor and its directors and executive officers have agreed not to transfer, assign or sell any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any
30-trading
day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company complete a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property. Any permitted transferees would be subject to the same restrictions and other agreements of the Sponsor and its directors and executive officers with respect to any founder shares. Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor with respect to any Founder Shares. The Company refers to such transfer restrictions throughout the Public Offering as the lock- up.
 
14
In addition, pursuant to the registration and expected shareholder rights agreement, the Sponsor, upon and following consummation of an initial Business Combination, will be entitled to nominate three individuals for election to the board of directors, as long as the Sponsor holds any securities covered by the registration and expected shareholder rights agreement.
Underwriting Agreement
The underwriters were entitled to a deferred
underwriters fee
of 3.5% of the gross proceeds of the Public Offering upon the completion of the Company’s initial Business Combination. In April 2023, the underwriters waived any right to receive the deferred
underwriters fee
and will therefore receive no additional
underwriters fee
in connection with the Closing. As a result, the Company recognized $425,040 of other income on the statement of operations and $9,234,960 was recorded to accumulated deficit on the statements of changes in ordinary shares subject to possible redemption and shareholders’ deficit in relation to the reduction of the deferred underwriter
s
fee. As of September 30, 2023 and December 31, 2022, the deferred underwrit
ers
fee is $0 and $9,660,000, respectively.
To account for the waiver of the deferred
underwriters
fee, the Company analogized to the SEC staff’s guidance on accounting for reducing a liability for “trailing fees”. Upon the waiver of the deferred
underwriters
fee, the Company reduced the deferred
underwriters fee
to $0 and reversed the previously recorded cost of issuing the instruments in the IPO, which included recognizing a contra-expense of $425,040, which is the amount previously allocated to liability classified warrants and expensed upon the IPO, and reduced the accumulated deficit and increased income available to Class B ordinary shares by $9,234,960, which was previously allocated to the Class A ordinary shares subject to redemption and accretion recognized at the IPO date.
Proposed Business Combination
On April 19, 2023, the Company entered into a Business Combination Agreement, by and among the Company, ESGEN OpCo, LLC, a Delaware limited liability company and wholly-owned subsidiary of ESGEN (“OpCo”), Sunergy Renewables, LLC, a Nevada limited liability company (“Sunergy”), the Sunergy equityholders set forth on the signature pages thereto (collectively, “Sellers” and each, a “Seller”, and collectively with Sunergy, the “Sunergy Parties”), for limited purposes, the Sponsor, and for limited purposes, Timothy Bridgewater, an individual, in his capacity as the Sellers Representative (the “Business Combination Agreement”).
In accordance with the terms and subject to the conditions of the Business Combination Agreement, among other things: (i) prior to the consummation of the Business Combination (the “Closing”), each issued and outstanding Class B ordinary share of ESGEN will convert into one Class A ordinary share of ESGEN (the “ESGEN Share Conversion”); and (ii) following the ESGEN Share Conversion but prior to the Closing, ESGEN will, subject to the receipt of the requisite shareholder approval, transfer by way of continuation from the Cayman Islands to the State of Delaware and domesticate as a Delaware corporation (the “Domestication”) and will change its name as to be determined by the parties to the Business Combination Agreement (“New PubCo”).
In connection with the Domestication, (A) each outstanding Class A ordinary share will become one share of Class A common stock, par value $0.0001 per share, of New PubCo (the “New PubCo Class A Common Stock”), (B) each outstanding warrant to purchase one Class A ordinary share (each, an “ESGEN Warrant”) will become a warrant to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share, and (C) New PubCo will file its certificate of incorporation and will adopt bylaws to serve as its governing documents upon consummation of the Domestication. In connection with the ESGEN Share Conversion and the Domestication, each issued and outstanding unit of ESGEN, each consisting of one Class A ordinary share and
one-half
of one ESGEN Warrant (each, an “ESGEN Unit”), that has not been previously separated into the underlying Class A ordinary shares and underlying ESGEN Warrants prior to the Domestication will be cancelled and will entitle the holder thereof to (x) one share of New PubCo Class A Common Stock and
(y) 
one-half
of one warrant representing the right to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share on the terms and subject to the conditions applicable to ESGEN Warrants set forth in the Warrant Agreement, dated as of October 22, 2021, between ESGEN and Continental Stock Transfer & Trust Company (the “Trustee”).
 
15
In accordance with the terms and subject to the conditions of the Business Combination Agreement, Sunergy will cause all holders of any options, warrants or rights to subscribe for or purchase any equity interests of Sunergy or its subsidiaries or securities (including debt securities) convertible into or exchangeable for, or that otherwise confer on the holder any right to acquire, any equity interests of Sunergy or any subsidiary thereof (collectively, the “Sunergy Convertible Interests”) existing immediately prior to the Closing either to exchange or convert all such holder’s Sunergy Convertible Interests into limited liability interests of Sunergy (the “Sunergy Company Interests”) in accordance with the governing documents of Sunergy or the Sunergy Convertible Interests (collectively, the “Sunergy Exchanges”).
At the Closing, ESGEN will contribute to OpCo (1) all of its assets (excluding its interests in OpCo, but including the amount of cash in the Trust Account as of immediately prior to the Closing (after giving effect to the exercise of redemption rights by any ESGEN shareholders)), and (2) a number of newly issued shares of Class V common stock of ESGEN, par value $0.0001 per share, which will generally have only voting rights (the “ESGEN Class V Common Stock”), equal to the number of Seller OpCo Units (as defined in the Business Combination Agreement) (the “Seller Class V Shares”) and (y) in exchange, OpCo shall issue to ESGEN (i) a number of common units of OpCo (the “OpCo Units”) which shall equal the number of total shares of ESGEN Class A Common Stock issued and outstanding immediately after the Closing and (ii) a number of warrants to purchase OpCo Units which shall equal the number of SPAC Warrants issued and outstanding immediately after the Closing (the transactions described above in this paragraph, the “ESGEN Contribution”). Immediately following the ESGEN Contribution, (x) the Sellers will contribute to OpCo the Sunergy Company Interests and (y) in exchange therefor, OpCo will transfer to the Sellers the Seller OpCo Units and the Seller Class V Shares.
The obligation of ESGEN, the Sunergy Parties and OpCo to consummate the Business Combination is subject to certain customary closing conditions, including, but not limited to, (i) the absence of any order, law or other legal restraint or prohibition enacted, issued or promulgated by any court of competent jurisdiction or other governmental entity of competent jurisdiction having the effect of making the Business Combination illegal or otherwise prohibiting the consummation of the Business Combination, (ii) the termination or expiration of any applicable waiting period applicable to the consummation of the Business Combination under the Hart-Scott-Rodino Act, (iii) the effectiveness of the Registration Statement on Form S-4 (the “Registration Statement”) in accordance with the provisions of the Securities Act, registering the ESGEN Class A Common Stock to be issued in connection with the Business Combination Agreement, (iv) receipt of the required approvals of ESGEN’s shareholders at a meeting of the shareholders of ESGEN in connection with the Business Combination, (v) the ESGEN Class A Common Stock to be issued in connection with the Business Combination immediately after Closing shall be listed on Nasdaq and ESGEN will be able to satisfy any continued listing requirements of Nasdaq immediately after Closing, (vi) if the ESGEN shareholders do not approve the Redemption Limitation Amendment (as defined in the Business Combination Agreement), ESGEN having at least $5,000,001 of net tangible assets (as determined in accordance with Rule 3a5-51(g)(1) of the Exchange Act) remaining immediately after any holders of the ESGEN Class A Ordinary Shares exercise their redemption rights, (vii) the members of the post-Business Combination ESGEN board of directors shall have been elected or appointed in accordance with the Business Combination Agreement and (viii) the aggregate transaction proceeds, including from the Trust Account after giving effect to the exercise of redemption rights by any ESGEN shareholders pursuant to the ESGEN amended and restated memorandum and articles of association, as amended, and the proceeds resulting from the Initial PIPE Investment (as defined below) and any financing agreements executed in furtherance of the Business Combination Agreement, shall be greater or equal to $20,000,000.
 
16
Concurrently with the execution of the Business Combination Agreement, ESGEN entered into a subscription agreement (the “Initial Subscription Agreement”) with Sponsor. Pursuant to the Initial Subscription Agreement, Sponsor agreed to subscribe for and purchase, and ESGEN agreed to issue and sell to Sponsor, concurrently with the Closing, an aggregate of 1,000,000 shares of ESGEN Class A Common Stock for a purchase price of $10.00 per share, for aggregate gross proceeds of $10,000,000 (the “Initial PIPE Investment”). The closing of the Initial PIPE Investment is contingent upon, among other things, the substantially concurrent consummation of the Business Combination. The Initial Subscription Agreement provides that ESGEN will grant Sponsor certain customary registration rights. In addition to the Initial PIPE Investment, under the Business Combination Agreement, ESGEN and Sunergy have agreed to use their reasonable best efforts to identify other investors to enter into equity financing agreements (the “Additional Financing Agreements” and, together with the Initial Subscription Agreement, the “Financing Agreements”), in form and substance reasonably acceptable to ESGEN and Sunergy, to support the transaction (such equity financing under the Financing Agreements, collectively, herein referred to as the “Private Placements”).
The Business Combination is expected to close in the first quarter of 2024, following the receipt of the required approvals by our shareholders and the fulfillment of other customary closing conditions.
Note 7 — Warrant Liabilities
The Company accounts for the 27,840,000 warrants issued in connection with the Public Offering (13,800,000 Public Warrants and 14,040,000 Private Placement Warrants) in accordance with the guidance contained in ASC Topic
815-40.
Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company classifies each warrant as a liability at its fair value. This liability is subject to remeasurement at each balance sheet date.
With each such remeasurement, the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations.
Public Warrants
Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described adjacent to “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described adjacent to the caption “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.
The warrants will become exercisable 30 days after the completion of the Company’s initial Business Combination and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.
 
17
The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, it will use its commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement of which this prospectus forms a part or a new registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, it will not be required to file or maintain in effect a registration statement, but the Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60
th
day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption, but it will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value and (B) 0.361. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent.
Redemption of warrants when the price per Class
 A ordinary share equals or exceeds $18.00.
Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants (except as described herein with respect to the Private Placement Warrants):
 
  •
in whole and not in part;
 
  •
at a price of $0.01 per warrant;
 
  •
upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and
 
  •
if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within a 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders.
Redemption of warrants when the price per Class
 A ordinary share equals or exceeds $10.00.
Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants:
 
  •
in whole and not in part;
 
  •
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; and
 
  •
if, and only if, the closing price of the Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within the
30-trading
day period ending three trading days before the Company sends the notice of redemption to the warrant holders;
 
18
Private Warrants
If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units sold in the Public Offering. Any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants will require a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants.
The accounting treatment of derivative financial instruments requires that the Company record a derivative liability upon the closing of the IPO. Accordingly, the Company has classified each warrant as a liability at its fair value and the warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value.
These liabilities are
subject to
re-measurement
at each balance sheet date. With each such
re-measurement,
the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification.
Note 8 — Recurring Fair Value Measurements
As of September 30, 2023 and December 31, 2022, investments held in the Trust Account are determined by Level 1 inputs utilizing quoted prices (unadjusted) in active markets for identical assets.
The Company’s Public Warrants are traded on the Nasdaq. As such, the Public Warrant valuation is based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. The fair value of the Public Warrant liabilities is classified within Level 1 of the fair value hierarchy.
At September 30, 2023 and December 31, 2022, the Company considers the Private Warrants to be economically equivalent to the Public Warrants. As such, the valuation of the Public Warrants was used to value the Private Warrants. The fair value of the Private Warrant liabilities is classified within Level 2 of the fair value hierarchy.
The following tables presents fair value information as of September 30, 2023 and December 31, 2022 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.
 
    
September 30, 2023
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
                             
Assets:
                                    
Marketable securities held in Trust Account
    $   32,393,380      $ —        $ —        $   32,393,380  
Liabilities:
                                    
Public Warrants
      496,800        —          —          496,800  
Private Warrants
      —          505,440        —          505,440  
    
 
 
     
 
 
     
 
 
     
 
 
  
Total liabilities
    $ 496,800      $ 505,440      $ —        $ 1,002,240  
    
 
 
     
 
 
     
 
 
     
 
 
  
 
    
December 31, 2022
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
                             
Assets:
                                    
Marketable securities held in Trust Account
    $ 285,506,568      $ —        $ —        $ 285,506,568  
Liabilities:
                                    
Public Warrants
      394,680        —          —          394,680  
Private Warrants
      —          401,544        —          401,544  
    
 
 
     
 
 
     
 
 
     
 
 
  
Total liabilities
    $ 394,680      $ 401,544      $ —        $ 796,224  
    
 
 
     
 
 
     
 
 
     
 
 
  
There were no transfers to or from Levels 1, 2 or 3 for the three or nine months ended September 30, 2023 or 2022.
 
19
Note 9 — Shareholders’ Deficit
Preference shares
— The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2023 and December 31, 2022, there were no preference shares issued or outstanding.
Class
 A ordinary shares
— The Company is authorized to issue 250,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of September 30, 2023 and December 31, 2022, there were no Class A ordinary shares issued or outstanding other than the 2,896,555 and 27,600,000 Class A ordinary shares subject to possible redemption that are accounted for outside of the shareholders’ deficit section of the condensed balance sheets, respectively.
Class
 B ordinary shares
— The Company is authorized to issue 25,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for each share of Class B ordinary shares. As of September 30, 2023 and December 31, 2022, there were 6,900,000 Class B ordinary shares issued and outstanding.
Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as required by law. Unless specified in the Company’s amended and restated memorandum and articles of association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the Company’s ordinary shares that are voted is required to approve any such matter voted on by its shareholders.
The Class B ordinary shares will automatically convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have any redemption rights or be entitled to liquidating distributions from the Trust Account if the Company fails to consummate an initial Business Combination) at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an
as-converted
basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, any of its affiliates or any members of the Company’s management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than
one-to-one.
This is different than some other similarly structured blank check companies in which the initial shareholders will only be issued an aggregate of 20% of the total number of shares to be outstanding prior to the initial Business Combination.
Note 10 — Subsequent Events
Promissory Note
On October 17, 2023, the Company issued the Restated Note in the principal amount of up to $2,500,000 to the Sponsor. The Restated Note amends, restates, replaces and supersedes
the Note
dated April 5, 2023. The Restated Note may be drawn down by the Company from time to time prior to the consummation of the Company’s initial Business Combination. The Restated Note does not bear interest, matures on the date of consummation the Business Combination and is subject to customary events of default. The Restated Note will be repaid only to the extent that the Company has funds available to it outside of its Trust Account.
Extraordinary General Meeting
On October 20, 2023, the Company held an extraordinary general meeting of shareholders (the “Meeting”), and approved the Extension Proposal to amend the Company’s amended and restated memorandum and articles of association to: (i) extend from October 22, 2023 to January 22, 2024 (the “Extended Date”), the date by which, if the Company has not consummated a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving one or more businesses or entities, the Company must: (a) cease all operations except for the purpose of winding up; (b) as promptly as reasonably possible but not more than ten business days thereafter, redeem the shares sold in the Company’s initial public offering (in a redemption that will completely extinguish the rights of the owners of the Public Shares as shareholders (including the right to receive further liquidation distributions, if any)) at a per-share price, payable in cash, equal to (1) the aggregate amount then on deposit in the Trust Account, including interest or dividends earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, less up to
 $100,000
of interest or dividends to pay winding up and dissolution expenses (net of any taxes payable), divided by (2) the number of the then-outstanding Public Shares; and (c) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s Board, liquidate and dissolve, subject in the case of clauses (b) and (c) to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law, and (ii) in the event that the Company has not consummated an initial Business Combination by the Extended Date, to allow the Company, by resolution of the Board and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to the Extended Date, to extend the Termination Date up to six times (with each such extension being upon five days’ advance notice), each by one additional month (for a total of up to six additional months to complete a business combination), provided that the Company’s Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (a)
 $35,000 or (b) $0.0175 for each Public Share that is then-outstanding, in exchange for one or more
non-interest
bearing, unsecured promissory notes issued by the Company to the Lender. If the Company completes its initial Business Combination, it will, at the option of the Lender, repay the amounts loaned under the promissory note(s) or convert a portion or all of the amounts loaned under such promissory note(s) into warrants at a price of $1.00 per warrant, which warrants will be identical to the private placement warrants, each exercisable to purchase one Class A ordinary share at $11.50 per share, subject to adjustment, at a price of $1.00 per warrant issued to the Sponsor at the time of the Company’s initial public offering. If the Company does not complete a business combination by the deadline to consummate an initial Business Combination, such promissory notes will be repaid only from funds held outside of the Trust Account.
Additionally, the shareholders approved a proposal to amend, by special resolution, the Company’s amended and restated memorandum and articles of association to change certain provisions which restrict the Class B ordinary shares from converting to Class A ordinary shares prior to the consummation of an initial Business Combination.
In connection with the vote to approve the above proposals, the holders of 1,488,000 Class A ordinary shares of ESGEN properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.21 per share, for an aggregate redemption amount of $16,679,055.
In connection with the approval of the Extension Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor contributed into the Trust Account $0.0525 per share for each Class A ordinary share that was not redeemed at the Meeting, for an aggregate contribution of $73,949.
In connection with the approval of the Conversion Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor converted all of its 5,619,077 Class B ordinary shares into Class A ordinary shares. As a result of the Sponsor Share Conversion and redemptions made in connection with the Extension Proposal and Conversion Proposal, 7,027,632 Class A ordinary shares remain outstanding. Notwithstanding the Sponsor Share Conversion, the Sponsor will be not entitled to receive any funds held in the Trust Account with respect to any Class A ordinary shares issued to the Sponsor as a result of the Sponsor Share Conversion and no additional amounts will be deposited into the Trust Account in respect of shares of Class A ordinary shares held by the Sponsor in connection with the extension of the Termination Date to the Extended Date or any Additional Extension Dates.
 
20

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References to the “Company,” “our,” “us” or “we” refer to ESGEN Acquisition Corporation. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly Report”). Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding:

 

  •  

our ability to select an appropriate target business or businesses;

 

  •  

our ability to complete our initial business combination;

 

  •  

our expectations around the performance of a prospective target business or businesses;

 

  •  

our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;

 

  •  

our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination;

 

  •  

our potential ability to obtain additional financing to complete our initial business combination;

 

  •  

our pool of prospective target businesses;

 

  •  

the ability of our officers and directors to generate a number of potential business combination opportunities;

 

  •  

our public securities’ potential liquidity and trading;

 

  •  

the lack of a market for our securities;

 

  •  

the use of proceeds not held in the trust account or available to us from interest or dividend income on the trust account balance;

 

  •  

the trust account not being subject to claims of third parties; or

 

  •  

our financial performance following our initial public offering.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, those factors described under the heading “Risk Factors.” Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You should not take any statement regarding past trends or activities as representation that the trends or activities will continue in the future. Accordingly, you should not put undue reliance on these statements.

Overview

We were incorporated as a Cayman Islands exempted company on April 19, 2021 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). We will not be limited to a particular industry or geographic region in our identification and acquisition of a target company.

Our sponsor is ESGEN LLC, a Delaware limited liability company (the “Sponsor”).

 

 

21

Table of Contents

The registration statement for our initial public offering (“initial public offering”, “IPO” or “Public Offering”) was declared effective on October 19, 2021. On October 22, 2021, we consummated our initial public offering of 27,600,000 units (the “Units” and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”) at $10.00 per Unit (which included the full exercise of the underwriters’ over-allotment option), and the sale of 14,040,000 warrants (the “Private Placement Warrants”) each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per Private Placement Warrant in a private placement to our Sponsor that closed simultaneously with the initial public offering.

Following the closing of our initial public offering on October 22, 2021, $281,520,000 ($10.20 per Unit) from the net proceeds sold in our initial public offering, including proceeds of the sale of the Private Placement Warrants, was deposited in a trust account (“Trust Account”) and, until October 16, 2023, was only invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. To mitigate the risk of being deemed to have been operating as an unregistered investment company under the Investment Company Act, on October 16, 2023, we instructed the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in demand deposits (i.e., in one or more bank accounts) until the earliest of ESGEN’s completion of an initial business combination or January 22, 2024 (unless extended as described below), as applicable.

Prior to shareholder approval of the First Extension Charter Amendment (as defined below), we had 15 months from the closing of our initial public offering to consummate the initial Business Combination. If we have not consummated the initial Business Combination within the Combination Period, we will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to us to pay income taxes, if any (less up to $100,000 of interest or dividends to pay winding up and dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

On January 18, 2023, the Company held an extraordinary general meeting of shareholders to consider and vote upon, among other things, a proposal to amend the Company’s amended and restated memorandum and articles of association (the “First Extension Charter Amendment”) to (i) extend the date by which the Company must consummate its initial Business Combination (the “Termination Date”) from January 22, 2023 to April 22, 2023 and (ii) in the event that the Company has not consummated an initial Business Combination by April 22, 2023, to allow the Company, by resolution of the Company’s board of directors (the “Board”) and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to each Additional Extension, to extend the Termination Date up to six times (with each such extension being upon five days’ advance notice), each by one additional month (for a total of up to six additional months to complete a business combination) (each, an “Additional Extension” and such date, an “Additional Extension Date”), provided that the Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (a) $140,000 or (b) $0.04 for each Public Share that is then-outstanding, in exchange for one or more non-interest bearing, unsecured promissory notes issued by the Company to the Sponsor or the Sponsor’s affiliates or permitted designees (the “Lenders” and each a “Lender”). In connection with the vote to approve the First Extension Charter Amendment, the holders of 24,703,445 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.35 per share, for an aggregate redemption amount of $255,875,758. The Company currently has until January 22, 2024 (after giving effect to the second extension described below) to complete an initial Business Combination.

On October 20, 2023, the Company held an extraordinary general meeting (the “Meeting”) and approved (i) (a) the extension (such proposal, the “Extension Proposal”) of the time period the Company has to complete an initial Business Combination from October 22, 2023 to January 22, 2024 (the “Charter Amendment”) and (b) in the event that the Company has not consummated an initial Business Combination by January 22, 2024, to allow the Company, by resolution of the Board and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to each Additional Extension, to complete six Additional Extensions, provided that the Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (x) $35,000 or (y) $0.0175 for each Public Share that is then-outstanding, in exchange for one or more non-interest bearing, unsecured promissory notes issued by a Lender, and (ii) the amendment of the Company’s amended and restated memorandum and articles of association to change certain provisions which restrict the Class B ordinary shares, par value $0.0001, of the Company (the “Class B ordinary shares”) from converting to Class A ordinary shares, par value $0.0001 (the “Class A ordinary shares”) prior to the consummation of an initial Business Combination (such proposal, the “Conversion Proposal”).

In connection with the vote to approve the above proposals, the holders of 1,488,000 Class A ordinary shares of ESGEN properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.21 per share, for an aggregate redemption amount of $16,679,055.

In connection with the approval of the Extension Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor contributed into the Trust Account $0.0525 per share for each Class A ordinary share that was not redeemed at the Meeting, for an aggregate contribution of $73,949.

In connection with the approval of the Conversion Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor converted all of its 5,619,077 Class B ordinary shares into Class A ordinary shares (the “Sponsor Share Conversion”). As a result of the Sponsor Share Conversion and redemptions made in connection with the Extension Proposal and Conversion Proposal, 7,027,632 Class A ordinary shares remain outstanding. Notwithstanding the Sponsor Share Conversion, the Sponsor will be not entitled to receive any funds held in the Trust Account with respect to any Class A ordinary shares issued to the Sponsor as a result of the Sponsor Share Conversion and no additional amounts will be deposited into the Trust Account in respect of shares of Class A ordinary shares held by the Sponsor in connection with the extension of the Termination Date to the Extended Date or any Additional Extension Dates.

On April 19, 2023, the Company entered into a Business Combination Agreement, by and among the Company, ESGEN OpCo, LLC, a Delaware limited liability company and wholly-owned subsidiary of ESGEN (“OpCo”), Sunergy Renewables, LLC, a Nevada limited liability company (“Sunergy”), the Sunergy equity holders set forth on the signature pages thereto (collectively, “Sellers” and each, a “Seller”, and collectively with Sunergy, the “Sunergy Parties”), for limited purposes, the Sponsor, and for limited purposes, Timothy Bridgewater, an individual, in his capacity as the Sellers Representative (the “Business Combination Agreement”).

In accordance with the terms and subject to the conditions of the Business Combination Agreement, among other things: (i) prior to the consummation of the Business Combination (the “Closing”), each issued and outstanding Class B ordinary share of ESGEN will convert into one Class A ordinary share of ESGEN (the “ESGEN Share Conversion”); and (ii) following the ESGEN Share Conversion but prior to the Closing, ESGEN will, subject to the receipt of the requisite shareholder approval, transfer by way of continuation from the Cayman Islands to the State of Delaware and domesticate as a Delaware corporation (the “Domestication”) and will change its name as to be determined by the parties to the Business Combination Agreement (“New PubCo”).

In connection with the Domestication, (A) each outstanding Class A ordinary share will become one share of Class A common stock, par value $0.0001 per share, of New PubCo (the “New PubCo Class A Common Stock”), (B) each outstanding warrant to purchase one Class A ordinary share (each, an “ESGEN Warrant”) will become a warrant to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share, and (C) New PubCo will file its certificate of incorporation and will adopt bylaws to serve as its governing documents upon consummation of the Domestication. In connection with the ESGEN Share Conversion and the Domestication, each issued and outstanding unit of ESGEN, each consisting of one Class A ordinary share and one-half of one ESGEN Warrant (each, an “ESGEN Unit”), that has not been previously separated into the underlying Class A ordinary shares and underlying ESGEN Warrants prior to the Domestication will be cancelled and will entitle the holder thereof to (x) one share of New PubCo Class A Common Stock and (y) one-half of one warrant representing the right to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share on the terms and subject to the conditions applicable to ESGEN Warrants set forth in the Warrant Agreement, dated as of October 22, 2021, between ESGEN and Continental Stock Transfer & Trust Company (the “Trustee”).

 

 

22

Table of Contents

In accordance with the terms and subject to the conditions of the Business Combination Agreement, Sunergy will cause all holders of any options, warrants or rights to subscribe for or purchase any equity interests of Sunergy or its subsidiaries or securities (including debt securities) convertible into or exchangeable for, or that otherwise confer on the holder any right to acquire, any equity interests of Sunergy or any subsidiary thereof (collectively, the “Sunergy Convertible Interests”) existing immediately prior to the Closing either to exchange or convert all such holder’s Sunergy Convertible Interests into limited liability interests of Sunergy (the “Sunergy Company Interests”) in accordance with the governing documents of Sunergy or the Sunergy Convertible Interests (collectively, the “Sunergy Exchanges”).

At the Closing, ESGEN will contribute to OpCo (1) all of its assets (excluding its interests in OpCo, but including the amount of cash in the Trust Account as of immediately prior to the Closing (after giving effect to the exercise of redemption rights by any ESGEN shareholders)), and (2) a number of newly issued shares of Class V common stock of ESGEN, par value $0.0001 per share, which will generally have only voting rights (the “ESGEN Class V Common Stock”), equal to the number of Seller OpCo Units (as defined in the Business Combination Agreement) (the “Seller Class V Shares”) and (y) in exchange, OpCo shall issue to ESGEN (i) a number of common units of OpCo (the “OpCo Units”) which shall equal the number of total shares of ESGEN Class A Common Stock issued and outstanding immediately after the Closing and (ii) a number of warrants to purchase OpCo Units which shall equal the number of SPAC Warrants issued and outstanding immediately after the Closing (the transactions described above in this paragraph, the “ESGEN Contribution”). Immediately following the ESGEN Contribution, (x) the Sellers will contribute to OpCo the Sunergy Company Interests and (y) in exchange therefor, OpCo will transfer to the Sellers the Seller OpCo Units and the Seller Class V Shares.

The obligation of ESGEN, the Sunergy Parties and OpCo to consummate the Business Combination is subject to certain customary closing conditions, including, but not limited to, (i) the absence of any order, law or other legal restraint or prohibition enacted, issued or promulgated by any court of competent jurisdiction or other governmental entity of competent jurisdiction having the effect of making the Business Combination illegal or otherwise prohibiting the consummation of the Business Combination, (ii) the termination or expiration of any applicable waiting period applicable to the consummation of the Business Combination under the Hart-Scott-Rodino Act, (iii) the effectiveness of the Registration Statement on Form S-4 (the “Registration Statement”) in accordance with the provisions of the Securities Act, registering the ESGEN Class A Common Stock to be issued in connection with the Business Combination Agreement, (iv) receipt of the required approvals of ESGEN’s shareholders at a meeting of the shareholders of ESGEN in connection with the Business Combination, (v) the ESGEN Class A Common Stock to be issued in connection with the Business Combination immediately after Closing shall be listed on Nasdaq and ESGEN will be able to satisfy any continued listing requirements of Nasdaq immediately after Closing, (vi) if the ESGEN shareholders do not approve the Redemption Limitation Amendment (as defined in the Business Combination Agreement), ESGEN having at least $5,000,001 of net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act) remaining immediately after any holders of the ESGEN Class A Ordinary Shares exercise their redemption rights, (vii) the members of the post-Business Combination ESGEN board of directors shall have been elected or appointed in accordance with the Business Combination Agreement and (viii) the aggregate transaction proceeds, including from the Trust Account after giving effect to the exercise of redemption rights by any ESGEN shareholders pursuant to the ESGEN amended and restated memorandum and articles of association, as amended, and the proceeds resulting from the Initial PIPE Investment (as defined below) and any financing agreements executed in furtherance of the Business Combination Agreement, shall be greater or equal to $20,000,000.

Concurrently with the execution of the Business Combination Agreement, ESGEN entered into a subscription agreement (the “Initial Subscription Agreement”) with Sponsor. Pursuant to the Initial Subscription Agreement, Sponsor agreed to subscribe for and purchase, and ESGEN agreed to issue and sell to Sponsor, concurrently with the Closing, an aggregate of 1,000,000 shares of ESGEN Class A Common Stock for a purchase price of $10.00 per share, for aggregate gross proceeds of $10,000,000 (the “Initial PIPE Investment”). The closing of the Initial PIPE Investment is contingent upon, among other things, the substantially concurrent consummation of the Business Combination. The Initial Subscription Agreement provides that ESGEN will grant Sponsor certain customary registration rights. In addition to the Initial PIPE Investment, under the Business Combination Agreement, ESGEN and Sunergy have agreed to use their reasonable best efforts to identify other investors to enter into equity financing agreements (the “Additional Financing Agreements” and, together with the Initial Subscription Agreement, the “Financing Agreements”), in form and substance reasonably acceptable to ESGEN and Sunergy, to support the transaction (such equity financing under the Financing Agreements, collectively, herein referred to as the “Private Placements”).

For additional information regarding the Business Combination Agreement, see the Company’s Current Report on Form 8-K filed with the SEC on April 20, 2023.

The Business Combination is expected to close in the first quarter of 2024, following the receipt of the required approvals by our shareholders and the fulfillment of other customary closing conditions.

On April 5, 2023, the Company issued an unsecured promissory note (the “Note”) in the principal amount of up to $1,500,000 to the Sponsor, which may be drawn down by the Company from time to time prior to the consummation of the Company’s Business Combination. The Note does not bear interest, matures on the date of consummation of the Business Combination and is subject to customary events of default. As of September 30, 2023, there was $1,238,449 outstanding under the Note.

In addition, on October 17, 2023, the Company issued an amended and restated promissory note (the “Restated Note”) in the principal amount of up to $2,500,000 to the Sponsor. The Restated Note amends, restates, replaces and supersedes the Note dated April 5, 2023. The Restated Note may be drawn down by the Company from time to time prior to the consummation of the Company’s initial Business Combination. The Restated Note does not bear interest, matures on the date of consummation the Business Combination and is subject to customary events of default. The Restated Note will be repaid only to the extent that the Company has funds available to it outside of its Trust Account.

 

 

23

Table of Contents

Results of Operations

All of our activity from April 19, 2021 (inception) through September 30, 2023, was in preparation for our initial public offering, and since our initial public offering, including the effectuation of the Charter Amendment and the negotiation and entry into the Business Combination Agreement. We will not generate any operating revenues until the closing and completion of our initial Business Combination.

For the three months ended September 30, 2023, we had net income of $631,724, which consisted of a change in fair value of warrant liabilities of $1,046,784 and dividends earned on marketable securities held in the Trust Account of $413,940, partially offset by operating costs of $829,000.

For the three months ended September 30, 2022, we had net income of $4,262,070, which consisted of a gain on change in fair value of warrant liabilities of $3,345,600, dividends earned on marketable securities held in trust account of $1,245,745, partially offset by operating costs of $329,275.

For the nine months ended September 30, 2023, we had a net loss of $2,225,459, which consisted of a change in fair value of warrant liabilities of $206,016 and operating costs of $4,164,293, partially offset by dividends earned on marketable securities held in the Trust Account of $1,719,810 and recovery of offering costs related to the IPO allocated to warrants of $425,040.

For the nine months ended September 30, 2022, we had net income of $11,637,242, which consisted of a gain on change in fair value of warrant liabilities of $11,608,560 and dividends earned on marketable securities held in trust account of $1,632,690, partially offset by operating costs of $1,604,008.

Liquidity and Capital Resources

As of September 30, 2023, we had cash of $267,058 and owe $5,296,038 in accounts payable and accrued expenses and an additional $1,718,988 payable to related parties.

Prior to the completion of our initial public offering, our liquidity needs had been satisfied through a capital contribution from the Sponsor of $25,000 and a loan to us of up to $300,000 by our Sponsor under an unsecured promissory note, which had an outstanding balance of $171,346 at September 30, 2023 and December 31, 2022. The Sponsor has agreed to defer repayment of the loan until the close of the Business Combination. On April 5, 2023, we issued the Note in the principal amount of up to $1,500,000 to our Sponsor, which may be drawn down by us from time to time prior to the consummation of the initial Business Combination. As of September 30, 2023, there was $1,238,449 outstanding under the Note.

In addition, in order to finance transaction costs in connection with a business combination, our Sponsor, an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, provide us Working Capital Loans. As of September 30, 2023 and December 31, 2022, there were no amounts outstanding under any Working Capital Loans.

Based on the foregoing, management believes that we will not have sufficient working capital and borrowing capacity to meet our needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, we will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.

In connection with the company’s assessment of going concern considerations in accordance with ASC Subtopic 205-40, “Presentation of Financial Statements – Going Concern”, the company has until January 22, 2024 (unless extended as described above) to consummate a Business Combination. If a Business Combination is not consummated by this date and an Additional Extension not obtained, there will be a mandatory liquidation and subsequent dissolution of the company. It is uncertain whether the Company will be able to consummate a Business Combination by this time. Management has determined that the mandatory liquidation, should a Business Combination not occur, and an extension is not obtained, as well as the potential for us to have insufficient funds available to operate our business prior to a Business Combination, and potential subsequent dissolution, raises substantial doubt about the Company’s ability to continue as a going concern. It is uncertain whether the company will be able to consummate a Business Combination or obtain an Additional Extension by this time. No adjustments have been made to the carrying amounts of assets or liabilities should the company be required to liquidate after January 22, 2024 (unless extended as described above).

Contractual Obligations

Other than the below, we do not have any long-term debt obligations, capital lease obligations, operating lease obligations, purchase obligations or long-term liabilities.

Underwriting Agreement

The IPO underwriters were entitled to a deferred underwriters fee of 3.5% of the gross proceeds of our IPO upon the completion of our initial Business Combination. In April 2023, the IPO underwriters waived any right to receive such deferred underwriters fee and will therefore receive no additional underwriters fee in connection with the Closing.

 

 

24

Table of Contents

Office Space, Secretarial and Administrative Services

Through the earlier of consummation of the initial Business Combination or the liquidation, the Company incurs $10,000 per month for office space, utilities, secretarial support and administrative services provided by the Sponsor. For the three and nine months ended September 30, 2023, the Company incurred $30,000 and $90,000, respectively, pursuant to this agreement. For the three and nine months ended September 30, 2022, the Company incurred $30,000 and $90,000, respectively, pursuant to this agreement. No amounts have been paid for these services. As of September 30, 2023 and December 31, 2022, the Company reported on the balance sheets $165,000 and $120,000, respectively, pursuant to this agreement, in “Due to related party”.

Registration Rights

The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration and shareholder rights agreement signed at the closing of our initial public offering (the “IPO Registration Rights Agreement”). The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to our completion of the initial Business Combination. However, the registration and shareholder rights agreement provides that we will not permit any registration statement filed under the Securities Act of 1933, as amended (the “Securities Act”) to become effective until termination of the applicable lock-up period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares issuable upon exercise of the Private Placement Warrants, 30 days after the completion of the initial Business Combination. We will bear the expenses incurred in connection with the filing of any such registration statements. The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Working Capital Loans and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our initial public offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the company register such securities.

In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of its initial Business Combination. However, the registration and shareholder rights agreement provides that we will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. We will bear the expenses incurred in connection with the filing of any such registration statements.

Except as described herein, the Sponsor and its directors and executive officers have agreed not to transfer, assign or sell any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which we complete a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property. Any permitted transferees would be subject to the same restrictions and other agreements of the Sponsor and its directors and executive officers with respect to any founder shares. Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor with respect to any Founder Shares.

In addition, pursuant to the registration and shareholder rights agreement, the Sponsor, upon and following consummation of an initial Business Combination, will be entitled to nominate three individuals for election to the board of directors, as long as the Sponsor holds any securities covered by the registration and shareholder rights agreement.

A&R Registration Rights Agreement

The Business Combination Agreement contemplates that, at the Closing, Sunergy, Sunergy’s underlying equityholders and the Initial Shareholders (as defined below) (collectively, the “New PubCo Holders”) and New PubCo will enter into an amended and restated IPO Registration Rights Agreement (the “A&R Registration Rights Agreement”), pursuant to which, among other things, New PubCo and the Initial Shareholders will agree to amend and restate the Registration and Shareholder Rights Agreement, dated as of October 22, 2021, entered into by them in connection with ESGEN’s IPO. Pursuant to the A&R Registration Rights Agreement, New PubCo will agree that, within 30 days following the consummation of the Business Combination, it will use its commercially reasonable efforts to file a resale shelf registration statement on behalf of Sunergy, Sunergy’s underlying equityholders and the Initial Shareholders registering (i) New PubCo’s private placement warrants, (ii) any outstanding shares of New PubCo Class A Common Stock held by the New PubCo Holders, (iii) any shares of New PubCo Class A Common Stock issued or issuable upon exchange of an equivalent number of Class B units of OpCo and Class V common stock of New PubCo, par value $0.0001 per share, issued to the Sellers pursuant to the Business Combination Agreement, (iv) any shares of New PubCo Class A Common Stock issued or to be issued to any of the New PubCo Holders in connection with the Business Combination and (v) any other equity security of New PubCo issued or issuable with respect to any of the foregoing by way of a stock dividend or stock split or in connection

 

 

25

Table of Contents

with a combination of shares, recapitalization, merger, consolidation or reorganization (collectively, the “Registrable Securities”); provided, however, that as to any particular Registrable Securities, such securities shall cease to be Registrable Securities when (A) a registration statement with respect to the sale of such Registrable Securities becomes effective under the Securities Act and such Registrable Securities shall have been sold, transferred, disposed of or exchanged in accordance with such registration statement, (B) such Registrable Securities shall have been otherwise transferred and such transferee is not entitled to the registration rights provided in the A&R Registration Rights Agreement, (C) such Registrable Securities shall have ceased to be outstanding, or (D) such Registrable Securities may be sold without registration pursuant to Rule 144 and Rule 145, as applicable, promulgated under the Securities Act (or any successor rule promulgated thereto) (but with no volume or other restrictions or limitations).

Additionally, the A&R Registration Rights Agreement will also provide, subject to certain underwriter cutbacks and suspension periods, (i) certain demand rights entitling the New PubCo Holders the right to require New PubCo to effect an underwritten offering and (ii) certain piggyback rights entitling the New PubCo Holders the right to include such New PubCo Holder’s Registrable Securities in any underwritten offering that New PubCo proposes to consummate for its own account or for the account of its stockholders.

Amendment to the Letter Agreement

Concurrently with the execution of the Business Combination Agreement, the Sponsor, the independent directors of the board of directors of ESGEN and one or more client accounts of Westwood Group Holdings, Inc. (successor to Salient Capital Advisors, LLC) (collectively, the “Initial Shareholders”) entered into an amendment (as amended, the “Amendment to the Letter Agreement”) to that certain Letter Agreement, dated as of October 22, 2021, by and between the Initial Shareholders, pursuant to which, among other things, each of the Initial Shareholders agreed (i) not to transfer his, her or its ESGEN Class B ordinary shares (or the ESGEN Class A Common Stock issuable in exchange for such ESGEN Class B ordinary shares pursuant to the Business Combination Agreement) prior to the earlier of (A) six months after the Closing or (B) subsequent to the Closing (x) if the last sale price of the ESGEN Class A Common Stock quoted on Nasdaq is greater than or equal to $12 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-consecutive trading day period commencing at least 90 days after Closing, or (y) the date on which ESGEN completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company’s shareholders having the right to exchange their ESGEN Class A ordinary shares (including any shares of ESGEN Class A Common Stock issuable in exchange for such ESGEN Class A ordinary shares) for cash, securities or other property and (ii) each Initial Shareholder agreed to waive any adjustment to the conversion ratio set forth in the governing documents of ESGEN with respect to the ESGEN Class B ordinary shares prior to the earlier of the ESGEN Share Conversion or the Closing.

Critical Accounting Estimates

The preparation of these financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. We have not identified any critical accounting estimates.

Recent Accounting Pronouncements

Refer to Note 2 (“Significant Accounting Policies”) in the financial statements for the recent accounting pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and are not required to provide the information otherwise required under this item. As of September 30, 2023, we were not subject to any market or interest rate risk. The net proceeds of the Public Offering, including amounts in the Trust Account, were invested in U.S. government securities with a maturity of 185 days or less or in money market funds that meet certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended, that invest only in direct U.S. government treasury obligations. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.

We have not engaged in any hedging activities since our inception, and we do not expect to engage in any hedging activities with respect to the market risk to which we are exposed.

 

 

26

Table of Contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report, is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our principal executive officer and principal financial and accounting officer (our “Certifying Officers”), the effectiveness of our disclosure controls and procedures as of September 30, 2023, pursuant to Rule 13a-15(b) under the Exchange Act and determined that our disclosures controls and procedures were not effective as the material weakness identified as of December 31, 2022 and detailed in our Annual Report on Form 10-K continues to exist as of September 30, 2023. A material weakness, as defined in the SEC regulations, is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022, our disclosure controls and procedures were not effective because of the identification of a material weakness in our internal control over financial reporting. We identified material weaknesses in our internal control over financial reporting, specifically, we did not design and maintain an effective control environment to prevent or detect material misstatements to the financial statements. Specifically, we lacked a sufficient complement of personnel with an appropriate level of internal controls and accounting knowledge, training and experience commensurate with our financial reporting requirements. Specifically, management did not design and maintain effective controls over the calculation of earnings per share and classification of the reinvestment of interest and dividend income in the Trust Account in the statement of cash flows.

Remediation Plan

Management plans to remediate the material weakness identified above by enhancing our processes to identify and appropriately apply applicable accounting requirements and increased communication among our personnel and third-party professionals with whom we consult regarding accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

Other than the remediation plan described above, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors.

As of the date of this Quarterly Report, except as described below, there have been no material changes from the risk factors previously disclosed in the Company’s Annual Report on Form 10-K as filed with the SEC on March 31, 2023 (the “Annual Report”).

 

 

27

Table of Contents

There are no assurances that the approval of the Charter Amendment or the execution of the Business Combination Agreement will enable us to complete our proposed Business Combination.

In connection with the Charter Amendment, our amended and restated memorandum and articles of association were amended to, among other things, (i) extend the date by which the Company must consummate its initial Business Combination from January 22, 2023 to the Extended Date and (ii) in the event that the Company has not consummated an initial Business Combination by the Extended Date, to allow the Company, by resolution of the Board and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to the Extended Date, to extend the Extended Date up to six times (with each such extension being upon five days’ advance notice), each by one additional month (for a total of up to six additional months to complete a business combination), provided that the Lenders will deposit into the Trust Account for each Additional Extension Date the lesser of (a) $140,000 or (b) $0.04 for each Public Share that is then-outstanding, in exchange for one or more non-interest bearing, unsecured promissory notes issued by the Company to the Lender. The purpose of the Charter Amendment is to allow the Company more time to complete its initial Business Combination and reduce the amount of funds to be deposited in the Trust Account to secure the extension.

Even though such extension was approved by our shareholders, the Company can provide no assurances that we will be able to complete our proposed Business Combination prior to the final Additional Extension Date. Our ability to consummate the Business Combination is dependent on a variety of factors, many of which are beyond our control. Additionally, we will be required to offer stockholders redemption rights again in connection with any stockholder vote to approve our proposed Business Combination. Other than in connection with a redemption offer or liquidation, our stockholders may be unable to recover their investment except through sales of our shares on the open market. The price of our shares may be volatile, and there can be no assurance that stockholders will be able to dispose of our shares at favorable prices, or at all.

We and our proposed target pursuant to the Business Combination Agreement will incur significant transaction and transition costs in connection with the proposed Business Combination.

We and our proposed target pursuant to the Business Combination Agreement expect to incur significant, non-recurring costs in connection with consummating the Business Combination and operating as a public company following the consummation of the Business Combination. We and such company may also incur additional costs to retain key employees. We will incur and be responsible for the expenses and fees as set forth in, and in connection with, the Business Combination Agreement. There can be no assurance that such fees and expenses will not be greater than expected or that there will be no unexpected costs related to the Business Combination.

If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete our initial Business Combination.

If we are deemed to be an investment company under the Investment Company Act of 1940 (the “Investment Company Act”), our activities may be restricted, including:

 

  •  

restrictions on the nature of our investments; and

 

  •  

restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial Business Combination.

In addition, we may have imposed upon us burdensome requirements, including:

 

  •  

registration as an investment company with the SEC;

 

  •  

adoption of a specific form of corporate structure; and

 

  •  

reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations that we are currently not subject to.

In order not to be regulated as an investment company under the Investment Company Act, unless we can qualify for an exclusion, we must ensure that we are engaged primarily in a business other than investing, reinvesting or trading of securities and that our activities do not include investing, reinvesting, owning, holding or trading “investment securities” constituting more than 40% of our assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis.

We do not believe that our principal activities and the Business Combination will subject us to the Investment Company Act. To this end, the proceeds held in the Trust Account may only be invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. Pursuant to the trust agreement, the Trustee is not permitted to invest in other securities or assets. By restricting the investment of the proceeds to these instruments, and by having a business plan targeted at acquiring and growing businesses for the long term (rather than on buying and selling businesses in the manner of a merchant bank or private equity fund), we intend to avoid being deemed an “investment company” within the meaning of the Investment Company Act. An investment in our securities is not intended for persons who are seeking a return on investments in government securities or investment securities. The Trust Account is intended as a holding place for funds pending the earliest to occur of either: (i) the completion of our initial Business Combination (which shall be the Business Combination pursuant to the Business Combination Agreement should it occur); (ii) the redemption of any Class A ordinary shares properly tendered in connection with a shareholder vote to amend the Existing Charter (a) to modify the substance or timing of our obligation to provide holders of our Class A ordinary shares the right to have their shares redeemed in connection with our initial Business Combination (which shall be the Business Combination pursuant to the Business Combination Agreement should it occur) or to redeem 100% of our Class A ordinary shares if we do not complete our initial Business Combination by July 22, 2024 (assuming the Sponsor deposits the required amount into the Trust Account for each Additional Extension Date and unless shareholders approve one or more further Additional Extensions) or (b) with respect to any other provision relating to the rights of holders of our Class A ordinary shares; or (iii) absent an initial Business Combination (which shall be the Business Combination pursuant to the Business Combination Agreement should it occur) by July 22, 2024 (assuming the Sponsor deposits the required amount into the Trust Account for each Additional Extension Date and unless shareholders approve one or more further Additional Extensions), our return of the funds held in the Trust Account to the public shareholders as part of our redemption of the Class A ordinary shares. If we do not invest the proceeds as discussed above, we may be deemed to be subject to the Investment Company Act. If we were deemed to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses for which we have not allotted funds and may hinder our ability to complete a Business Combination. If we are unable to complete a Business Combination, the public shareholders may only receive their pro rata portion of the funds in the Trust Account that are available for distribution to the public shareholders, and our warrants will expire worthless.

If we are deemed to be an investment company for purposes of the Investment Company Act, we may be forced to abandon our efforts to complete an initial Business Combination and instead be required to liquidate ESGEN. To mitigate the risk of that result, on or about the 24-month anniversary of the effective date of the IPO Registration Statement, we will instruct the Trustee to liquidate the securities held in the Trust Account and instead hold all funds in the Trust Account in cash. As a result, following such change, we will likely receive minimal, if any, interest, on the funds held in the Trust Account, which would reduce the dollar amount that the public shareholders would have otherwise received upon any redemption or liquidation of ESGEN if the assets in the Trust Account had remained in U.S. government securities or money market funds.

On March 30, 2022, the SEC issued proposals (the “SPAC Rule Proposals”), relating, among other things, to circumstances in which SPACs such as us could potentially be subject to the Investment Company Act and the regulations thereunder. The SPAC Rule Proposals would provide a safe harbor for such companies from the definition of “investment company” under Section 3(a)(1)(A) of the Investment Company Act, provided that a SPAC satisfies certain criteria. To comply with the duration limitation of the proposed safe harbor, a SPAC would have a limited time period to announce and complete a Business Combination transaction. Specifically, to comply with the safe harbor, the SPAC Rule Proposals would require a company to file a report on Form 8-K announcing that it has entered into an agreement with a target company for an initial Business Combination no later than 18 months after the effective date of the registration statement filed in connection with the IPO (the “IPO Registration Statement”). ESGEN would then be required to complete its initial Business Combination no later than 24 months after the date of the IPO Registration Statement.

There is currently uncertainty concerning the applicability of the Investment Company Act to a SPAC, such as ESGEN. As indicated above, we completed the IPO in October 2021 and have operated as a blank check company searching for a target business with which to consummate an initial Business Combination since such time (or approximately 24 months after the effective date of the IPO, as of the date hereof). As a result, it is possible that a claim could be made that we have been operating as an unregistered investment company. Furthermore, in connection with the approval of the Extension Proposal, the Company has until July 22, 2024 to consummate an initial Business Combination, which is a total of up to 33 months from the consummation of the Company’s IPO to complete an initial Business Combination. If we were deemed to be an investment company for purposes of the Investment Company Act, we might be forced to abandon our efforts to complete an initial Business Combination and instead be required to liquidate ESGEN. If we are required to liquidate ESGEN, our investors would not be able to realize the benefits of owning shares in a successor operating business, including the potential appreciation in the value of our shares and warrants or rights following such a transaction, and our warrants or rights would expire worthless.

The funds in the Trust Account have, since the IPO, been held only in cash or U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in money market funds investing solely in U.S. government treasury obligations and meeting certain conditions under Rule 2a-7 under the Investment Company Act. To mitigate the risk of us being deemed to have been operating as an unregistered investment company under the Investment Company Act, prior to October 22, 2023, we instructed the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (i.e., in one or more bank accounts) until the earliest of ESGEN’s completion of an initial Business Combination or July 22, 2024, as applicable. Following such liquidation of the assets in the Trust Account, we will likely receive minimal interest, if any, on the funds held in the Trust Account, which would reduce the dollar amount the public shareholders would have otherwise received upon any redemption or liquidation of ESGEN if the assets in the Trust Account had remained in U.S. government securities or money market funds. This means that the amount available for redemption will not increase at the same rate in the future.

In addition, even prior to the 24-month anniversary of the effective date of the IPO Registration Statement, we may be deemed to be an investment company. The longer that the funds in the Trust Account are held in short-term U.S. government treasury obligations or in money market funds invested exclusively in such securities, even prior to the 24-month anniversary of the effective date of the IPO Registration Statement, the greater the risk that we may be considered an unregistered investment company under Section 3(a)(1)(A) of the Investment Company Act, in which case we may be required to liquidate ESGEN. If we are required to liquidate, our shareholders will miss the opportunity to benefit from an investment in a target company and the potential appreciation in value of such investment through a Business Combination. Additionally, if we are required to liquidate, there will be no redemption rights or liquidating distributions with respect to our warrants, which will expire worthless in the event of our winding up. The risk of being deemed subject to the Investment Company Act may increase the longer ESGEN holds securities, and also may increase to the extent the funds in the Trust Account are not held in cash (which may include an interest-bearing demand deposit account at a national bank).

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities

None

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

 

28

Table of Contents

Item 6. Exhibits

 

Exhibit

No.

    Description
3.1    Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on October 25, 2021)
3.2    Amendment to the Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on January 20, 2023)
3.3    Amendment to the Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on October 24, 2023)
3.4    Amendment to the Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on October 24, 2023)
10.1    Amended and Restated Promissory Note in favor of ESGEN LLC, dated October 17, 2023 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on October 17, 2023)
31.1*    Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*    Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**    Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002
32.2**    Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002
101.INS    Inline XBRL Instance Document
101.SCH    Inline XBRL Taxonomy Extension Schema Document
101.CAL    Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF    Inline XBRL Taxonomy Extension Definition Document
101.LAB    Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE    Inline XBRL Taxonomy Extension Presentation Linkbase Document
EX-104    Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 

*

Filed herewith.

**

Furnished herewith.

 

 

29

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 14, 2023     ESGEN Acquisition Corporation
    By:  

/s/ Andrea Bernatova

      Andrea Bernatova
      Chief Executive Officer
Date: November 14, 2023     ESGEN Acquisition Corporation
    By:  

/s/ Nader Daylami

      Nader Daylami
      Chief Financial Officer

 

 

 

30

EX-31.1 2 d500566dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATION

PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrea Bernatova, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 of ESGEN Acquisition Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date:

November 14, 2023

 

By:  

/s/ Andrea Bernatova

Name:   Andrea Bernatova
Title:  

Chief Executive Officer

(Principal Executive Officer)

 

 EX-31.2 3 d500566dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATION

PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Nader Daylami, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 of ESGEN Acquisition Corporation:

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date:

November 14, 2023

 

By:  

/s/ Nader Daylami

Name:   Nader Daylami
Title:  

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

 

 EX-32.1 4 d500566dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ESGEN Acquisition Corporation (the “Company”) on Form 10-Q for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Andrea Bernatova, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2023

 

By:  

/s/ Andrea Bernatova

Name:   Andrea Bernatova
Title:  

Chief Executive Officer

(Principal Executive Officer)

 

 EX-32.2 5 d500566dex322.htm EX-32.2 EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ESGEN Acquisition Corporation (the “Company”) on Form 10-Q for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nader Daylami, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2023

 

By:  

/s/ Nader Daylami

Name:   Nader Daylami
Title:  

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

 EX-101.SCH 6 esac-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Statements of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Statements of Changes in Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1007 - Disclosure - Organization and Business Operation link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Prepaid Expenses link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Accounts Payable and Accrued Expense link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Commitments & Contingencies link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Warrant Liabilities link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Recurring Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Shareholder's Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Prepaid Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Accounts Payable and Accrued Expense (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Recurring Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Organization and Business Operation (Details) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Prepaid Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Accounts Payable and Accrued Expense - Schedule of Company's Accounts Payable and Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Commitments & Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Warrant Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Recurring Fair Value Measurements - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Shareholder's Equity - Preferred Stock Shares (Details) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Shareholder's Equity-Common Stock Shares (Details) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 esac-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 esac-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 esac-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 esac-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2023
Nov. 14, 2023
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2023  
Entity File Number 001-40927  
Entity Registrant Name ESGEN Acquisition Corporation  
Entity Incorporation, State or Country Code E9  
Entity Tax Identification Number 98-1601409  
Entity Address, Address Line One 5956 Sherry Lane  
Entity Address, Address Line Two Suite 1400  
Entity Address, City or Town Dallas  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 75225  
City Area Code 214  
Local Phone Number 987-6100  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company true  
Entity Central Index Key 0001865506  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Class A common stock [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   7,027,632
Title of 12(b) Security Class A ordinary shares included as part of the units  
Trading Symbol ESAC  
Security Exchange Name NASDAQ  
Class B Common Stock [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   1,280,923
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant [Member]    
Document Information [Line Items]    
Title of 12(b) Security Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant  
Trading Symbol ESACU  
Security Exchange Name NASDAQ  
Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50[Member]    
Document Information [Line Items]    
Title of 12(b) Security Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50  
Trading Symbol ESACW  
Security Exchange Name NASDAQ  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash $ 267,058 $ 614,767
Prepaid expenses 4,261 31,110
Total current assets 271,319 645,877
Non-current assets:    
Marketable securities held in Trust Account 32,393,380 285,506,568
Total Assets 32,664,699 286,152,445
Current liabilities:    
Accounts payable and accrued expenses 5,296,038 1,866,992
Due to related party 309,193 144,193
Promissory note—related party 1,409,795 171,346
Total current liabilities 7,015,026 2,182,531
Non-current liabilities:    
Warrant Liabilities 1,002,240 796,224
Deferred underwriters fee 0 9,660,000
Total Liabilities 8,017,266 12,638,755
Commitments and Contingencies
Class A ordinary shares subject to possible redemption, $0.0001 par value; 2,896,555 and 27,600,000 shares at redemption value as of September 30, 2023 and December 31, 2022, respectively 32,393,380 285,506,568
Shareholders' Deficit:    
Preferred shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding 0 0
Accumulated deficit (7,746,637) (11,993,568)
Total shareholders' deficit (7,745,947) (11,992,878)
Total Liabilities, Redeemable Ordinary Shares and Shareholders' Deficit 32,664,699 286,152,445
Class A common stock [Member]    
Shareholders' Deficit:    
Common stock 0 0
Class B Common Stock [Member]    
Shareholders' Deficit:    
Common stock $ 690 $ 690
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Preferred stock, par value, (per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Class A common stock [Member]    
Temporary equity, par value, (per share) $ 0.0001 $ 0.0001
Temporary equity, shares outstanding 2,896,555 27,600,000
Common shares, par value, (per share) $ 0.0001 $ 0.0001
Common shares, shares authorized 250,000,000 250,000,000
Common shares, shares issued 0 0
Common shares, shares outstanding 0 0
Class B Common Stock [Member]    
Common shares, par value, (per share) $ 0.0001 $ 0.0001
Common shares, shares authorized 25,000,000 25,000,000
Common shares, shares issued 6,900,000 6,900,000
Common shares, shares outstanding 6,900,000 6,900,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Legal and professional fees $ 707,780 $ 145,588 $ 3,752,583 $ 937,110
Insurance 2,913 133,302 25,479 395,559
Other operating costs 88,307 20,385 296,231 181,339
Operating cost—related party 30,000 30,000 90,000 90,000
Loss from operations (829,000) (329,275) (4,164,293) (1,604,008)
Other income (expense):        
Dividends earned on marketable securities held in Trust Account 413,940 1,245,745 1,719,810 1,632,690
Recovery of offering costs related to the IPO allocated to warrants 0 0 425,040 0
Change in fair value of warrant liabilities 1,046,784 3,345,600 (206,016) 11,608,560
Total other income, net 1,460,724 4,591,345 1,938,834 13,241,250
Net income (loss) $ 631,724 $ 4,262,070 $ (2,225,459) $ 11,637,242
Class A common stock [Member]        
Other income (expense):        
Weighted Average Number of Shares Outstanding, Basic 2,896,555 27,600,000 4,615,842 27,600,000
Weighted Average Number of Shares Outstanding, Diluted 2,896,555 27,600,000 4,615,842 27,600,000
Basic net income (loss) per share $ 0.25 $ 0.13 $ (1.03) $ 0.35
Diluted net income (loss) per share $ 0.25 $ 0.13 $ (1.03) $ 0.35
Class B Common Stock [Member]        
Other income (expense):        
Weighted Average Number of Shares Outstanding, Basic 6,900,000 6,900,000 6,900,000 6,900,000
Weighted Average Number of Shares Outstanding, Diluted 6,900,000 6,900,000 6,900,000 6,900,000
Basic net income (loss) per share $ (0.01) $ 0.09 $ 0.37 $ 0.29
Diluted net income (loss) per share $ (0.01) $ 0.09 $ 0.37 $ 0.29
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Changes in Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit - USD ($)
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Class A common stock [Member]
Common Stock [Member]
Class B Common Stock [Member]
Common Stock [Member]
Balance at the beginning at Dec. 31, 2021 $ (22,340,560)   $ 0 $ (22,341,250) $ 281,520,000 $ 690
Balance at the beginning (in shares) at Dec. 31, 2021         27,600,000 6,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Accretion of ordinary shares subject to possible redemption (20,308)     (20,308) $ 20,308  
Net income (loss) 5,880,541     5,880,541    
Balance at the end at Mar. 31, 2022 (16,480,327)   0 (16,481,017) $ 281,540,308 $ 690
Balance at the end (in shares) at Mar. 31, 2022         27,600,000 6,900,000
Balance at the beginning at Dec. 31, 2021 (22,340,560)   0 (22,341,250) $ 281,520,000 $ 690
Balance at the beginning (in shares) at Dec. 31, 2021         27,600,000 6,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) 11,637,242 $ 11,637,242        
Balance at the end at Sep. 30, 2022 (12,338,145)   0 (12,338,835) $ 283,154,827 $ 690
Balance at the end (in shares) at Sep. 30, 2022         27,600,000 6,900,000
Balance at the beginning at Mar. 31, 2022 (16,480,327)   0 (16,481,017) $ 281,540,308 $ 690
Balance at the beginning (in shares) at Mar. 31, 2022         27,600,000 6,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Accretion of ordinary shares subject to possible redemption (368,774)     (368,774) $ 368,774  
Net income (loss) 1,494,631     1,494,631    
Balance at the end at Jun. 30, 2022 (15,354,470)   0 (15,355,160) $ 281,909,082 $ 690
Balance at the end (in shares) at Jun. 30, 2022         27,600,000 6,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Accretion of ordinary shares subject to possible redemption (1,245,745)     (1,245,745) $ 1,245,745  
Net income (loss) 4,262,070 4,262,070   4,262,070    
Balance at the end at Sep. 30, 2022 (12,338,145)   0 (12,338,835) $ 283,154,827 $ 690
Balance at the end (in shares) at Sep. 30, 2022         27,600,000 6,900,000
Balance at the beginning at Dec. 31, 2022 (11,992,878)   0 (11,993,568) $ 285,506,568 $ 690
Balance at the beginning (in shares) at Dec. 31, 2022         27,600,000 6,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Accretion of ordinary shares subject to possible redemption (1,288,233)     (1,288,233) $ 1,288,233  
Redemption of Class A ordinary shares subject to possible redemption         $ (255,875,758)  
Redemption of Class A ordinary shares subject to possible redemption (in shares)         (24,703,445)  
Net income (loss) (1,446,111)     (1,446,111)    
Balance at the end at Mar. 31, 2023 (14,727,222)   0 (14,727,912) $ 30,919,043 $ 690
Balance at the end (in shares) at Mar. 31, 2023         2,896,555 6,900,000
Balance at the beginning at Dec. 31, 2022 (11,992,878)   0 (11,993,568) $ 285,506,568 $ 690
Balance at the beginning (in shares) at Dec. 31, 2022         27,600,000 6,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Waiver of deferred underwriters fee 9,234,960          
Net income (loss) (2,225,459) (2,225,459)        
Balance at the end at Sep. 30, 2023 (7,745,947)   0 (7,746,637) $ 32,393,380 $ 690
Balance at the end (in shares) at Sep. 30, 2023         2,896,555 6,900,000
Balance at the beginning at Mar. 31, 2023 (14,727,222)   0 (14,727,912) $ 30,919,043 $ 690
Balance at the beginning (in shares) at Mar. 31, 2023         2,896,555 6,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Accretion of ordinary shares subject to possible redemption (712,810)     (712,810) $ 712,810  
Waiver of deferred underwriters fee 9,234,960     9,234,960    
Net income (loss) (1,411,072)     (1,411,072)    
Balance at the end at Jun. 30, 2023 (7,616,144)   0 (7,616,834) $ 31,631,853 $ 690
Balance at the end (in shares) at Jun. 30, 2023         2,896,555 6,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Accretion of ordinary shares subject to possible redemption (761,527)     (761,527) $ 761,527  
Net income (loss) 631,724 $ 631,724   631,724    
Balance at the end at Sep. 30, 2023 $ (7,745,947)   $ 0 $ (7,746,637) $ 32,393,380 $ 690
Balance at the end (in shares) at Sep. 30, 2023         2,896,555 6,900,000
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from Operating Activities:    
Net (loss) income $ (2,225,459) $ 11,637,242
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:    
Dividends earned on marketable securities held in Trust Account 0 (1,632,690)
Recovery of offering costs related to the IPO allocated to warrants (425,040) 0
Change in fair value of warrant liabilities 206,016 (11,608,560)
Changes in current assets and liabilities:    
Prepaid expenses 26,849 402,258
Accounts payable and accrued expenses 3,429,046 678,120
Due to related party 165,000 90,000
Net cash provided by (used in) operating activities 1,176,412 (433,630)
Cash flows from investing activities:    
Reinvestment of marketable securities held in Trust Account (1,719,810) 0
Extension funding of Trust Account (1,042,760) 0
Cash withdrawn from Trust Account in connection with redemption 255,875,758 0
Net cash provided by investing activities 253,113,188 0
Cash flows from financing activities:    
Redemption of Class A ordinary shares subject to possible redemption (255,875,758) 0
Proceeds from note payable-related party 1,238,449 0
Net cash used in financing activities (254,637,309) 0
Net change in cash (347,709) (433,630)
Cash, beginning of the period 614,767 1,323,903
Cash, end of the period 267,058 890,273
Supplemental disclosure of cash flow information:    
Change in value of Class A ordinary shares subject to possible redemption 2,762,570 1,634,827
Impact of the waiver of deferred underwriters fee $ 9,234,960 $ 0
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Business Operation
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Business Operation
Note 1 — Organization and Business Operation
ESGEN Acquisition Corporation (the “Company”) was incorporated as a Cayman Islands exempted company on April 19, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company.
As of September 30, 2023, the Company had not commenced any operations. All activity for the period from April 19, 2021 (inception) through September 30, 2023, relates to the Company’s formation and the initial public offering (“Public Offering” or “IPO”) described below and since the closing of the IPO, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate
non-operating
income in the form of interest or dividend income on cash and cash equivalents from the proceeds derived from the Public Offering (as defined below).
The Company’s sponsor is ESGEN LLC, a Delaware limited liability company (the “Sponsor”).
The registration statement for the Company’s IPO was declared effective on October 19, 2021. On October 22, 2021, the Company consummated its IPO of 27,600,000 units (the “Units” and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”) at $10.00 per Unit and the sale of 14,040,000 warrants (the “Private Placement Warrants”) each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor that closed simultaneously with the Public Offering.
The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred
underwriters fee
 
and taxes payable on the interest or dividends earned on the Trust Account) at the time of signing a definitive agreement in connection with the initial Business Combination. However, the Company will complete the initial Business Combination only if the post-Business Combination company in which its public shareholders own shares will own or acquire 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act (the “Investment Company Act”). There is no assurance that the Company will be able to complete a Business Combination successfully.
Following the closing of the IPO on October 22, 2021, $281,520,000 ($10.20 per Unit) from the net proceeds sold in the IPO, including proceeds of the sale of the Private Placement Warrants, was deposited in a trust account (“Trust Account”) and, until October 16, 2023, was only invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. To mitigate the risk of being deemed to have been operating as an unregistered investment company under the Investment Company Act, on October 16, 2023, the Company instructed the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in demand deposits (i.e., in one or more bank accounts) until the earliest of ESGEN’s completion of an initial business combination or J
anuary 22, 2024 (unless extended as described below), as applicable.
Except with respect to interest or other income earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the amended and restated memorandum and articles of association, as discussed below and subject to the requirements of law and regulation, will provide that the proceeds from the Public Offering and the sale of the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the public shareholders, until the earliest of (a) the completion of the initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, subject to the limitations described herein, (b) the redemption of any public shares properly
tendered in connection with a shareholder vote to amend the amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company did not complete its initial Business Combination within 15 months (which was extended pursuant to shareholder approval of the Charter Amendment (as defined below)) from the closing of this offering (the “Combination Period”) or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares, and (c) the redemption of the public shares if the Company has not consummated the Business Combination within Combination Period, subject to applicable law. Public shareholders who redeem their Class A ordinary shares in connection with a shareholder vote described in clause (b) in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within Combination Period, with respect to such Class A ordinary shares so redeemed.
The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek shareholder approval under applicable law or stock exchange listing requirement.
The Company will provide its public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of its initial Business Combination at a
per-share
price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest or dividends earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then-outstanding public shares, subject to the limitations described herein. The amount in the Trust Account is initially $10.20 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred
underwriters fee
 
the Company will pay to the underwriters.
The ordinary shares subject to redemption were recorded at redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.
The Company has until
January 22, 2024 (unless extended as described below),
as
 described in Note 10, to consummate the initial Business Combination. If the Company has not consummated the initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at
a per-share
price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest or dividends earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest or dividends to pay winding up and dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
 
On January 18, 2023, the Company held an extraordinary general meeting of shareholders to consider and vote upon, among other things, a proposal to amend the Company’s amended and restated memorandum and articles of association (the “First Extension Charter Amendment”) to (i) extend the date by which the Company must consummate its initial Business Combination (the “Termination Date”) from January 22, 2023 to April 22, 2023 and (ii) in the event that the Company has not consummated an initial business combination by April 22, 2023, to allow the Company, by resolution of the Company’s board of directors (the “Board”) and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to each Additional Extension, to extend the Termination Date up to six times (with each such extension being upon five days’ advance notice), each by one additional month (for a total of up to six additional months to complete a business combination) (each, an “Additional Extension” and such date, the “Additional Extension Date”), provided that the Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (a) $140,000 or (b) $0.04 for each Public Share that is then-outstanding, in exchange for one or more non-interest bearing, unsecured promissory notes issued by the Company to the Sponsor or the Sponsor’s affiliates or permitted designees (the “Lenders” and each a “Lender”). In connection with the vote to approve the First Extension Charter Amendment, the holders of 24,703,445 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.35 per share, for an aggregate redemption amount of approximately $255,875,758.
The Sponsor and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares; (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem
100
% of the public shares if the Company did not complete its initial Business Combination within
15
months from the closing of the Public Offering (which was extended pursuant to shareholder approval of the Charter Amendment) or (B) with respect to any other provision relating to the rights of holders of the Company’s Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an initial Business Combination within Combination Period.
The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company’s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per public share due to reductions in the value of the Trust Account, in each case net of the interest or dividends that may be withdrawn to pay the Company’s income tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.
On October 20, 2023, at the Company’s extraordinary general meeting, the shareholders approved, among other proposals, (i) (a) the extension (such proposal, the “Extension Proposal”) of the time period the Company has to complete an initial Business Combination from October 22, 2023 to January 22, 2024 (the “Charter Amendment”) and (b) in the event that the Company has not consummated an initial Business Combination by January 22, 2024, to allow the Company, by resolution of the Board and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to each Additional Extension, to complete six Additional Extensions, provided that the Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (x) $35,000 or (y) $0.0175 for each Public Share that is then-outstanding, in exchange for one or more non-interest bearing, unsecured promissory notes issued by a Lender, and (ii) the amendment of the Company’s amended and restated memorandum and articles of association to change certain provisions which restrict the Class B ordinary shares, par value $0.0001, of the Company (the “Class B ordinary shares”) from converting to Class A ordinary shares, par value $0.0001 (the “Class A ordinary shares”) prior to the consummation of an initial
Business Combination (such proposal, the “Conversion Proposal”).
 
Founder Shares
Founder Shares refers to the Class B ordinary shares (the “Founder Shares”) acquired by the initial shareholders prior to the Company’s IPO.
The initial shareholders and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of the Business Combination; (ii) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with a shareholder vote to approve an amendment to the amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the Business Combination or to redeem 100% of the Company’s public shares if it does not complete the Business Combination by the Termination Date or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an Business Combination by the Termination Date (although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the Business Combination within the prescribed time frame). If the Company seeks shareholder approval, it will complete the Business Combination only if it is approved by an ordinary resolution or such higher approval threshold as may be required by Cayman Islands law and pursuant to the amended and restated memorandum and articles of association. In such case, the initial shareholders and each member of the management team have agreed to vote their Founder Shares and Public Shares in favor of the Business Combination.
In connection with the approval of the Conversion Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor converted all of its 5,619,077 Class B ordinary shares into Class A ordinary shares (the “Sponsor Share Conversion”). As a result of the Sponsor Share Conversion and redemptions made in connection with the Extension Proposal and Conversion Proposal, 7,027,632 Class A ordinary shares remain outstanding. Notwithstanding the Sponsor Share Conversion, the Sponsor will be not entitled to receive any funds held in the Trust Account with respect to any Class A ordinary shares issued to the Sponsor as a result of the Sponsor Share Conversion and no additional amounts will be deposited into the Trust Account in respect of shares of Class A ordinary shares held by the Sponsor in connection with the extension of the Termination Date to the Extended Date or any Additional Extension Dates.
Risks and Uncertainties
The credit and financial markets have experienced extreme volatility and disruptions due to the current conflict between Ukraine and Russia. The conflict is expected to have further global economic consequences, including but not limited to the possibility of severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in inflation rates and uncertainty about economic and political stability. In addition, the United States and other countries have imposed sanctions on Russia which increases the risk that Russia, as a retaliatory action, may launch cyberattacks against the United States, its government, infrastructure and businesses. Any of the foregoing consequences, including those we cannot yet predict, may cause our business, financial condition, results of operations and the price of our ordinary shares to be adversely affected.
Going Concern
As of September 30, 2023, the Company had $267,058 in cash held outside of the Trust Account and owes $5,296,038 in accounts payable and accrued expenses and $1,718,988 to related parties. The Company anticipates that the cash held outside of the Trust Account as of September 30, 2023 will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans.
In connection with the Company’s assessment of going concern considerations in accordance with ASC Subtopic
205-40,
“Presentation of Financial Statements – Going Concern”, the Company has until January 22, 2024 to consummate a Business Combination. If a Business Combination is not consummated by this date and an Additional Extension not obtained, there will be a mandatory liquidation and subsequent dissolution of the Company. It is uncertain whether the Company will be able to consummate a Business Combination by this time. Management has determined that the mandatory liquidation, should a Business Combination not occur, and an extension is not obtained, as well as the potential for us to have insufficient funds available to operate our business prior to a Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Accounting Policies
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Significant Accounting Policies
Note 2 — Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and Article 8 of Regulation
S-X
of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on
Form 10-K,
which contains the initial audited financial statements and notes thereto for the period ended December 31, 2022, as filed with the SEC on March 31, 2023. The interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the period ending December 31, 2023 or for any future interim periods.
The breakout of loss from operations on the condensed statement of operations for the three and nine months ended September 30, 2022, has been revised to conform to the current presentation. This presentation did not impact any other financial statement line items.
Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
 
Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of September 30, 2023 and December 31, 2022, respectively.
Marketable Securities Held in Trust Account
Substantially all of the assets held in the Trust Account were held in U.S. Money Market Funds. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in investment income on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information.
Fair Value Measurement
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the balance sheet, primarily due to its short-term nature.
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level 1, Level 2 or Level 3. These tiers include:
 
  •
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
  •
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
  •
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheets as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Warrant Liabilities
The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC Topic
815-40
and ASC Topic 480. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. These liabilities are subject to
re-measurement
at each balance sheet date. With each such
re-measurement,
the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations.
 
Net Income (Loss) Per Ordinary Share
The Company has two classes of shares, which are referred to as redeemable Class A ordinary shares and
non-redeemable
Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. With respect to the accretion of Class A ordinary shares subject to possible redemption, the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share.
The earnings per share presented in the statement of operations is based on the following:
 
    
For the Three Months Ended

September 30,
     
For the Nine Months Ended

September 30,
  
    
2023
     
2022
     
2023
     
2022
  
                             
Net income (loss)
    $    631,724      $ 4,262,070      $ (2,225,459 )     $ 11,637,242  
Accretion of temporary equity to redemption value
      (761,527 )       (1,245,745 )       6,472,390        (1,632,690 ) 
  
 
 
     
 
 
     
 
 
     
 
 
  
Net income including accretion of temporary equity to redemption value
    $ (129,803 )     $     3,016,325      $ 4,246,931      $ 10,004,552  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
    
For the Three Months Ended

September 30,
  
    
2023
     
2022
  
    
Redeemable
Class A
     
Non-redeemable

Class B
     
Redeemable
Class A
     
Non-redeemable

Class B
  
                             
Basic and diluted net income (loss) per share:
            
Numerator:
            
Allocation of net income including accretion of temporary equity
    $ (38,941 )     $ (90,861 )     $ 2,413,060      $ 603,265  
Allocation of accretion of temporary equity to redemption value
      761,527        —          1,245,745        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
Allocation of net income (loss)
    $ 722,586      $ (90,861 )     $ 3,658,805      $ 603,265  
  
 
 
     
 
 
     
 
 
     
 
 
  
Denominator:
            
Weighted-average shares outstanding
      2,896,555        6,900,000        27,600,000        6,900,000  
Basic and diluted net income (loss) per share
    $ 0.25      $ (0.01 )     $ 0.13      $ 0.09  
 
    
For the Nine Months Ended

September 30,
  
    
2023
     
2022
  
    
Redeemable
Class A
     
Non-redeemable

Class B
     
Redeemable
Class A
     
Non-redeemable

Class B
  
                             
Basic and diluted net (loss) income per share:
            
Numerator:
            
Allocation of net income including accretion of temporary equity
    $ 1,698,772      $ 2,548,159      $ 8,003,642      $ 2,000,910  
Allocation of accretion of temporary equity to redemption value
      (6,472,390 )       —          1,632,690        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
Allocation of net (loss) income
    $ (4,773,618 )     $ 2,548,159      $ 9,636,332      $ 2,000,910  
  
 
 
     
 
 
     
 
 
     
 
 
  
Denominator:
            
Weighted-average shares outstanding
      4,615,842        6,900,000        27,600,000        6,900,000  
Basic and diluted net (loss) income per share
    $ (1.03 )     $ 0.37      $ 0.35      $ 0.29  
 
Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding during the period. The Company has not considered the effect of the 27,840,000 ordinary shares issuable upon exercise of the Public Warrants and Private Placement Warrants in the calculation of diluted income (loss) per share, since
th
e exercise of such warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares sold in the IPO feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events.
The Company has made a policy election in accordance with
ASC 480-10-S99-3A
and recognizes changes in redemption value in additional
paid-in
capital (or accumulated deficit in the absence of additional
paid-in
capital) immediately as they occur. The Company recorded accretion of $761,527 and $2,762,570 in accumulated deficit for three and nine months ended September 30, 2023, respectively, and $1,245,745 and $1,634,827 in accumulated deficit for the three and nine months ended September 30, 2022, respectively. For the period ended September 30, 2023, the Company recorded redemption of $255,875,758 and $1,042,760 was deposited in the Trust Account for extension funding.
Income Taxes
The Company accounts for income taxes under ASC Topic 740, “Income Taxes” (“ASC 740”).
ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2023 and December 31, 2022.
The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s unaudited condensed financial statements. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September 30, 2023 and December 31, 2022, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
Recent Accounting Pronouncements
Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions
Note 3 — Related Party Transactions
Promissory Notes — Related Party
On April 27, 2021, the Sponsor agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the Public Offering. The Company borrowed a total of $262,268. This loan was
non-interest
bearing, unsecured and due at the earlier of December 31, 2021 or the closing of the Public Offering. The loan was to be repaid upon the closing of the Public Offering out of the offering proceeds not held in the Trust Account. In connection with the closing of the Public Offering, the Company paid down $90,922 of the outstanding balance. As of September 30, 2023 and December 31, 2022, the Company had $171,346 outstanding under the promissory note and as is included on the balance sheet as promissory note
—
related party. The Sponsor has agreed to defer repayment of the loan until the close of the Business Combination.
On April 5, 2023, the Company issued an unsecured promissory note (the “Note”) in the principal amount of up to $1,500,000 to the Sponsor, which may be drawn down by the Company from time to time prior to the consummation of the Company’s Business Combination. The Note does not bear interest, matures on the date of consummation of the Business Combination and is subject to customary events of default. As of September 30, 2023, the Company had $1,238,449 outstanding under the Note and is included on the balance sheet as promissory note
—
related party.
In addition, on October 17, 2023, the Company issued an amended and restated promissory note (the “Restated Note”) in the principal amount of up to $2,500,000 to the Sponsor. The Restated Note amends, restates, replaces and supersedes
 
the Note
 dated April 5, 2023, in the principal amount of $1,500,000. The Restated Note may be drawn down by the Company from time to time prior to the consummation of the Company’s initial Business Combination. The Restated Note does not bear interest, matures on the date of consummation the Business Combination and is subject to customary events of default. The Restated Note will be repaid only to the extent that the Company has funds available to it outside of its Trust Account (see Note 10).
Working Capital Loans
In order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. As of September 30, 2023 and December 31, 2022, the Company had no borrowings under the Working Capital Loans.
Office Space, Secretarial and Administrative Services
Through the earlier of consummation of the initial Business Combination and the liquidation, the Company incurs $10,000 per month for office space, utilities, secretarial support and administrative services provided by the Sponsor. For the three and nine months ended September 30, 2023, the Company has incurred $30,000 and $90,000, respectively. No amounts have been paid for these services. For the three and nine months ended September 30, 2022, the Company incurred $30,000 and $90,000, respectively. No amounts have been paid for these services. As of September 30, 2023 and December 31, 2022, the Company reported on the balance sheets $165,000 and $120,000, respectively, pursuant to this agreement, in “Due to related party”.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Prepaid Expenses
 9 Months Ended
Sep. 30, 2023
Prepaid Expense, Current [Abstract]  
Prepaid Expenses
Note 4 — Prepaid Expenses
The Company’s prepaid expenses as of September 30, 2023 and December 31, 2022 primarily consisted of the following:
 
    
September 30, 2023
     
December 31, 2022
  
               
Prepaid insurance
    $ 602      $ 26,081  
Other prepaid expenses
      3,659        5,029  
  
 
 
     
 
 
  
   $ 4,261      $ 31,110  
  
 
 
     
 
 
  
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts Payable and Accrued Expense
 9 Months Ended
Sep. 30, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Accounts Payable and Accrued Expense
Note 5 — Accounts Payable and Accrued Expense
The Company’s accounts payable and accrued expenses as of September 30, 2023 and December 31, 2022 primarily consisted of legal accruals.
 
    
September 30, 2023
     
December 31, 2022
  
               
Legal accrual
    $ 5,041,722      $ 1,705,049  
Other payables and expenses
      254,316        161,943  
  
 
 
     
 
 
  
   $ 5,296,038      $ 1,866,992  
  
 
 
     
 
 
  
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments & Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments & Contingencies
Note 6 — Commitments & Contingencies
Registration and Shareholder Rights
The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable
lock-up
period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the private placement warrants and the respective Class A ordinary shares issuable upon exercise of the private placement warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Working Capital Loans and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company’s register such securities.
In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Except as described herein, the Sponsor and its directors and executive officers have agreed not to transfer, assign or sell any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any
30-trading
day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company complete a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property. Any permitted transferees would be subject to the same restrictions and other agreements of the Sponsor and its directors and executive officers with respect to any founder shares. Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor with respect to any Founder Shares. The Company refers to such transfer restrictions throughout the Public Offering as the lock- up.
 
In addition, pursuant to the registration and expected shareholder rights agreement, the Sponsor, upon and following consummation of an initial Business Combination, will be entitled to nominate three individuals for election to the board of directors, as long as the Sponsor holds any securities covered by the registration and expected shareholder rights agreement.
Underwriting Agreement
The underwriters were entitled to a deferred
underwriters fee
of 3.5% of the gross proceeds of the Public Offering upon the completion of the Company’s initial Business Combination. In April 2023, the underwriters waived any right to receive the deferred
underwriters fee
and will therefore receive no additional
underwriters fee
in connection with the Closing. As a result, the Company recognized $425,040 of other income on the statement of operations and $9,234,960 was recorded to accumulated deficit on the statements of changes in ordinary shares subject to possible redemption and shareholders’ deficit in relation to the reduction of the deferred underwriter
s
fee. As of September 30, 2023 and December 31, 2022, the deferred underwrit
ers
fee is $0 and $9,660,000, respectively.
To account for the waiver of the deferred
underwriters
fee, the Company analogized to the SEC staff’s guidance on accounting for reducing a liability for “trailing fees”. Upon the waiver of the deferred
underwriters
fee, the Company reduced the deferred
underwriters fee
to $0 and reversed the previously recorded cost of issuing the instruments in the IPO, which included recognizing a contra-expense of $425,040, which is the amount previously allocated to liability classified warrants and expensed upon the IPO, and reduced the accumulated deficit and increased income available to Class B ordinary shares by $9,234,960, which was previously allocated to the Class A ordinary shares subject to redemption and accretion recognized at the IPO date.
Proposed Business Combination
On April 19, 2023, the Company entered into a Business Combination Agreement, by and among the Company, ESGEN OpCo, LLC, a Delaware limited liability company and wholly-owned subsidiary of ESGEN (“OpCo”), Sunergy Renewables, LLC, a Nevada limited liability company (“Sunergy”), the Sunergy equityholders set forth on the signature pages thereto (collectively, “Sellers” and each, a “Seller”, and collectively with Sunergy, the “Sunergy Parties”), for limited purposes, the Sponsor, and for limited purposes, Timothy Bridgewater, an individual, in his capacity as the Sellers Representative (the “Business Combination Agreement”).
In accordance with the terms and subject to the conditions of the Business Combination Agreement, among other things: (i) prior to the consummation of the Business Combination (the “Closing”), each issued and outstanding Class B ordinary share of ESGEN will convert into one Class A ordinary share of ESGEN (the “ESGEN Share Conversion”); and (ii) following the ESGEN Share Conversion but prior to the Closing, ESGEN will, subject to the receipt of the requisite shareholder approval, transfer by way of continuation from the Cayman Islands to the State of Delaware and domesticate as a Delaware corporation (the “Domestication”) and will change its name as to be determined by the parties to the Business Combination Agreement (“New PubCo”).
In connection with the Domestication, (A) each outstanding Class A ordinary share will become one share of Class A common stock, par value $0.0001 per share, of New PubCo (the “New PubCo Class A Common Stock”), (B) each outstanding warrant to purchase one Class A ordinary share (each, an “ESGEN Warrant”) will become a warrant to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share, and (C) New PubCo will file its certificate of incorporation and will adopt bylaws to serve as its governing documents upon consummation of the Domestication. In connection with the ESGEN Share Conversion and the Domestication, each issued and outstanding unit of ESGEN, each consisting of one Class A ordinary share and
one-half
of one ESGEN Warrant (each, an “ESGEN Unit”), that has not been previously separated into the underlying Class A ordinary shares and underlying ESGEN Warrants prior to the Domestication will be cancelled and will entitle the holder thereof to (x) one share of New PubCo Class A Common Stock and
(y) 
one-half
of one warrant representing the right to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share on the terms and subject to the conditions applicable to ESGEN Warrants set forth in the Warrant Agreement, dated as of October 22, 2021, between ESGEN and Continental Stock Transfer & Trust Company (the “Trustee”).
 
In accordance with the terms and subject to the conditions of the Business Combination Agreement, Sunergy will cause all holders of any options, warrants or rights to subscribe for or purchase any equity interests of Sunergy or its subsidiaries or securities (including debt securities) convertible into or exchangeable for, or that otherwise confer on the holder any right to acquire, any equity interests of Sunergy or any subsidiary thereof (collectively, the “Sunergy Convertible Interests”) existing immediately prior to the Closing either to exchange or convert all such holder’s Sunergy Convertible Interests into limited liability interests of Sunergy (the “Sunergy Company Interests”) in accordance with the governing documents of Sunergy or the Sunergy Convertible Interests (collectively, the “Sunergy Exchanges”).
At the Closing, ESGEN will contribute to OpCo (1) all of its assets (excluding its interests in OpCo, but including the amount of cash in the Trust Account as of immediately prior to the Closing (after giving effect to the exercise of redemption rights by any ESGEN shareholders)), and (2) a number of newly issued shares of Class V common stock of ESGEN, par value $0.0001 per share, which will generally have only voting rights (the “ESGEN Class V Common Stock”), equal to the number of Seller OpCo Units (as defined in the Business Combination Agreement) (the “Seller Class V Shares”) and (y) in exchange, OpCo shall issue to ESGEN (i) a number of common units of OpCo (the “OpCo Units”) which shall equal the number of total shares of ESGEN Class A Common Stock issued and outstanding immediately after the Closing and (ii) a number of warrants to purchase OpCo Units which shall equal the number of SPAC Warrants issued and outstanding immediately after the Closing (the transactions described above in this paragraph, the “ESGEN Contribution”). Immediately following the ESGEN Contribution, (x) the Sellers will contribute to OpCo the Sunergy Company Interests and (y) in exchange therefor, OpCo will transfer to the Sellers the Seller OpCo Units and the Seller Class V Shares.
The obligation of ESGEN, the Sunergy Parties and OpCo to consummate the Business Combination is subject to certain customary closing conditions, including, but not limited to, (i) the absence of any order, law or other legal restraint or prohibition enacted, issued or promulgated by any court of competent jurisdiction or other governmental entity of competent jurisdiction having the effect of making the Business Combination illegal or otherwise prohibiting the consummation of the Business Combination, (ii) the termination or expiration of any applicable waiting period applicable to the consummation of the Business Combination under the Hart-Scott-Rodino Act, (iii) the effectiveness of the Registration Statement on Form S-4 (the “Registration Statement”) in accordance with the provisions of the Securities Act, registering the ESGEN Class A Common Stock to be issued in connection with the Business Combination Agreement, (iv) receipt of the required approvals of ESGEN’s shareholders at a meeting of the shareholders of ESGEN in connection with the Business Combination, (v) the ESGEN Class A Common Stock to be issued in connection with the Business Combination immediately after Closing shall be listed on Nasdaq and ESGEN will be able to satisfy any continued listing requirements of Nasdaq immediately after Closing, (vi) if the ESGEN shareholders do not approve the Redemption Limitation Amendment (as defined in the Business Combination Agreement), ESGEN having at least $5,000,001 of net tangible assets (as determined in accordance with Rule 3a5-51(g)(1) of the Exchange Act) remaining immediately after any holders of the ESGEN Class A Ordinary Shares exercise their redemption rights, (vii) the members of the post-Business Combination ESGEN board of directors shall have been elected or appointed in accordance with the Business Combination Agreement and (viii) the aggregate transaction proceeds, including from the Trust Account after giving effect to the exercise of redemption rights by any ESGEN shareholders pursuant to the ESGEN amended and restated memorandum and articles of association, as amended, and the proceeds resulting from the Initial PIPE Investment (as defined below) and any financing agreements executed in furtherance of the Business Combination Agreement, shall be greater or equal to $20,000,000.
 
Concurrently with the execution of the Business Combination Agreement, ESGEN entered into a subscription agreement (the “Initial Subscription Agreement”) with Sponsor. Pursuant to the Initial Subscription Agreement, Sponsor agreed to subscribe for and purchase, and ESGEN agreed to issue and sell to Sponsor, concurrently with the Closing, an aggregate of 1,000,000 shares of ESGEN Class A Common Stock for a purchase price of $10.00 per share, for aggregate gross proceeds of $10,000,000 (the “Initial PIPE Investment”). The closing of the Initial PIPE Investment is contingent upon, among other things, the substantially concurrent consummation of the Business Combination. The Initial Subscription Agreement provides that ESGEN will grant Sponsor certain customary registration rights. In addition to the Initial PIPE Investment, under the Business Combination Agreement, ESGEN and Sunergy have agreed to use their reasonable best efforts to identify other investors to enter into equity financing agreements (the “Additional Financing Agreements” and, together with the Initial Subscription Agreement, the “Financing Agreements”), in form and substance reasonably acceptable to ESGEN and Sunergy, to support the transaction (such equity financing under the Financing Agreements, collectively, herein referred to as the “Private Placements”).
The Business Combination is expected to close in the first quarter of 2024, following the receipt of the required approvals by our shareholders and the fulfillment of other customary closing conditions.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Warrant Liabilities
 9 Months Ended
Sep. 30, 2023
Warrant Liabilities  
Warrant Liabilities
Note 7 — Warrant Liabilities
The Company accounts for the 27,840,000 warrants issued in connection with the Public Offering (13,800,000 Public Warrants and 14,040,000 Private Placement Warrants) in accordance with the guidance contained in ASC Topic
815-40.
Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company classifies each warrant as a liability at its fair value. This liability is subject to remeasurement at each balance sheet date.
With each such remeasurement, the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations.
Public Warrants
Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described adjacent to “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described adjacent to the caption “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.
The warrants will become exercisable 30 days after the completion of the Company’s initial Business Combination and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.
 
The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, it will use its commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement of which this prospectus forms a part or a new registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, it will not be required to file or maintain in effect a registration statement, but the Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60
th
day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption, but it will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value and (B) 0.361. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent.
Redemption of warrants when the price per Class
 A ordinary share equals or exceeds $18.00.
Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants (except as described herein with respect to the Private Placement Warrants):
 
  •
in whole and not in part;
 
  •
at a price of $0.01 per warrant;
 
  •
upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and
 
  •
if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within a 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders.
Redemption of warrants when the price per Class
 A ordinary share equals or exceeds $10.00.
Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants:
 
  •
in whole and not in part;
 
  •
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; and
 
  •
if, and only if, the closing price of the Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within the
30-trading
day period ending three trading days before the Company sends the notice of redemption to the warrant holders;
 
Private Warrants
If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units sold in the Public Offering. Any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants will require a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants.
The accounting treatment of derivative financial instruments requires that the Company record a derivative liability upon the closing of the IPO. Accordingly, the Company has classified each warrant as a liability at its fair value and the warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value.
These liabilities are
subject to
re-measurement
at each balance sheet date. With each such
re-measurement,
the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Recurring Fair Value Measurements
 9 Months Ended
Sep. 30, 2023
Derivative Instrument Detail [Abstract]  
Recurring Fair Value Measurements
Note 8 — Recurring Fair Value Measurements
As of September 30, 2023 and December 31, 2022, investments held in the Trust Account are determined by Level 1 inputs utilizing quoted prices (unadjusted) in active markets for identical assets.
The Company’s Public Warrants are traded on the Nasdaq. As such, the Public Warrant valuation is based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. The fair value of the Public Warrant liabilities is classified within Level 1 of the fair value hierarchy.
At September 30, 2023 and December 31, 2022, the Company considers the Private Warrants to be economically equivalent to the Public Warrants. As such, the valuation of the Public Warrants was used to value the Private Warrants. The fair value of the Private Warrant liabilities is classified within Level 2 of the fair value hierarchy.
The following tables presents fair value information as of September 30, 2023 and December 31, 2022 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.
 
    
September 30, 2023
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
                             
Assets:
                                    
Marketable securities held in Trust Account
    $   32,393,380      $ —        $ —        $   32,393,380  
Liabilities:
                                    
Public Warrants
      496,800        —          —          496,800  
Private Warrants
      —          505,440        —          505,440  
    
 
 
     
 
 
     
 
 
     
 
 
  
Total liabilities
    $ 496,800      $ 505,440      $ —        $ 1,002,240  
    
 
 
     
 
 
     
 
 
     
 
 
  
 
    
December 31, 2022
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
                             
Assets:
                                    
Marketable securities held in Trust Account
    $ 285,506,568      $ —        $ —        $ 285,506,568  
Liabilities:
                                    
Public Warrants
      394,680        —          —          394,680  
Private Warrants
      —          401,544        —          401,544  
    
 
 
     
 
 
     
 
 
     
 
 
  
Total liabilities
    $ 394,680      $ 401,544      $ —        $ 796,224  
    
 
 
     
 
 
     
 
 
     
 
 
  
There were no transfers to or from Levels 1, 2 or 3 for the three or nine months ended September 30, 2023 or 2022.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholder's Equity (Deficit)
 9 Months Ended
Sep. 30, 2023
Stockholders' Equity Note [Abstract]  
Shareholder's Equity (Deficit)
Note 9 — Shareholders’ Deficit
Preference shares
— The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2023 and December 31, 2022, there were no preference shares issued or outstanding.
Class
 A ordinary shares
— The Company is authorized to issue 250,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of September 30, 2023 and December 31, 2022, there were no Class A ordinary shares issued or outstanding other than the 2,896,555 and 27,600,000 Class A ordinary shares subject to possible redemption that are accounted for outside of the shareholders’ deficit section of the condensed balance sheets, respectively.
Class
 B ordinary shares
— The Company is authorized to issue 25,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for each share of Class B ordinary shares. As of September 30, 2023 and December 31, 2022, there were 6,900,000 Class B ordinary shares issued and outstanding.
Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as required by law. Unless specified in the Company’s amended and restated memorandum and articles of association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the Company’s ordinary shares that are voted is required to approve any such matter voted on by its shareholders.
The Class B ordinary shares will automatically convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have any redemption rights or be entitled to liquidating distributions from the Trust Account if the Company fails to consummate an initial Business Combination) at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an
as-converted
basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, any of its affiliates or any members of the Company’s management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than
one-to-one.
This is different than some other similarly structured blank check companies in which the initial shareholders will only be issued an aggregate of 20% of the total number of shares to be outstanding prior to the initial Business Combination.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events
 9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events
Note 10 — Subsequent Events
Promissory Note
On October 17, 2023, the Company issued the Restated Note in the principal amount of up to $2,500,000 to the Sponsor. The Restated Note amends, restates, replaces and supersedes
the Note
dated April 5, 2023. The Restated Note may be drawn down by the Company from time to time prior to the consummation of the Company’s initial Business Combination. The Restated Note does not bear interest, matures on the date of consummation the Business Combination and is subject to customary events of default. The Restated Note will be repaid only to the extent that the Company has funds available to it outside of its Trust Account.
Extraordinary General Meeting
On October 20, 2023, the Company held an extraordinary general meeting of shareholders (the “Meeting”), and approved the Extension Proposal to amend the Company’s amended and restated memorandum and articles of association to: (i) extend from October 22, 2023 to January 22, 2024 (the “Extended Date”), the date by which, if the Company has not consummated a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving one or more businesses or entities, the Company must: (a) cease all operations except for the purpose of winding up; (b) as promptly as reasonably possible but not more than ten business days thereafter, redeem the shares sold in the Company’s initial public offering (in a redemption that will completely extinguish the rights of the owners of the Public Shares as shareholders (including the right to receive further liquidation distributions, if any)) at a per-share price, payable in cash, equal to (1) the aggregate amount then on deposit in the Trust Account, including interest or dividends earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, less up to
 $100,000
of interest or dividends to pay winding up and dissolution expenses (net of any taxes payable), divided by (2) the number of the then-outstanding Public Shares; and (c) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s Board, liquidate and dissolve, subject in the case of clauses (b) and (c) to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law, and (ii) in the event that the Company has not consummated an initial Business Combination by the Extended Date, to allow the Company, by resolution of the Board and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to the Extended Date, to extend the Termination Date up to six times (with each such extension being upon five days’ advance notice), each by one additional month (for a total of up to six additional months to complete a business combination), provided that the Company’s Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (a)
 $35,000 or (b) $0.0175 for each Public Share that is then-outstanding, in exchange for one or more
non-interest
bearing, unsecured promissory notes issued by the Company to the Lender. If the Company completes its initial Business Combination, it will, at the option of the Lender, repay the amounts loaned under the promissory note(s) or convert a portion or all of the amounts loaned under such promissory note(s) into warrants at a price of $1.00 per warrant, which warrants will be identical to the private placement warrants, each exercisable to purchase one Class A ordinary share at $11.50 per share, subject to adjustment, at a price of $1.00 per warrant issued to the Sponsor at the time of the Company’s initial public offering. If the Company does not complete a business combination by the deadline to consummate an initial Business Combination, such promissory notes will be repaid only from funds held outside of the Trust Account.
Additionally, the shareholders approved a proposal to amend, by special resolution, the Company’s amended and restated memorandum and articles of association to change certain provisions which restrict the Class B ordinary shares from converting to Class A ordinary shares prior to the consummation of an initial Business Combination.
In connection with the vote to approve the above proposals, the holders of 1,488,000 Class A ordinary shares of ESGEN properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.21 per share, for an aggregate redemption amount of $16,679,055.
In connection with the approval of the Extension Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor contributed into the Trust Account $0.0525 per share for each Class A ordinary share that was not redeemed at the Meeting, for an aggregate contribution of $73,949.
In connection with the approval of the Conversion Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor converted all of its 5,619,077 Class B ordinary shares into Class A ordinary shares. As a result of the Sponsor Share Conversion and redemptions made in connection with the Extension Proposal and Conversion Proposal, 7,027,632 Class A ordinary shares remain outstanding. Notwithstanding the Sponsor Share Conversion, the Sponsor will be not entitled to receive any funds held in the Trust Account with respect to any Class A ordinary shares issued to the Sponsor as a result of the Sponsor Share Conversion and no additional amounts will be deposited into the Trust Account in respect of shares of Class A ordinary shares held by the Sponsor in connection with the extension of the Termination Date to the Extended Date or any Additional Extension Dates.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and Article 8 of Regulation
S-X
of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on
Form 10-K,
which contains the initial audited financial statements and notes thereto for the period ended December 31, 2022, as filed with the SEC on March 31, 2023. The interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the period ending December 31, 2023 or for any future interim periods.
The breakout of loss from operations on the condensed statement of operations for the three and nine months ended September 30, 2022, has been revised to conform to the current presentation. This presentation did not impact any other financial statement line items.
Emerging Growth Company Status
Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
Use of Estimates
The preparation of unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash Equivalents
Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of September 30, 2023 and December 31, 2022, respectively.
Marketable Securities Held in Trust Account
Marketable Securities Held in Trust Account
Substantially all of the assets held in the Trust Account were held in U.S. Money Market Funds. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in investment income on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information.
Fair Value Measurement
Fair Value Measurement
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the balance sheet, primarily due to its short-term nature.
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level 1, Level 2 or Level 3. These tiers include:
 
  •
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
  •
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
  •
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
Derivative Financial Instruments
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheets as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Warrant Liabilities
Warrant Liabilities
The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC Topic
815-40
and ASC Topic 480. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. These liabilities are subject to
re-measurement
at each balance sheet date. With each such
re-measurement,
the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations.
Net Income (Loss) Per Ordinary Share
Net Income (Loss) Per Ordinary Share
The Company has two classes of shares, which are referred to as redeemable Class A ordinary shares and
non-redeemable
Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. With respect to the accretion of Class A ordinary shares subject to possible redemption, the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share.
The earnings per share presented in the statement of operations is based on the following:
 
    
For the Three Months Ended

September 30,
     
For the Nine Months Ended

September 30,
  
    
2023
     
2022
     
2023
     
2022
  
                             
Net income (loss)
    $    631,724      $ 4,262,070      $ (2,225,459 )     $ 11,637,242  
Accretion of temporary equity to redemption value
      (761,527 )       (1,245,745 )       6,472,390        (1,632,690 ) 
  
 
 
     
 
 
     
 
 
     
 
 
  
Net income including accretion of temporary equity to redemption value
    $ (129,803 )     $     3,016,325      $ 4,246,931      $ 10,004,552  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
    
For the Three Months Ended

September 30,
  
    
2023
     
2022
  
    
Redeemable
Class A
     
Non-redeemable

Class B
     
Redeemable
Class A
     
Non-redeemable

Class B
  
                             
Basic and diluted net income (loss) per share:
            
Numerator:
            
Allocation of net income including accretion of temporary equity
    $ (38,941 )     $ (90,861 )     $ 2,413,060      $ 603,265  
Allocation of accretion of temporary equity to redemption value
      761,527        —          1,245,745        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
Allocation of net income (loss)
    $ 722,586      $ (90,861 )     $ 3,658,805      $ 603,265  
  
 
 
     
 
 
     
 
 
     
 
 
  
Denominator:
            
Weighted-average shares outstanding
      2,896,555        6,900,000        27,600,000        6,900,000  
Basic and diluted net income (loss) per share
    $ 0.25      $ (0.01 )     $ 0.13      $ 0.09  
 
    
For the Nine Months Ended

September 30,
  
    
2023
     
2022
  
    
Redeemable
Class A
     
Non-redeemable

Class B
     
Redeemable
Class A
     
Non-redeemable

Class B
  
                             
Basic and diluted net (loss) income per share:
            
Numerator:
            
Allocation of net income including accretion of temporary equity
    $ 1,698,772      $ 2,548,159      $ 8,003,642      $ 2,000,910  
Allocation of accretion of temporary equity to redemption value
      (6,472,390 )       —          1,632,690        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
Allocation of net (loss) income
    $ (4,773,618 )     $ 2,548,159      $ 9,636,332      $ 2,000,910  
  
 
 
     
 
 
     
 
 
     
 
 
  
Denominator:
            
Weighted-average shares outstanding
      4,615,842        6,900,000        27,600,000        6,900,000  
Basic and diluted net (loss) income per share
    $ (1.03 )     $ 0.37      $ 0.35      $ 0.29  
 
Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding during the period. The Company has not considered the effect of the 27,840,000 ordinary shares issuable upon exercise of the Public Warrants and Private Placement Warrants in the calculation of diluted income (loss) per share, since
th
e exercise of such warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.
Class A Ordinary Shares Subject to Possible Redemption
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares sold in the IPO feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events.
The Company has made a policy election in accordance with
ASC 480-10-S99-3A
and recognizes changes in redemption value in additional
paid-in
capital (or accumulated deficit in the absence of additional
paid-in
capital) immediately as they occur. The Company recorded accretion of $761,527 and $2,762,570 in accumulated deficit for three and nine months ended September 30, 2023, respectively, and $1,245,745 and $1,634,827 in accumulated deficit for the three and nine months ended September 30, 2022, respectively. For the period ended September 30, 2023, the Company recorded redemption of $255,875,758 and $1,042,760 was deposited in the Trust Account for extension funding.
Income Taxes
Income Taxes
The Company accounts for income taxes under ASC Topic 740, “Income Taxes” (“ASC 740”).
ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2023 and December 31, 2022.
The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s unaudited condensed financial statements. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September 30, 2023 and December 31, 2022, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Schedule of compute basic and diluted net income per share
The earnings per share presented in the statement of operations is based on the following:
 
    
For the Three Months Ended

September 30,
     
For the Nine Months Ended

September 30,
  
    
2023
     
2022
     
2023
     
2022
  
                             
Net income (loss)
    $    631,724      $ 4,262,070      $ (2,225,459 )     $ 11,637,242  
Accretion of temporary equity to redemption value
      (761,527 )       (1,245,745 )       6,472,390        (1,632,690 ) 
  
 
 
     
 
 
     
 
 
     
 
 
  
Net income including accretion of temporary equity to redemption value
    $ (129,803 )     $     3,016,325      $ 4,246,931      $ 10,004,552  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
    
For the Three Months Ended

September 30,
  
    
2023
     
2022
  
    
Redeemable
Class A
     
Non-redeemable

Class B
     
Redeemable
Class A
     
Non-redeemable

Class B
  
                             
Basic and diluted net income (loss) per share:
            
Numerator:
            
Allocation of net income including accretion of temporary equity
    $ (38,941 )     $ (90,861 )     $ 2,413,060      $ 603,265  
Allocation of accretion of temporary equity to redemption value
      761,527        —          1,245,745        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
Allocation of net income (loss)
    $ 722,586      $ (90,861 )     $ 3,658,805      $ 603,265  
  
 
 
     
 
 
     
 
 
     
 
 
  
Denominator:
            
Weighted-average shares outstanding
      2,896,555        6,900,000        27,600,000        6,900,000  
Basic and diluted net income (loss) per share
    $ 0.25      $ (0.01 )     $ 0.13      $ 0.09  
 
    
For the Nine Months Ended

September 30,
  
    
2023
     
2022
  
    
Redeemable
Class A
     
Non-redeemable

Class B
     
Redeemable
Class A
     
Non-redeemable

Class B
  
                             
Basic and diluted net (loss) income per share:
            
Numerator:
            
Allocation of net income including accretion of temporary equity
    $ 1,698,772      $ 2,548,159      $ 8,003,642      $ 2,000,910  
Allocation of accretion of temporary equity to redemption value
      (6,472,390 )       —          1,632,690        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
Allocation of net (loss) income
    $ (4,773,618 )     $ 2,548,159      $ 9,636,332      $ 2,000,910  
  
 
 
     
 
 
     
 
 
     
 
 
  
Denominator:
            
Weighted-average shares outstanding
      4,615,842        6,900,000        27,600,000        6,900,000  
Basic and diluted net (loss) income per share
    $ (1.03 )     $ 0.37      $ 0.35      $ 0.29  
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Prepaid Expenses (Tables)
 9 Months Ended
Sep. 30, 2023
Prepaid Expense, Current [Abstract]  
Summary of Prepaid expenses
The Company’s prepaid expenses as of September 30, 2023 and December 31, 2022 primarily consisted of the following:
 
    
September 30, 2023
     
December 31, 2022
  
               
Prepaid insurance
    $ 602      $ 26,081  
Other prepaid expenses
      3,659        5,029  
  
 
 
     
 
 
  
   $ 4,261      $ 31,110  
  
 
 
     
 
 
  
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts Payable and Accrued Expense (Tables)
 9 Months Ended
Sep. 30, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Schedule of company's accounts payable and accrued expenses
The Company’s accounts payable and accrued expenses as of September 30, 2023 and December 31, 2022 primarily consisted of legal accruals.
 
    
September 30, 2023
     
December 31, 2022
  
               
Legal accrual
    $ 5,041,722      $ 1,705,049  
Other payables and expenses
      254,316        161,943  
  
 
 
     
 
 
  
   $ 5,296,038      $ 1,866,992  
  
 
 
     
 
 
  
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Recurring Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2023
Derivative Instrument Detail [Abstract]  
Schedule of fair value hierarchy for liabilities measured at fair value on recurring basis
The following tables presents fair value information as of September 30, 2023 and December 31, 2022 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.
 
    
September 30, 2023
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
                             
Assets:
                                    
Marketable securities held in Trust Account
    $   32,393,380      $ —        $ —        $   32,393,380  
Liabilities:
                                    
Public Warrants
      496,800        —          —          496,800  
Private Warrants
      —          505,440        —          505,440  
    
 
 
     
 
 
     
 
 
     
 
 
  
Total liabilities
    $ 496,800      $ 505,440      $ —        $ 1,002,240  
    
 
 
     
 
 
     
 
 
     
 
 
  
 
    
December 31, 2022
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
                             
Assets:
                                    
Marketable securities held in Trust Account
    $ 285,506,568      $ —        $ —        $ 285,506,568  
Liabilities:
                                    
Public Warrants
      394,680        —          —          394,680  
Private Warrants
      —          401,544        —          401,544  
    
 
 
     
 
 
     
 
 
     
 
 
  
Total liabilities
    $ 394,680      $ 401,544      $ —        $ 796,224  
    
 
 
     
 
 
     
 
 
     
 
 
  
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Business Operation (Details) - USD ($)
 9 Months Ended
Oct. 20, 2023
Jan. 18, 2023
Oct. 22, 2021
Sep. 30, 2023
Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]          
Shares Issued, Price Per Share       $ 10  
Net tangible assets       $ 5,000,001  
Condition for future business combination threshold Percentage Ownership       50  
Redemption of shares calculated based on business days prior to consummation of business combination       15 months  
Condition for future business combination threshold Net Tangible Assets       $ 100,000  
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)       100.00%  
Cash held outside of the Trust Account   $ 140,000   $ 267,058  
Accrued Offering Costs And Expenses       5,296,038  
Due to related party       $ 309,193 $ 144,193
Public share   $ 0.04   $ 9.2  
Redemption Price Per Share   $ 10.35      
Aggregate redemption amount   $ 255,875,758      
Subsequent Event [Member]          
Subsidiary, Sale of Stock [Line Items]          
Condition for future business combination threshold Net Tangible Assets $ 100,000        
Cash held outside of the Trust Account $ 35,000        
Public share $ 0.0175        
Redemption Price Per Share $ 11.21        
Aggregate redemption amount $ 16,679,055        
Common shares, shares outstanding 7,027,632        
Class A common stock [Member]          
Subsidiary, Sale of Stock [Line Items]          
Shares Issued, Price Per Share       10  
Common shares, par value, (per share)       $ 0.0001 $ 0.0001
Stock issued during period, shares, new issues   24,703,445      
Common shares, shares outstanding       0 0
Class A common stock [Member] | Subsequent Event [Member]          
Subsidiary, Sale of Stock [Line Items]          
Shares Issued, Price Per Share $ 0.0525        
Common shares, par value, (per share) $ 0.0001        
Stock issued during period, shares, new issues 1,488,000        
Sponsor share conversion 5,619,077        
Common shares, shares outstanding 7,027,632        
Class B common stock [Member]          
Subsidiary, Sale of Stock [Line Items]          
Common shares, par value, (per share)       $ 0.0001 $ 0.0001
Common shares, shares outstanding       6,900,000 6,900,000
Class B common stock [Member] | Subsequent Event [Member]          
Subsidiary, Sale of Stock [Line Items]          
Common shares, par value, (per share) $ 0.0001        
Initial Public Offering [Member]          
Subsidiary, Sale of Stock [Line Items]          
Sale of Units, net of underwriting discounts (in shares)     27,600,000    
Shares Issued, Price Per Share     $ 10.2 $ 10  
Proceeds from Issuance Initial Public Offering     $ 281,520,000    
Initial Public Offering [Member] | Private Placement Warrants [Member]          
Subsidiary, Sale of Stock [Line Items]          
Shares Issued, Price Per Share     $ 11.5    
Sale of Private Placement Warrants (in shares)     14,040,000    
Price of warrant     $ 1    
Initial Public Offering [Member] | Private Placement Warrants [Member] | Subsequent Event [Member]          
Subsidiary, Sale of Stock [Line Items]          
Price of warrant $ 1        
Initial Public Offering [Member] | Public Warrants [Member]          
Subsidiary, Sale of Stock [Line Items]          
Shares Issued, Price Per Share       $ 10.2  
Private Placement [Member] | Private Placement Warrants [Member]          
Subsidiary, Sale of Stock [Line Items]          
Percentage of business combinations aggregate fair market value       80.00%  
Over-allotment option [Member]          
Subsidiary, Sale of Stock [Line Items]          
Shares Issued, Price Per Share     $ 10    
Sponsor [Member]          
Subsidiary, Sale of Stock [Line Items]          
Redemption of shares calculated based on business days prior to consummation of business combination       15 months  
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)       100.00%  
Related Party [Member]          
Subsidiary, Sale of Stock [Line Items]          
Due to related party       $ 1,718,988  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Accounting Policies (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Cash and cash equivalents $ 0   $ 0   $ 0
Unrecognized tax benefits 0   0   0
Unrecognized tax benefits accrued for interest and penalties 0   $ 0   0
Anti-dilutive securities attributable to warrants (in shares)     27,840,000    
Accretion of carrying value to redemption value     $ 255,875,758    
Payments to Acquire Restricted Investments     1,042,760 $ 0  
Accumulated Deficit [Member]          
Accretion of carrying value to redemption value 761,527 $ 1,245,745 2,762,570 $ 1,634,827  
Class A common stock [Member]          
Unrecognized tax benefits $ 0   $ 0   $ 0
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Net income (loss) $ 631,724 $ (1,411,072) $ (1,446,111) $ 4,262,070 $ 1,494,631 $ 5,880,541 $ (2,225,459) $ 11,637,242
Common Stock [Member]                
Net income (loss) 631,724     4,262,070     (2,225,459) 11,637,242
Accretion of temporary equity to redemption value (761,527)     (1,245,745)     6,472,390 (1,632,690)
Net income including accretion of temporary equity to redemption value $ (129,803)     $ 3,016,325     $ 4,246,931 $ 10,004,552
Class A common stock [Member]                
Weighted-average shares outstanding, basic 2,896,555     27,600,000     4,615,842 27,600,000
Weighted average shares outstanding, diluted 2,896,555     27,600,000     4,615,842 27,600,000
Basic net income (loss) per share $ 0.25     $ 0.13     $ (1.03) $ 0.35
Diluted net income (loss) per share $ 0.25     $ 0.13     $ (1.03) $ 0.35
Class A common stock [Member] | Common Stock [Member]                
Accretion of temporary equity to redemption value $ 761,527     $ 1,245,745     $ (6,472,390) $ 1,632,690
Net income including accretion of temporary equity to redemption value (38,941)     2,413,060     1,698,772 8,003,642
Allocation of net income (loss) $ 722,586     $ 3,658,805     $ (4,773,618) $ 9,636,332
Weighted-average shares outstanding, basic 2,896,555     27,600,000     4,615,842 27,600,000
Weighted average shares outstanding, diluted 2,896,555     27,600,000     4,615,842 27,600,000
Basic net income (loss) per share $ 0.25     $ 0.13     $ (1.03) $ 0.35
Diluted net income (loss) per share $ 0.25     $ 0.13     $ (1.03) $ 0.35
Class B Common Stock [Member]                
Weighted-average shares outstanding, basic 6,900,000     6,900,000     6,900,000 6,900,000
Weighted average shares outstanding, diluted 6,900,000     6,900,000     6,900,000 6,900,000
Basic net income (loss) per share $ (0.01)     $ 0.09     $ 0.37 $ 0.29
Diluted net income (loss) per share $ (0.01)     $ 0.09     $ 0.37 $ 0.29
Class B Common Stock [Member] | Common Stock [Member]                
Accretion of temporary equity to redemption value $ 0     $ 0     $ 0 $ 0
Net income including accretion of temporary equity to redemption value (90,861)     603,265     2,548,159 2,000,910
Allocation of net income (loss) $ (90,861)     $ 603,265     $ 2,548,159 $ 2,000,910
Weighted-average shares outstanding, basic 6,900,000     6,900,000     6,900,000 6,900,000
Weighted average shares outstanding, diluted 6,900,000     6,900,000     6,900,000 6,900,000
Basic net income (loss) per share $ (0.01)     $ 0.09     $ 0.37 $ 0.29
Diluted net income (loss) per share $ (0.01)     $ 0.09     $ 0.37 $ 0.29
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Oct. 17, 2023
Apr. 05, 2023
Dec. 31, 2022
Apr. 27, 2021
Related Party Transaction [Line Items]                
Due to related party $ 309,193   $ 309,193       $ 144,193  
Payments To Related Parties     0 $ 0        
Selling, general and administrative expense 30,000 $ 30,000 90,000 $ 90,000        
Related Party [Member]                
Related Party Transaction [Line Items]                
Outstanding balance of related party note               $ 90,922
Expenses incurred and paid     10,000          
Due to related party 1,718,988   1,718,988          
Unsecured Promissory Note [Member]                
Related Party Transaction [Line Items]                
Borrowed amount           $ 1,500,000    
Debt Instrument, Interest Rate, Stated Percentage           0.00%    
Long-Term Debt, Gross 1,238,449   1,238,449          
Restated Note [Member]                
Related Party Transaction [Line Items]                
Borrowed amount           $ 1,500,000    
Debt Instrument, Interest Rate, Stated Percentage           0.00%    
Restated Note [Member] | Subsequent Event [Member]                
Related Party Transaction [Line Items]                
Borrowed amount         $ 2,500,000      
Working capital loans warrant [Member]                
Related Party Transaction [Line Items]                
Loan conversion agreement warrant $ 1,500,000   $ 1,500,000          
Price of warrant $ 1   $ 1          
Working Capital Loan $ 0   $ 0       0  
Promissory Note with Related Party [Member]                
Related Party Transaction [Line Items]                
Maximum borrowing capacity of related party promissory note               300,000
Outstanding amount 171,346   171,346       171,346  
Borrowed amount               $ 262,268
Selling, General and Administrative Expenses [Member] | Related Party [Member]                
Related Party Transaction [Line Items]                
Due to related party $ 165,000   $ 165,000       $ 120,000  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Prepaid Expenses (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Prepaid Expense, Current [Abstract]    
Prepaid insurance, Current $ 602 $ 26,081
Other prepaid expenses, Current 3,659 5,029
Prepaid Expense, Current, Total $ 4,261 $ 31,110
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts Payable and Accrued Expense - Schedule of Company's Accounts Payable and Accrued Expenses (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Accounts Payable and Accrued Liabilities, Current [Abstract]    
Legal accrual $ 5,041,722 $ 1,705,049
Other payables and expenses 254,316 161,943
Total $ 5,296,038 $ 1,866,992
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments & Contingencies (Details)
 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 19, 2023
USD ($)
$ / shares
shares
Oct. 22, 2021
$ / shares
Sep. 30, 2023
USD ($)
Day
$ / shares
Jun. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Day
$ / shares
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
$ / shares
Related Party Transaction [Line Items]                
Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination           30 days    
Maximum number of demands for registration of securities | Day     3     3    
Recovery of offering costs related to the IPO allocated to warrants | $     $ 0   $ 0 $ 425,040 $ 0  
Waiver of deferred underwriter fees | $       $ 9,234,960   9,234,960    
Deferred underwriting fees | $           0   $ 9,660,000
Proceeds from sale of restricted investments | $           $ 255,875,758 $ 0  
Shares Issued, Price Per Share     $ 10     $ 10    
Decrease in deferred underwriting liability | $           $ 0    
Reversal of offering costs | $           $ 425,040    
Business Combination Agreement [Member]                
Related Party Transaction [Line Items]                
Minimum Net Worth Required For Compliance | $ $ 5,000,001              
Proceeds from sale of restricted investments | $ $ 20,000,000              
Class A common stock [Member]                
Related Party Transaction [Line Items]                
Common shares, par value, (per share)     0.0001     $ 0.0001   $ 0.0001
Shares Issued, Price Per Share     10     10    
Class B Common Stock [Member]                
Related Party Transaction [Line Items]                
Common shares, par value, (per share)     0.0001     $ 0.0001   $ 0.0001
Temporary equity, carrying amount, period increase (decrease) | $           $ 9,234,960    
ESGEN Common Class A [Member] | Business Combination Agreement [Member]                
Related Party Transaction [Line Items]                
Common shares, par value, (per share) $ 0.0001              
New PubCo Common Class A [Member]                
Related Party Transaction [Line Items]                
Common shares, par value, (per share) $ 0.0001              
Class Of Warrant Or Right Description each outstanding warrant to purchase one Class A ordinary share (each, an “ESGEN Warrant”) will become a warrant to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share              
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares 1              
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 11.5              
New PubCo Common Class A [Member] | Warrant [Member]                
Related Party Transaction [Line Items]                
Class Of Warrant Or Right Description           one-half of one warrant representing the right to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share    
Common Stock, Conversion Basis each issued and outstanding unit of ESGEN, each consisting of one Class A ordinary share and one-half of one ESGEN Warrant              
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares 1              
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 11.5              
Initial Public Offering [Member]                
Related Party Transaction [Line Items]                
Deferred Underwriting Discount   3.50%            
Shares Issued, Price Per Share   $ 10.2 $ 10     $ 10    
Sponsor [Member] | Class A common stock [Member]                
Related Party Transaction [Line Items]                
Warrants And Rights Outstanding Exercisable Term After Business Combinations           30 days    
Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination           1 year    
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences           150 days    
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | Day           20    
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)           $ 12    
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | Day           30    
Sponsor [Member] | Class A common stock [Member] | Initial Subscription Agreement [Member]                
Related Party Transaction [Line Items]                
Stock Issued During Period, Shares, Issued for Services | shares 1,000,000              
Shares Issued, Price Per Share $ 10              
Stock Issued During Period, Value, Issued for Services | $ $ 10,000,000              
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Warrant Liabilities (Details) - $ / shares
 9 Months Ended
Sep. 30, 2023
Jan. 18, 2023
Oct. 22, 2021
Warrants outstanding     27,840,000
Share Price $ 9.2 $ 0.04  
Threshold Period For Registration Statement To Be Effective After Which Warrants Can Be Exercised 60 days    
Fair Market Value Price $ 0.361    
Public Warrants expiration term 5 years    
Percentage Of Gross Proceeds On Total Equity Proceeds 60.00%    
Adjustment of exercise price of warrants based on market value (as a percent) 115.00%    
Percentage of adjustment of redemption price of stock based on market value. 180.00%    
Stock price trigger for redemption of public warrants $ 18    
Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination 30 days    
Shares Issued, Price Per Share $ 10    
Class A common stock [Member]      
Trading Day Prior To The Date On Which The Notice Of Exercise 10 days    
Shares Issued, Price Per Share $ 10    
Redemption Of Warrant Price Per Share Equals Or Exceeds18.00 [Member]      
Share Price 18    
Redemption price per public warrant (in dollars per share) $ 0.01    
Minimum threshold written notice period for redemption of public warrants 30 days    
Threshold trading days for redemption of public warrants 20 days    
Redemption Of Warrant Price Per Share Equals Or Exceeds10.00 [Member]      
Share Price $ 0.1    
Redemption price per public warrant (in dollars per share) $ 10    
Minimum threshold written notice period for redemption of public warrants 30 days    
Threshold trading days for redemption of public warrants 20 days    
Shares Issued, Price Per Share $ 10    
Public Warrants [Member]      
Warrants outstanding     13,800,000
Public Warrants [Member] | Class A common stock [Member]      
Shares Issued, Price Per Share $ 11.5    
Private Warrants [Member]      
Warrants outstanding     14,040,000
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities held in Trust Account $ 32,393,380 $ 285,506,568
Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities held in Trust Account 32,393,380 285,506,568
Total warrant liabilities 1,002,240 796,224
Recurring [Member] | Public Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 496,800 394,680
Recurring [Member] | Private Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 505,440 401,544
Level 1 [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities held in Trust Account 32,393,380 285,506,568
Total warrant liabilities 496,800 394,680
Level 1 [Member] | Recurring [Member] | Public Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 496,800 394,680
Level 2 [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 505,440 401,544
Level 2 [Member] | Recurring [Member] | Private Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 505,440 401,544
Level 3 [Member] | Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities 0 0
Level 3 [Member] | Recurring [Member] | Private Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total warrant liabilities $ 0 $ 0
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Recurring Fair Value Measurements - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Derivative Instrument Detail [Abstract]        
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net $ 0 $ 0 $ 0 $ 0
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholder's Equity - Preferred Stock Shares (Details) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Stockholders' Equity Note [Abstract]    
Preferred shares, shares authorized 1,000,000 1,000,000
Preferred stock, par value, (per share) $ 0.0001 $ 0.0001
Preferred shares, shares issued 0 0
Preferred shares, shares outstanding 0 0
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholder's Equity-Common Stock Shares (Details)
 9 Months Ended
Sep. 30, 2023
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Class of Stock [Line Items]    
Aggregate Percentage of Outstanding Shares Issued to Initial Shareholders Prior to Business Combination 20.00%  
Class A common stock [Member]    
Class of Stock [Line Items]    
Common shares, shares authorized (in shares) 250,000,000 250,000,000
Common shares, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001
Common shares, shares issued (in shares) 0 0
Common shares, shares outstanding (in shares) 0 0
Class A common stock subject to possible redemption, outstanding (in shares) 2,896,555 27,600,000
Class B Common Stock [Member]    
Class of Stock [Line Items]    
Common shares, shares authorized (in shares) 25,000,000 25,000,000
Common shares, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001
Common shares, shares issued (in shares) 6,900,000 6,900,000
Common shares, shares outstanding (in shares) 6,900,000 6,900,000
Ratio to be applied to the stock in the conversion 20  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events - Additional Information (Details) - USD ($)
 9 Months Ended
Oct. 20, 2023
Jan. 18, 2023
Sep. 30, 2023
Sep. 30, 2022
Oct. 17, 2023
Apr. 05, 2023
Dec. 31, 2022
Oct. 22, 2021
Subsequent Event [Line Items]                
Deposits into the trust account   $ 140,000 $ 267,058          
Public share   $ 0.04 $ 9.2          
Redemption price per share   $ 10.35            
Aggregate redemption amount   $ 255,875,758            
Shares Issued, Price Per Share     $ 10          
Payments to Acquire Restricted Investments     $ 1,042,760 $ 0        
IPO [Member]                
Subsequent Event [Line Items]                
Shares Issued, Price Per Share     $ 10         $ 10.2
Private Placement Warrants [Member] | IPO [Member]                
Subsequent Event [Line Items]                
Shares Issued, Price Per Share               11.5
Class of Warrant or Right, Price of Warrants or Rights               $ 1
Unsecured Promissory Note [Member]                
Subsequent Event [Line Items]                
Debt Instrument, Face Amount           $ 1,500,000    
Debt Instrument, Interest Rate, Stated Percentage           0.00%    
Class A common stock [Member]                
Subsequent Event [Line Items]                
Stock issued during period, shares, new issues   24,703,445            
Shares Issued, Price Per Share     $ 10          
Common shares, shares outstanding     0       0  
Class B Common Stock [Member]                
Subsequent Event [Line Items]                
Common shares, shares outstanding     6,900,000       6,900,000  
Subsequent Event [Member]                
Subsequent Event [Line Items]                
Deposits into the trust account $ 35,000              
Public share $ 0.0175              
Redemption price per share $ 11.21              
Aggregate redemption amount $ 16,679,055              
Payments to Acquire Restricted Investments $ 73,949              
Common shares, shares outstanding 7,027,632              
Subsequent Event [Member] | Private Placement Warrants [Member] | IPO [Member]                
Subsequent Event [Line Items]                
Class of Warrant or Right, Price of Warrants or Rights $ 1              
Subsequent Event [Member] | Unsecured Promissory Note [Member] | Sponsor [Member] | Revision of Prior Period, Adjustment [Member]                
Subsequent Event [Line Items]                
Debt Instrument, Face Amount         $ 2,500,000      
Debt Instrument, Interest Rate, Stated Percentage         0.00%      
Subsequent Event [Member] | Class A common stock [Member]                
Subsequent Event [Line Items]                
Stock issued during period, shares, new issues 1,488,000              
Shares Issued, Price Per Share $ 0.0525              
Common shares, shares outstanding 7,027,632              
Subsequent Event [Member] | Class B Common Stock [Member]                
Subsequent Event [Line Items]                
Stock Issued During Period, Shares, Conversion of Convertible Securities 5,619,077              
Subsequent Event [Member] | ESGEN Common Class A [Member] | Warrant Agreement [Member]                
Subsequent Event [Line Items]                
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 11.5              
XML 45 d500566d10q_htm.xml IDEA: XBRL DOCUMENT 0001865506 2022-12-31 0001865506 2023-09-30 0001865506 2022-01-01 2022-09-30 0001865506 2023-01-01 2023-09-30 0001865506 2021-10-22 0001865506 2023-07-01 2023-09-30 0001865506 2022-07-01 2022-09-30 0001865506 2022-04-01 2022-06-30 0001865506 2022-01-01 2022-03-31 0001865506 2023-04-01 2023-06-30 0001865506 2023-01-01 2023-03-31 0001865506 2023-01-18 0001865506 2022-01-01 2022-12-31 0001865506 2023-01-18 2023-01-18 0001865506 2021-12-31 0001865506 2022-09-30 0001865506 2022-06-30 0001865506 2022-03-31 0001865506 2023-06-30 0001865506 2023-03-31 0001865506 us-gaap:CommonClassAMember 2023-09-30 0001865506 us-gaap:CommonClassBMember 2023-09-30 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 us-gaap:IPOMember 2023-09-30 0001865506 esac:PublicWarrantsMember us-gaap:IPOMember 2023-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member 2023-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member 2023-09-30 0001865506 esac:WorkingCapitalLoansWarrantMember 2023-09-30 0001865506 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:RelatedPartyMember 2023-09-30 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2023-09-30 0001865506 us-gaap:CommonClassAMember esac:PublicWarrantsMember 2023-09-30 0001865506 us-gaap:RelatedPartyMember 2023-09-30 0001865506 esac:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 esac:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001865506 esac:UnsecuredPromissoryNoteMember 2023-09-30 0001865506 us-gaap:CommonClassAMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:CommonClassBMember 2022-12-31 0001865506 esac:WorkingCapitalLoansWarrantMember 2022-12-31 0001865506 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:RelatedPartyMember 2022-12-31 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2022-12-31 0001865506 esac:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 esac:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001865506 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassBMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001865506 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001865506 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001865506 esac:SponsorMember us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001865506 us-gaap:CommonClassBMember 2023-01-01 2023-09-30 0001865506 us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001865506 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member 2023-01-01 2023-09-30 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member 2023-01-01 2023-09-30 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2023-01-01 2023-09-30 0001865506 esac:SponsorMember 2023-01-01 2023-09-30 0001865506 esac:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember 2023-01-01 2023-09-30 0001865506 esac:UnitsEachConsistingOfOneShareOfClassCommonStockAndOneHalfOfOneWarrantMember 2023-01-01 2023-09-30 0001865506 esac:NewPubcoCommonClassAMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001865506 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001865506 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001865506 us-gaap:CommonClassBMember 2023-07-01 2023-09-30 0001865506 us-gaap:CommonClassAMember 2023-07-01 2023-09-30 0001865506 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001865506 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001865506 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001865506 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001865506 us-gaap:IPOMember 2021-10-22 2021-10-22 0001865506 esac:PublicWarrantsMember 2021-10-22 0001865506 esac:PrivateWarrantsMember 2021-10-22 0001865506 us-gaap:IPOMember 2021-10-22 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:IPOMember 2021-10-22 0001865506 us-gaap:OverAllotmentOptionMember 2021-10-22 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2021-04-27 0001865506 us-gaap:RelatedPartyMember 2021-04-27 0001865506 esac:RestatedNoteMember 2023-04-05 0001865506 esac:UnsecuredPromissoryNoteMember 2023-04-05 0001865506 esac:NewPubcoCommonClassAMember 2023-04-19 0001865506 esac:EsgenCommonClassAMember esac:BusinessCombinationAgreementMember 2023-04-19 0001865506 esac:NewPubcoCommonClassAMember us-gaap:WarrantMember 2023-04-19 0001865506 esac:BusinessCombinationAgreementMember 2023-04-19 0001865506 esac:SponsorMember us-gaap:CommonClassAMember esac:InitialSubscriptionAgreementMember 2023-04-19 0001865506 esac:NewPubcoCommonClassAMember 2023-04-19 2023-04-19 0001865506 esac:NewPubcoCommonClassAMember us-gaap:WarrantMember 2023-04-19 2023-04-19 0001865506 esac:BusinessCombinationAgreementMember 2023-04-19 2023-04-19 0001865506 esac:SponsorMember us-gaap:CommonClassAMember esac:InitialSubscriptionAgreementMember 2023-04-19 2023-04-19 0001865506 us-gaap:SubsequentEventMember 2023-10-20 0001865506 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2023-10-20 0001865506 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2023-10-20 0001865506 esac:EsgenCommonClassAMember us-gaap:SubsequentEventMember esac:WarrantAgreementMember 2023-10-20 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:SubsequentEventMember us-gaap:IPOMember 2023-10-20 0001865506 esac:RestatedNoteMember us-gaap:SubsequentEventMember 2023-10-17 0001865506 srt:RestatementAdjustmentMember esac:UnsecuredPromissoryNoteMember esac:SponsorMember us-gaap:SubsequentEventMember 2023-10-17 0001865506 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2023-10-20 2023-10-20 0001865506 us-gaap:SubsequentEventMember 2023-10-20 2023-10-20 0001865506 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2023-10-20 2023-10-20 0001865506 us-gaap:CommonClassAMember 2023-01-18 2023-01-18 0001865506 us-gaap:CommonClassAMember 2023-11-14 0001865506 us-gaap:CommonClassBMember 2023-11-14 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2022-09-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-09-30 0001865506 us-gaap:RetainedEarningsMember 2023-09-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-09-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-09-30 0001865506 us-gaap:RetainedEarningsMember 2023-06-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-06-30 0001865506 us-gaap:RetainedEarningsMember 2022-12-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001865506 us-gaap:RetainedEarningsMember 2023-03-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-03-31 0001865506 us-gaap:RetainedEarningsMember 2022-06-30 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001865506 us-gaap:RetainedEarningsMember 2021-12-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001865506 us-gaap:RetainedEarningsMember 2022-03-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 iso4217:USD shares pure utr:Day utr:Year utr:Month iso4217:USD shares false 0001865506 --12-31 Q3 false 10-Q true 2023-09-30 2023 ESGEN Acquisition Corporation E9 001-40927 98-1601409 5956 Sherry Lane Suite 1400 Dallas TX 75225 214 987-6100 Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant ESACU NASDAQ Class A ordinary shares included as part of the units ESAC NASDAQ Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 ESACW NASDAQ Yes Yes Non-accelerated Filer true true false true 7027632 1280923 267058 614767 4261 31110 271319 645877 32393380 285506568 32664699 286152445 5296038 1866992 309193 144193 1409795 171346 7015026 2182531 1002240 796224 0 9660000 8017266 12638755 0.0001 0.0001 2896555 27600000 32393380 285506568 0.0001 0.0001 1000000 1000000 0 0 0 0 0 0 0.0001 0.0001 250000000 250000000 0 0 0 0 2896555 27600000 0 0 0.0001 0.0001 25000000 25000000 6900000 6900000 6900000 6900000 690 690 -7746637 -11993568 -7745947 -11992878 32664699 286152445 707780 145588 3752583 937110 2913 133302 25479 395559 88307 20385 296231 181339 30000 30000 90000 90000 -829000 -329275 -4164293 -1604008 413940 1245745 1719810 1632690 0 0 425040 0 -1046784 -3345600 206016 -11608560 1460724 4591345 1938834 13241250 631724 4262070 -2225459 11637242 2896555 2896555 27600000 27600000 4615842 4615842 27600000 27600000 0.25 0.25 0.13 0.13 -1.03 -1.03 0.35 0.35 6900000 6900000 6900000 6900000 6900000 6900000 6900000 6900000 -0.01 -0.01 0.09 0.09 0.37 0.37 0.29 0.29 27600000 285506568 6900000 690 0 -11993568 -11992878 -1288233 1288233 1288233 24703445 255875758 -1446111 -1446111 2896555 30919043 6900000 690 0 -14727912 -14727222 -712810 712810 712810 9234960 9234960 -1411072 -1411072 2896555 31631853 6900000 690 0 -7616834 -7616144 -761527 761527 761527 631724 631724 2896555 32393380 6900000 690 0 -7746637 -7745947 27600000 281520000 6900000 690 0 -22341250 -22340560 -20308 20308 20308 5880541 5880541 27600000 281540308 6900000 690 0 -16481017 -16480327 -368774 368774 368774 1494631 1494631 27600000 281909082 6900000 690 0 -15355160 -15354470 -1245745 1245745 1245745 4262070 4262070 27600000 283154827 6900000 690 0 -12338835 -12338145 -2225459 11637242 0 1632690 425040 0 206016 -11608560 -26849 -402258 3429046 678120 165000 90000 1176412 -433630 1719810 0 1042760 0 255875758 0 253113188 0 255875758 0 1238449 0 -254637309 0 -347709 -433630 614767 1323903 267058 890273 2762570 1634827 9234960 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1 — Organization and Business Operation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ESGEN Acquisition Corporation (the “Company”) was incorporated as a Cayman Islands exempted company on April 19, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">As of September 30, 2023, the Company had not commenced any operations. All activity for the period from April 19, 2021 (inception) through September 30, 2023, relates to the Company’s formation and the initial public offering (“Public Offering” or “IPO”) described below and since the closing of the IPO, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest or dividend income on cash and cash equivalents from the proceeds derived from the Public Offering (as defined below). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s sponsor is ESGEN LLC, a Delaware limited liability company (the “Sponsor”). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company’s IPO was declared effective on October 19, 2021. On October 22, 2021, the Company consummated its IPO of 27,600,000 units (the “Units” and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”) at $10.00 per Unit and the sale of 14,040,000 warrants (the “Private Placement Warrants”) each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor that closed simultaneously with the Public Offering. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred </div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">underwriters fee<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and taxes payable on the interest or dividends earned on the Trust Account) at the time of signing a definitive agreement in connection with the initial Business Combination. However, the Company will complete the initial Business Combination only if the post-Business Combination company in which its public shareholders own shares will own or acquire 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act (the “Investment Company Act”). There is no assurance that the Company will be able to complete a Business Combination successfully. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the closing of the IPO on October 22, 2021, $281,520,000 ($10.20 per Unit) from the net proceeds sold in the IPO, including proceeds of the sale of the Private Placement Warrants, was deposited in a trust account (“Trust Account”) and, until October 16, 2023, was only invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. To mitigate the risk of being deemed to have been operating as an unregistered investment company under the Investment Company Act, on October 16, 2023, the Company instructed the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in demand deposits (i.e., in one or more bank accounts) until the earliest of ESGEN’s completion of an initial business combination or J</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">anuary 22, 2024 (unless extended as described below), as applicable.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except with respect to interest or other income earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the amended and restated memorandum and articles of association, as discussed below and subject to the requirements of law and regulation, will provide that the proceeds from the Public Offering and the sale of the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the public shareholders, until the earliest of (a) the completion of the initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, subject to the limitations described herein, (b) the redemption of any public shares properly </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tendered in connection with a shareholder vote to amend the amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company did not complete its initial Business Combination within 15 months (which was extended pursuant to shareholder approval of the Charter Amendment (as defined below)) from the closing of this offering (the “Combination Period”) or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares, and (c) the redemption of the public shares if the Company has not consummated the Business Combination within Combination Period, subject to applicable law. Public shareholders who redeem their Class A ordinary shares in connection with a shareholder vote described in clause (b) in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within Combination Period, with respect to such Class A ordinary shares so redeemed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek shareholder approval under applicable law or stock exchange listing requirement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">The Company will provide its public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of its initial Business Combination at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest or dividends earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then-outstanding public shares, subject to the limitations described herein. The amount in the Trust Account is initially $10.20 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">underwriters fee<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>the Company will pay to the underwriters. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ordinary shares subject to redemption were recorded at redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">The Company has until <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">January 22, 2024 (unless extended as described below),</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">as</div> described in Note 10, to consummate the initial Business Combination. If the Company has not consummated the initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest or dividends earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest or dividends to pay winding up and dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January 18, 2023, the Company held an extraordinary general meeting of shareholders to consider and vote upon, among other things, a proposal to amend the Company’s amended and restated memorandum and articles of association (the “First Extension Charter Amendment”) to (i) extend the date by which the Company must consummate its initial Business Combination (the “Termination Date”) from January 22, 2023 to April 22, 2023 and (ii) in the event that the Company has not consummated an initial business combination by April 22, 2023, to allow the Company, by resolution of the Company’s board of directors (the “Board”) and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to each Additional Extension, to extend the Termination Date up to six times (with each such extension being upon five days’ advance notice), each by one additional month (for a total of up to six additional months to complete a business combination) (each, an “Additional Extension” and such date, the “Additional Extension Date”), provided that the Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (a) $140,000 or (b) $0.04 for each Public Share that is then-outstanding, in exchange for one or more non-interest bearing, unsecured promissory notes issued by the Company to the Sponsor or the Sponsor’s affiliates or permitted designees (the “Lenders” and each a “Lender”). In connection with the vote to approve the First Extension Charter Amendment, the holders of 24,703,445 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.35 per share, for an aggregate redemption amount of approximately $255,875,758.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares; (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the public shares if the Company did not complete its initial Business Combination within </div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months from the closing of the Public Offering (which was extended pursuant to shareholder approval of the Charter Amendment) or (B) with respect to any other provision relating to the rights of holders of the Company’s Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an initial Business Combination within Combination Period.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company’s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per public share due to reductions in the value of the Trust Account, in each case net of the interest or dividends that may be withdrawn to pay the Company’s income tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October 20, 2023, at the Company’s extraordinary general meeting, the shareholders approved, among other proposals, (i) (a) the extension (such proposal, the “Extension Proposal”) of the time period the Company has to complete an initial Business Combination from October 22, 2023 to January 22, 2024 (the “Charter Amendment”) and (b) in the event that the Company has not consummated an initial Business Combination by January 22, 2024, to allow the Company, by resolution of the Board and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to each Additional Extension, to complete six Additional Extensions, provided that the Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (x) $35,000 or (y) $0.0175 for each Public Share that is then-outstanding, in exchange for one or more non-interest bearing, unsecured promissory notes issued by a Lender, and (ii) the amendment of the Company’s amended and restated memorandum and articles of association to change certain provisions which restrict the Class B ordinary shares, par value $0.0001, of the Company (the “Class B ordinary shares”) from converting to Class A ordinary shares, par value $0.0001 (the “Class A ordinary shares”) prior to the consummation of an initial </div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Business Combination (such proposal, the “Conversion Proposal”).</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Founder Shares refers to the Class B ordinary shares (the “Founder Shares”) acquired by the initial shareholders prior to the Company’s IPO. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The initial shareholders and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of the Business Combination; (ii) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with a shareholder vote to approve an amendment to the amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the Business Combination or to redeem 100% of the Company’s public shares if it does not complete the Business Combination by the Termination Date or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an Business Combination by the Termination Date (although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the Business Combination within the prescribed time frame). If the Company seeks shareholder approval, it will complete the Business Combination only if it is approved by an ordinary resolution or such higher approval threshold as may be required by Cayman Islands law and pursuant to the amended and restated memorandum and articles of association. In such case, the initial shareholders and each member of the management team have agreed to vote their Founder Shares and Public Shares in favor of the Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the approval of the Conversion Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor converted all of its 5,619,077 Class B ordinary shares into Class A ordinary shares (the “Sponsor Share Conversion”). As a result of the Sponsor Share Conversion and redemptions made in connection with the Extension Proposal and Conversion Proposal, 7,027,632 Class A ordinary shares remain outstanding. Notwithstanding the Sponsor Share Conversion, the Sponsor will be not entitled to receive any funds held in the Trust Account with respect to any Class A ordinary shares issued to the Sponsor as a result of the Sponsor Share Conversion and no additional amounts will be deposited into the Trust Account in respect of shares of Class A ordinary shares held by the Sponsor in connection with the extension of the Termination Date to the Extended Date or any Additional Extension Dates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The credit and financial markets have experienced extreme volatility and disruptions due to the current conflict between Ukraine and Russia. The conflict is expected to have further global economic consequences, including but not limited to the possibility of severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in inflation rates and uncertainty about economic and political stability. In addition, the United States and other countries have imposed sanctions on Russia which increases the risk that Russia, as a retaliatory action, may launch cyberattacks against the United States, its government, infrastructure and businesses. Any of the foregoing consequences, including those we cannot yet predict, may cause our business, financial condition, results of operations and the price of our ordinary shares to be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Going Concern </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2023, the Company had $267,058 in cash held outside of the Trust Account and owes $5,296,038 in accounts payable and accrued expenses and $1,718,988 to related parties. The Company anticipates that the cash held outside of the Trust Account as of September 30, 2023 will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the Company’s assessment of going concern considerations in accordance with ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> “Presentation of Financial Statements – Going Concern”, the Company has until January 22, 2024 to consummate a Business Combination. If a Business Combination is not consummated by this date and an Additional Extension not obtained, there will be a mandatory liquidation and subsequent dissolution of the Company. It is uncertain whether the Company will be able to consummate a Business Combination by this time. Management has determined that the mandatory liquidation, should a Business Combination not occur, and an extension is not obtained, as well as the potential for us to have insufficient funds available to operate our business prior to a Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern. </div> 27600000 10 14040000 11.5 1 0.80 50 281520000 10.2 1 P15M 10.2 5000001 100000 140000 0.04 24703445 10.35 255875758 1 P15M 10 10 35000 0.0175 0.0001 0.0001 1 5619077 7027632 267058 5296038 1718988 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2 — Significant Accounting Policies </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-K,</div> which contains the initial audited financial statements and notes thereto for the period ended December 31, 2022, as filed with the SEC on March 31, 2023. The interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the period ending December 31, 2023 or for any future interim periods. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The breakout of loss from operations on the condensed statement of operations for the three and nine months ended September 30, 2022, has been revised to conform to the current presentation. This presentation did not impact any other financial statement line items. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company Status </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Equivalents </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of September 30, 2023 and December 31, 2022, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantially all of the assets held in the Trust Account were held in U.S. Money Market Funds. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in investment income on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the balance sheet, primarily due to its short-term nature. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level 1, Level 2 or Level 3. These tiers include: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Financial Instruments </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheets as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement or conversion of the instrument could be required within 12 months of the balance sheet date. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liabilities </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> and ASC Topic 480. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. These liabilities are subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date. With each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement,</div> the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (Loss) Per Ordinary Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has two classes of shares, which are referred to as redeemable Class A ordinary shares and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. With respect to the accretion of Class A ordinary shares subject to possible redemption, the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The earnings per share presented in the statement of operations is based on the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%;"></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">   631,724</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,262,070</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,225,459</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,637,242</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(761,527</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,472,390</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income including accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(129,803</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">    3,016,325</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,246,931</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,004,552</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income including accretion of temporary equity</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38,941</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,861</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,413,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">761,527</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">722,586</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,861</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,658,805</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,896,555</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.25</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.13</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.09</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 86%;"></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income per share:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income including accretion of temporary equity</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,698,772</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,548,159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,003,642</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,472,390</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net (loss) income</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,773,618</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,548,159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,636,332</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,615,842</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income per share</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.37</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.35</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding during the period. The Company has not considered the effect of the 27,840,000 ordinary shares issuable upon exercise of the Public Warrants and Private Placement Warrants in the calculation of diluted income (loss) per share, since<div style="display:inline;"> th</div>e exercise of such warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class A Ordinary Shares Subject to Possible Redemption </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares sold in the IPO feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has made a policy election in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC 480-10-S99-3A</div></div></div> and recognizes changes in redemption value in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (or accumulated deficit in the absence of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital) immediately as they occur. The Company recorded accretion of $761,527 and $2,762,570 in accumulated deficit for three and nine months ended September 30, 2023, respectively, and $1,245,745 and $1,634,827 in accumulated deficit for the three and nine months ended September 30, 2022, respectively. For the period ended September 30, 2023, the Company recorded redemption of $255,875,758 and $1,042,760 was deposited in the Trust Account for extension funding. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, “Income Taxes” (“ASC 740”). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2023 and December 31, 2022. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s unaudited condensed financial statements. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September 30, 2023 and December 31, 2022, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-K,</div> which contains the initial audited financial statements and notes thereto for the period ended December 31, 2022, as filed with the SEC on March 31, 2023. The interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the period ending December 31, 2023 or for any future interim periods. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The breakout of loss from operations on the condensed statement of operations for the three and nine months ended September 30, 2022, has been revised to conform to the current presentation. This presentation did not impact any other financial statement line items. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company Status </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Equivalents </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of September 30, 2023 and December 31, 2022, respectively. </div></div> 0 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantially all of the assets held in the Trust Account were held in U.S. Money Market Funds. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in investment income on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the balance sheet, primarily due to its short-term nature. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level 1, Level 2 or Level 3. These tiers include: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Financial Instruments </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheets as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement or conversion of the instrument could be required within 12 months of the balance sheet date. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liabilities </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> and ASC Topic 480. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. These liabilities are subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date. With each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement,</div> the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (Loss) Per Ordinary Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has two classes of shares, which are referred to as redeemable Class A ordinary shares and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. With respect to the accretion of Class A ordinary shares subject to possible redemption, the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The earnings per share presented in the statement of operations is based on the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%;"></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">   631,724</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,262,070</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,225,459</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,637,242</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(761,527</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,472,390</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income including accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(129,803</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">    3,016,325</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,246,931</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,004,552</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income including accretion of temporary equity</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38,941</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,861</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,413,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">761,527</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">722,586</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,861</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,658,805</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,896,555</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.25</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.13</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.09</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 86%;"></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income per share:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income including accretion of temporary equity</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,698,772</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,548,159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,003,642</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,472,390</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net (loss) income</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,773,618</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,548,159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,636,332</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,615,842</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income per share</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.37</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.35</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding during the period. The Company has not considered the effect of the 27,840,000 ordinary shares issuable upon exercise of the Public Warrants and Private Placement Warrants in the calculation of diluted income (loss) per share, since<div style="display:inline;"> th</div>e exercise of such warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The earnings per share presented in the statement of operations is based on the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%;"></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">   631,724</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,262,070</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,225,459</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,637,242</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(761,527</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,472,390</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income including accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(129,803</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">    3,016,325</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,246,931</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,004,552</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income including accretion of temporary equity</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38,941</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,861</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,413,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">761,527</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,245,745</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">722,586</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,861</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,658,805</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">603,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,896,555</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.25</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.13</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.09</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 86%;"></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 1%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div><br/> Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income per share:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income including accretion of temporary equity</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,698,772</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,548,159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,003,642</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of accretion of temporary equity to redemption value</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,472,390</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,632,690</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net (loss) income</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,773,618</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,548,159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,636,332</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,615,842</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,600,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,900,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income per share</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.37</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.35</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> 631724 4262070 -2225459 11637242 761527 1245745 -6472390 1632690 -129803 3016325 4246931 10004552 -38941 -90861 2413060 603265 -761527 0 -1245745 0 722586 -90861 3658805 603265 2896555 2896555 6900000 6900000 27600000 27600000 6900000 6900000 0.25 0.25 -0.01 -0.01 0.13 0.13 0.09 0.09 1698772 2548159 8003642 2000910 6472390 0 -1632690 0 -4773618 2548159 9636332 2000910 4615842 4615842 6900000 6900000 27600000 27600000 6900000 6900000 -1.03 -1.03 0.37 0.37 0.35 0.35 0.29 0.29 27840000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class A Ordinary Shares Subject to Possible Redemption </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares sold in the IPO feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has made a policy election in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC 480-10-S99-3A</div></div></div> and recognizes changes in redemption value in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (or accumulated deficit in the absence of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital) immediately as they occur. The Company recorded accretion of $761,527 and $2,762,570 in accumulated deficit for three and nine months ended September 30, 2023, respectively, and $1,245,745 and $1,634,827 in accumulated deficit for the three and nine months ended September 30, 2022, respectively. For the period ended September 30, 2023, the Company recorded redemption of $255,875,758 and $1,042,760 was deposited in the Trust Account for extension funding. </div> 761527 2762570 1245745 1634827 255875758 1042760 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, “Income Taxes” (“ASC 740”). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2023 and December 31, 2022. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s unaudited condensed financial statements. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September 30, 2023 and December 31, 2022, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div> 0 0 0 0 0 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3 — Related Party Transactions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Notes — Related Party </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On April 27, 2021, the Sponsor agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the Public Offering. The Company borrowed a total of $262,268. This loan was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing, unsecured and due at the earlier of December 31, 2021 or the closing of the Public Offering. The loan was to be repaid upon the closing of the Public Offering out of the offering proceeds not held in the Trust Account. In connection with the closing of the Public Offering, the Company paid down $90,922 of the outstanding balance. As of September 30, 2023 and December 31, 2022, the Company had $171,346 outstanding under the promissory note and as is included on the balance sheet as promissory note<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div>related party. The Sponsor has agreed to defer repayment of the loan until the close of the Business Combination. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April 5, 2023, the Company issued an unsecured promissory note (the “Note”) in the principal amount of up to $1,500,000 to the Sponsor, which may be drawn down by the Company from time to time prior to the consummation of the Company’s Business Combination. The Note does not bear interest, matures on the date of consummation of the Business Combination and is subject to customary events of default. As of September 30, 2023, the Company had $1,238,449 outstanding under the Note and is included on the balance sheet as promissory note<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div>related party. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, on October 17, 2023, the Company issued an amended and restated promissory note (the “Restated Note”) in the principal amount of up to $2,500,000 to the Sponsor. The Restated Note amends, restates, replaces and supersedes<div style="display:inline;"> </div><div style="display:inline;">the Note</div> dated April 5, 2023, in the principal amount of $1,500,000. The Restated Note may be drawn down by the Company from time to time prior to the consummation of the Company’s initial Business Combination. The Restated Note does not bear interest, matures on the date of consummation the Business Combination and is subject to customary events of default. The Restated Note will be repaid only to the extent that the Company has funds available to it outside of its Trust Account (see Note 10). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Working Capital Loans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. As of September 30, 2023 and December 31, 2022, the Company had no borrowings under the Working Capital Loans. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Office Space, Secretarial and Administrative Services </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Through the earlier of consummation of the initial Business Combination and the liquidation, the Company incurs $10,000 per month for office space, utilities, secretarial support and administrative services provided by the Sponsor. For the three and nine months ended September 30, 2023, the Company has incurred $30,000 and $90,000, respectively. No amounts have been paid for these services. For the three and nine months ended September 30, 2022, the Company incurred $30,000 and $90,000, respectively. No amounts have been paid for these services. As of September 30, 2023 and December 31, 2022, the Company reported on the balance sheets $165,000 and $120,000, respectively, pursuant to this agreement, in “Due to related party”. </div></div> 300000 262268 90922 171346 171346 1500000 0 1238449 2500000 1500000 0 1500000 1 0 0 10000 30000 90000 0 30000 90000 0 165000 120000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4 — Prepaid Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s prepaid expenses as of September 30, 2023 and December 31, 2022 primarily consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"></td> <td style="width: 12%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 12%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid insurance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">602</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,081</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other prepaid expenses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,659</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,029</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,261</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,110</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s prepaid expenses as of September 30, 2023 and December 31, 2022 primarily consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"></td> <td style="width: 12%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 12%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid insurance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">602</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,081</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other prepaid expenses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,659</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,029</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,261</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,110</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 602 26081 3659 5029 4261 31110 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5 — Accounts Payable and Accrued Expense </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s accounts payable and accrued expenses as of September 30, 2023 and December 31, 2022 primarily consisted of legal accruals. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"></td> <td style="width: 9%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 9%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal accrual</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,041,722</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,705,049</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other payables and expenses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">254,316</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161,943</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,296,038</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,866,992</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s accounts payable and accrued expenses as of September 30, 2023 and December 31, 2022 primarily consisted of legal accruals. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"></td> <td style="width: 9%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 9%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal accrual</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,041,722</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,705,049</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other payables and expenses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">254,316</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161,943</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,296,038</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,866,992</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 5041722 1705049 254316 161943 5296038 1866992 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6 — Commitments &amp; Contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration and Shareholder Rights </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the private placement warrants and the respective Class A ordinary shares issuable upon exercise of the private placement warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Working Capital Loans and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company’s register such securities. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Except as described herein, the Sponsor and its directors and executive officers have agreed not to transfer, assign or sell any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company complete a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property. Any permitted transferees would be subject to the same restrictions and other agreements of the Sponsor and its directors and executive officers with respect to any founder shares. Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor with respect to any Founder Shares. The Company refers to such transfer restrictions throughout the Public Offering as the lock- up. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, pursuant to the registration and expected shareholder rights agreement, the Sponsor, upon and following consummation of an initial Business Combination, will be entitled to nominate three individuals for election to the board of directors, as long as the Sponsor holds any securities covered by the registration and expected shareholder rights agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters were entitled to a deferred </div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">underwriters fee</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of 3.5% of the gross proceeds of the Public Offering upon the completion of the Company’s initial Business Combination. In April 2023, the underwriters waived any right to receive the deferred </div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">underwriters fee</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and will therefore receive no additional </div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">underwriters fee</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in connection with the Closing. As a result, the Company recognized $425,040 of other income on the statement of operations and $9,234,960 was recorded to accumulated deficit on the statements of changes in ordinary shares subject to possible redemption and shareholders’ deficit in relation to the reduction of the deferred underwriter<div style="display:inline;">s</div> fee. As of September 30, 2023 and December 31, 2022, the deferred underwrit<div style="display:inline;">ers</div> fee is $0 and $9,660,000, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To account for the waiver of the deferred </div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">underwriters</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> fee, the Company analogized to the SEC staff’s guidance on accounting for reducing a liability for “trailing fees”. Upon the waiver of the deferred </div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">underwriters</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> fee, the Company reduced the deferred </div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">underwriters fee</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to $0 and reversed the previously recorded cost of issuing the instruments in the IPO, which included recognizing a contra-expense of $425,040, which is the amount previously allocated to liability classified warrants and expensed upon the IPO, and reduced the accumulated deficit and increased income available to Class B ordinary shares by $9,234,960, which was previously allocated to the Class A ordinary shares subject to redemption and accretion recognized at the IPO date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proposed Business Combination </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April 19, 2023, the Company entered into a Business Combination Agreement, by and among the Company, ESGEN OpCo, LLC, a Delaware limited liability company and wholly-owned subsidiary of ESGEN (“OpCo”), Sunergy Renewables, LLC, a Nevada limited liability company (“Sunergy”), the Sunergy equityholders set forth on the signature pages thereto (collectively, “Sellers” and each, a “Seller”, and collectively with Sunergy, the “Sunergy Parties”), for limited purposes, the Sponsor, and for limited purposes, Timothy Bridgewater, an individual, in his capacity as the Sellers Representative (the “Business Combination Agreement”). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the terms and subject to the conditions of the Business Combination Agreement, among other things: (i) prior to the consummation of the Business Combination (the “Closing”), each issued and outstanding Class B ordinary share of ESGEN will convert into one Class A ordinary share of ESGEN (the “ESGEN Share Conversion”); and (ii) following the ESGEN Share Conversion but prior to the Closing, ESGEN will, subject to the receipt of the requisite shareholder approval, transfer by way of continuation from the Cayman Islands to the State of Delaware and domesticate as a Delaware corporation (the “Domestication”) and will change its name as to be determined by the parties to the Business Combination Agreement (“New PubCo”). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">In connection with the Domestication, (A) each outstanding Class A ordinary share will become one share of Class A common stock, par value $0.0001 per share, of New PubCo (the “New PubCo Class A Common Stock”), (B) each outstanding warrant to purchase one Class A ordinary share (each, an “ESGEN Warrant”) will become a warrant to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share, and (C) New PubCo will file its certificate of incorporation and will adopt bylaws to serve as its governing documents upon consummation of the Domestication. In connection with the ESGEN Share Conversion and the Domestication, each issued and outstanding unit of ESGEN, each consisting of one Class A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one ESGEN Warrant (each, an “ESGEN Unit”), that has not been previously separated into the underlying Class A ordinary shares and underlying ESGEN Warrants prior to the Domestication will be cancelled and will entitle the holder thereof to (x) one share of New PubCo Class A Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(y) </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one warrant representing the right to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share on the terms and subject to the conditions applicable to ESGEN Warrants set forth in the Warrant Agreement, dated as of October 22, 2021, between ESGEN and Continental Stock Transfer &amp; Trust Company (the “Trustee”). </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the terms and subject to the conditions of the Business Combination Agreement, Sunergy will cause all holders of any options, warrants or rights to subscribe for or purchase any equity interests of Sunergy or its subsidiaries or securities (including debt securities) convertible into or exchangeable for, or that otherwise confer on the holder any right to acquire, any equity interests of Sunergy or any subsidiary thereof (collectively, the “Sunergy Convertible Interests”) existing immediately prior to the Closing either to exchange or convert all such holder’s Sunergy Convertible Interests into limited liability interests of Sunergy (the “Sunergy Company Interests”) in accordance with the governing documents of Sunergy or the Sunergy Convertible Interests (collectively, the “Sunergy Exchanges”). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, ESGEN will contribute to OpCo (1) all of its assets (excluding its interests in OpCo, but including the amount of cash in the Trust Account as of immediately prior to the Closing (after giving effect to the exercise of redemption rights by any ESGEN shareholders)), and (2) a number of newly issued shares of Class V common stock of ESGEN, par value $0.0001 per share, which will generally have only voting rights (the “ESGEN Class V Common Stock”), equal to the number of Seller OpCo Units (as defined in the Business Combination Agreement) (the “Seller Class V Shares”) and (y) in exchange, OpCo shall issue to ESGEN (i) a number of common units of OpCo (the “OpCo Units”) which shall equal the number of total shares of ESGEN Class A Common Stock issued and outstanding immediately after the Closing and (ii) a number of warrants to purchase OpCo Units which shall equal the number of SPAC Warrants issued and outstanding immediately after the Closing (the transactions described above in this paragraph, the “ESGEN Contribution”). Immediately following the ESGEN Contribution, (x) the Sellers will contribute to OpCo the Sunergy Company Interests and (y) in exchange therefor, OpCo will transfer to the Sellers the Seller OpCo Units and the Seller Class V Shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The obligation of ESGEN, the Sunergy Parties and OpCo to consummate the Business Combination is subject to certain customary closing conditions, including, but not limited to, (i) the absence of any order, law or other legal restraint or prohibition enacted, issued or promulgated by any court of competent jurisdiction or other governmental entity of competent jurisdiction having the effect of making the Business Combination illegal or otherwise prohibiting the consummation of the Business Combination, (ii) the termination or expiration of any applicable waiting period applicable to the consummation of the Business Combination under the Hart-Scott-Rodino Act, (iii) the effectiveness of the Registration Statement on Form S-4 (the “Registration Statement”) in accordance with the provisions of the Securities Act, registering the ESGEN Class A Common Stock to be issued in connection with the Business Combination Agreement, (iv) receipt of the required approvals of ESGEN’s shareholders at a meeting of the shareholders of ESGEN in connection with the Business Combination, (v) the ESGEN Class A Common Stock to be issued in connection with the Business Combination immediately after Closing shall be listed on Nasdaq and ESGEN will be able to satisfy any continued listing requirements of Nasdaq immediately after Closing, (vi) if the ESGEN shareholders do not approve the Redemption Limitation Amendment (as defined in the Business Combination Agreement), ESGEN having at least $5,000,001 of net tangible assets (as determined in accordance with Rule 3a5-51(g)(1) of the Exchange Act) remaining immediately after any holders of the ESGEN Class A Ordinary Shares exercise their redemption rights, (vii) the members of the post-Business Combination ESGEN board of directors shall have been elected or appointed in accordance with the Business Combination Agreement and (viii) the aggregate transaction proceeds, including from the Trust Account after giving effect to the exercise of redemption rights by any ESGEN shareholders pursuant to the ESGEN amended and restated memorandum and articles of association, as amended, and the proceeds resulting from the Initial PIPE Investment (as defined below) and any financing agreements executed in furtherance of the Business Combination Agreement, shall be greater or equal to $20,000,000. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Business Combination Agreement, ESGEN entered into a subscription agreement (the “Initial Subscription Agreement”) with Sponsor. Pursuant to the Initial Subscription Agreement, Sponsor agreed to subscribe for and purchase, and ESGEN agreed to issue and sell to Sponsor, concurrently with the Closing, an aggregate of 1,000,000 shares of ESGEN Class A Common Stock for a purchase price of $10.00 per share, for aggregate gross proceeds of $10,000,000 (the “Initial PIPE Investment”). The closing of the Initial PIPE Investment is contingent upon, among other things, the substantially concurrent consummation of the Business Combination. The Initial Subscription Agreement provides that ESGEN will grant Sponsor certain customary registration rights. In addition to the Initial PIPE Investment, under the Business Combination Agreement, ESGEN and Sunergy have agreed to use their reasonable best efforts to identify other investors to enter into equity financing agreements (the “Additional Financing Agreements” and, together with the Initial Subscription Agreement, the “Financing Agreements”), in form and substance reasonably acceptable to ESGEN and Sunergy, to support the transaction (such equity financing under the Financing Agreements, collectively, herein referred to as the “Private Placements”). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination is expected to close in the first quarter of 2024, following the receipt of the required approvals by our shareholders and the fulfillment of other customary closing conditions. </div></div> P30D P30D P1Y 12 20 30 P150D 3 0.035 425040 9234960 0 9660000 0 425040 9234960 0.0001 each outstanding warrant to purchase one Class A ordinary share (each, an “ESGEN Warrant”) will become a warrant to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share 1 11.5 each issued and outstanding unit of ESGEN, each consisting of one Class A ordinary share and one-half of one ESGEN Warrant one-half of one warrant representing the right to purchase one share of New PubCo Class A Common Stock at an exercise price of $11.50 per share 1 11.5 0.0001 5000001 20000000 1000000 10 10000000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7 — Warrant Liabilities </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for the 27,840,000 warrants issued in connection with the Public Offering (13,800,000 Public Warrants and 14,040,000 Private Placement Warrants) in accordance with the guidance contained in ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company classifies each warrant as a liability at its fair value. This liability is subject to remeasurement at each balance sheet date. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With each such remeasurement, the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Public Warrants </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described adjacent to “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described adjacent to the caption “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The warrants will become exercisable 30 days after the completion of the Company’s initial Business Combination and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, it will use its commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement of which this prospectus forms a part or a new registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, it will not be required to file or maintain in effect a registration statement, but the Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">th</div> day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption, but it will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value and (B) 0.361. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants when the price per Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> A ordinary share equals or exceeds $18.00. </div></div>Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within a 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants when the price per Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> A ordinary share equals or exceeds $10.00. </div></div>Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants: </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%; vertical-align: top;;text-align:left;">•</td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the closing price of the Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities—Warrants—Public Shareholders’ Warrants—Anti-dilution Adjustments”) for any 20 trading days within the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending three trading days before the Company sends the notice of redemption to the warrant holders; </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Warrants </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units sold in the Public Offering. Any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants will require a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting treatment of derivative financial instruments requires that the Company record a derivative liability upon the closing of the IPO. Accordingly, the Company has classified each warrant as a liability at its fair value and the warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value. <div style="letter-spacing: 0px; top: 0px;;display:inline;">These liabilities are</div> subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date. With each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement,</div> the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification. </div> 27840000 13800000 14040000 11.5 9.2 0.60 9.2 1.15 18 18 1.80 10 10 P30D P5Y P60D P10D 0.361 P10D 18 0.01 P30D 18 P20D P30D 10 0.1 P30D 10 P20D <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8 — Recurring Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2023 and December 31, 2022, investments held in the Trust Account are determined by Level 1 inputs utilizing quoted prices (unadjusted) in active markets for identical assets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s Public Warrants are traded on the Nasdaq. As such, the Public Warrant valuation is based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. The fair value of the Public Warrant liabilities is classified within Level 1 of the fair value hierarchy. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September 30, 2023 and December 31, 2022, the Company considers the Private Warrants to be economically equivalent to the Public Warrants. As such, the valuation of the Public Warrants was used to value the Private Warrants. The fair value of the Private Warrant liabilities is classified within Level 2 of the fair value hierarchy. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables presents fair value information as of September 30, 2023 and December 31, 2022 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 59%;"></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">  32,393,380</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">  32,393,380</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">496,800</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">496,800</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">505,440</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">505,440</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">496,800</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">505,440</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,002,240</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 59%;"></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">285,506,568</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">285,506,568</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">394,680</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">394,680</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">401,544</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">401,544</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">394,680</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">401,544</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">796,224</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers to or from Levels 1, 2 or 3 for the three or nine months ended September 30, 2023 or 2022. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables presents fair value information as of September 30, 2023 and December 31, 2022 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 59%;"></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">  32,393,380</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">  32,393,380</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">496,800</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">496,800</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">505,440</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">505,440</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">496,800</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">505,440</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,002,240</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 59%;"></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">285,506,568</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">285,506,568</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">394,680</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">394,680</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">401,544</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">401,544</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">394,680</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">401,544</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">796,224</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 32393380 32393380 496800 496800 505440 0 505440 496800 505440 0 1002240 285506568 285506568 394680 394680 401544 0 401544 394680 401544 0 796224 0 0 0 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9 — Shareholders’ Deficit </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference shares</div></div></div></div> — The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2023 and December 31, 2022, there were no preference shares issued or outstanding. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> A ordinary shares</div></div></div></div> — The Company is authorized to issue 250,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of September 30, 2023 and December 31, 2022, there were no Class A ordinary shares issued or outstanding other than the 2,896,555 and 27,600,000 Class A ordinary shares subject to possible redemption that are accounted for outside of the shareholders’ deficit section of the condensed balance sheets, respectively. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> B ordinary shares</div></div></div></div> — The Company is authorized to issue 25,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for each share of Class B ordinary shares. As of September 30, 2023 and December 31, 2022, there were 6,900,000 Class B ordinary shares issued and outstanding. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as required by law. Unless specified in the Company’s amended and restated memorandum and articles of association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the Company’s ordinary shares that are voted is required to approve any such matter voted on by its shareholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">The Class B ordinary shares will automatically convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have any redemption rights or be entitled to liquidating distributions from the Trust Account if the Company fails to consummate an initial Business Combination) at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, any of its affiliates or any members of the Company’s management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one.</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This is different than some other similarly structured blank check companies in which the initial shareholders will only be issued an aggregate of 20% of the total number of shares to be outstanding prior to the initial Business Combination. </div></div> 1000000 0.0001 0 0 0 0 250000000 0.0001 0 0 0 0 2896555 27600000 25000000 0.0001 6900000 6900000 6900000 6900000 20 0.20 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10 — Subsequent Events </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October 17, 2023, the Company issued the Restated Note in the principal amount of up to $2,500,000 to the Sponsor. The Restated Note amends, restates, replaces and supersedes <div style="display:inline;">the Note </div>dated April 5, 2023. The Restated Note may be drawn down by the Company from time to time prior to the consummation of the Company’s initial Business Combination. The Restated Note does not bear interest, matures on the date of consummation the Business Combination and is subject to customary events of default. The Restated Note will be repaid only to the extent that the Company has funds available to it outside of its Trust Account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Extraordinary General Meeting </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">On October 20, 2023, the Company held an extraordinary general meeting of shareholders (the “Meeting”), and approved the Extension Proposal to amend the Company’s amended and restated memorandum and articles of association to: (i) extend from October 22, 2023 to January 22, 2024 (the “Extended Date”), the date by which, if the Company has not consummated a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving one or more businesses or entities, the Company must: (a) cease all operations except for the purpose of winding up; (b) as promptly as reasonably possible but not more than ten business days thereafter, redeem the shares sold in the Company’s initial public offering (in a redemption that will completely extinguish the rights of the owners of the Public Shares as shareholders (including the right to receive further liquidation distributions, if any)) at a per-share price, payable in cash, equal to (1) the aggregate amount then on deposit in the Trust Account, including interest or dividends earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, less up to</div> $100,000 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">of interest or dividends to pay winding up and dissolution expenses (net of any taxes payable), divided by (2) the number of the then-outstanding Public Shares; and (c) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s Board, liquidate and dissolve, subject in the case of clauses (b) and (c) to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law, and (ii) in the event that the Company has not consummated an initial Business Combination by the Extended Date, to allow the Company, by resolution of the Board and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to the Extended Date, to extend the Termination Date up to six times (with each such extension being upon five days’ advance notice), each by one additional month (for a total of up to six additional months to complete a business combination), provided that the Company’s Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (a)</div> $35,000 or (b) $0.0175 for each Public Share that is then-outstanding, in exchange for one or more <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-interest</div> bearing, unsecured promissory notes issued by the Company to the Lender. If the Company completes its initial Business Combination, it will, at the option of the Lender, repay the amounts loaned under the promissory note(s) or convert a portion or all of the amounts loaned under such promissory note(s) into warrants at a price of $1.00 per warrant, which warrants will be identical to the private placement warrants, each exercisable to purchase one Class A ordinary share at $11.50 per share, subject to adjustment, at a price of $1.00 per warrant issued to the Sponsor at the time of the Company’s initial public offering. If the Company does not complete a business combination by the deadline to consummate an initial Business Combination, such promissory notes will be repaid only from funds held outside of the Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the shareholders approved a proposal to amend, by special resolution, the Company’s amended and restated memorandum and articles of association to change certain provisions which restrict the Class B ordinary shares from converting to Class A ordinary shares prior to the consummation of an initial Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the vote to approve the above proposals, the holders of 1,488,000 Class A ordinary shares of ESGEN properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.21 per share, for an aggregate redemption amount of $16,679,055. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the approval of the Extension Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor contributed into the Trust Account $0.0525 per share for each Class A ordinary share that was not redeemed at the Meeting, for an aggregate contribution of $73,949. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the approval of the Conversion Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor converted all of its 5,619,077 Class B ordinary shares into Class A ordinary shares. As a result of the Sponsor Share Conversion and redemptions made in connection with the Extension Proposal and Conversion Proposal, 7,027,632 Class A ordinary shares remain outstanding. Notwithstanding the Sponsor Share Conversion, the Sponsor will be not entitled to receive any funds held in the Trust Account with respect to any Class A ordinary shares issued to the Sponsor as a result of the Sponsor Share Conversion and no additional amounts will be deposited into the Trust Account in respect of shares of Class A ordinary shares held by the Sponsor in connection with the extension of the Termination Date to the Extended Date or any Additional Extension Dates. </div></div> 2500000 0 100000 35000 0.0175 1 11.5 1 1488000 11.21 16679055 0.0525 73949 5619077 7027632 EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&ULC93?;]HP$,??^2M.:55M$FI^ M "FE$*G05MM#-52Z[6':@TDNQ&IB9[93VO]^YR1D;*5H+XE]N>_'W\/<3;=2 M/>D,TO84D5369F<"UPJT%51,/4ZQUQN9X[O[ (/?),9&W"C:$%"LVE (7IS+GV)_.AS:\3OG'=DYGC6$.88&TM@ M]'K&!>:Y!9&-7RW3Z8ZTPOWUCGY7UTZUK)G&A? ML*UG9'FQS'7]A&V3.P@=B"MM9-&*R4'!1?-F+^WOL"<8>^\(@E80U+Z;@VJ7 M-\RP:*KD%I3-)II=U*76:C+'A;V4E5'TE9/.1$N%)>,)W+[0-6O4\.&1K7/4 M'Z>N(;Q-H9G>CLQ ^]JR.6AYWEX3%ZM&IZ!60*._?8WM0AJT=AAZW"8X:PD$7)Q.O9 MR3CP+ZXTE/^0,\@['MCO_>%J.JMXT$_'%W" MJ.\%E[U3&/:#T"<-87W?.W0Q[EX/%:@V]:30Y+\2IFFG+MH-H^NF!_^D-Y/L MGJD-V84<4Y)ZYQ6_W]D)&=,HFO:"?>?[OKO/SAWCK9!/*@?0Y*7@I9HXN=;5M>>I M-(>"JIZHH,23M9 %U6C*C:_'7D%9Z21CZUO(9"QJS5D)"TE4 M7114[F; Q7;B!,[>\< VN38.+QE7= -+T%^JA43+ZU@R5D"IF"B)A/7$F0;7 ML[Z)MP%?&6S5P9X8)2LAGHSQ*9LXOBD(.*3:,%!@:&+Q5 H?\*(&P!H:V[262K?$\U3<92;(DTTP7D[:,Y4N_&GL:4 M!NBE+?VLH0]?H1^1>U'J7)';,H/L3[R'I7;UAOMZ9^%)PB54/1+Y+@G],#K! M%W7Z(\L7_8_^.T97C#/-0+ED7DL)I2;?IRNE)7Y-/XY=1Y.M?SR;Z;!K5=$4 M)@ZVD +Y#$YR>1[$_LT)+?U.2_\4>[+$CLUJU"#6)!5%1/S:BA6(+LWMM'O(6V] M@?6&I)(,APCC.U2*$T)IY$(\APWE#3GEJG=VA.\OKK.[0Q"Y( /7[P?N%6:Y M(+CZQAZ=?=8Y@EH-RI;5%1\.^FX4Q"2( W?4C\X,1SB*73\:6HYA'+NC47CL MC;V#WBU ;NR$4L1>6=/&G;<;@M.F]W^'-Q/TGLH-*Q5>PAJA?N]JX!#93*7& MT**RDV E-,X5N\UQD(,T 7B^%D+O#9.@^VM(?@%02P,$% @ UX!N5^35 M/3B: P U @ !D !X;"]W;W)K&ULM59-;]LX M$+W[5PS4H-@%A$B69,=Q; /YV*(%&L!(LNUAL0=:&EM$*-(E*;O97[]#2E:< MQ#%ZZ<4D1S./;]YP2$^V2C^:$M'"STI(,PU*:]?C*#)YB14SIVJ-DKXLE:Z8 MI:5>16:MD14^J!)1$L?#J&)JYI%74H!:]0&JXD:%Q.@\O^^"IS_M[A&\>MV9N# MRV2AU*-;?"FF0>P(H<#<.@1&PP:O40@'1#1^M)A!MZ4+W)_OT#_YW"F7!3-X MK<1W7MAR&HP"*'#):F'OU/8SMOD,'%ZNA/&_L&U]XP#RVEA5M<'$H.*R&=G/ M5H=?"4C:@,3S;C;R+&^89;.)5EO0SIO0W,2GZJ.)')>N*/=6TU=.<79VAWFM M-98##[^*$_ MC"^.T,XZVMDQ]-D]=691"P2UA*6KVL97K>2HF<[+)Z!>!<'9@@MN.1JHFGH6 MP.Q^@&^K7?GI:'-S*-.C7 YG"@\E$@E!'>^@K3] X+^[$[5'@4.;A55K_VXME*57T$]+^MN! MVCG0]Z52=K=P&W1_9&;_ U!+ P04 " #7@&Y7S3IHSW$, !1A@ &0 M 'AL+W=O@.=UY<; 7BD7;0F7)1Y*3=MB''W6):\Q)L5VOP_S;'4NRUYN! M.7A[XE.\7)75$Z/9]29)XC5+BSA+2E"_>?YFGL."W6?)KW%4KFX&DP&)V"+<)N6G[/5OK'U#;L6;9TE1 M_T]>VVN- 9EOBS);MXEY#M9QVOP.O[8?Q%X"TSF2P&H36.?9*\NIJ3JO^J.6J4_,/.$ZK MDO54YOS5F*O$*,YFT@V@2RC@2:DH]96JX*0M.(17+Z$<_T+N?66\[O+"7P M85X.B65<\7^6W9.?>W7ROX?ID)B3H\G]EP*YY]K'L;)^+.(IYTW)%GL*$D6Q!GLIL_H7\]@]^*?E0 MLG7Q[YY\WC5R4=E3TV=,JY%#RH2BV++HBCWD\9^21Y:1^H4]A)4]7823,1\)H _-J M6-4=O\Q,XWKTLJ\;*)ZDF[O3S57J]D\^R"C#=!D_\]H9%@4KBSZQE!!=L9 P M'PFC[H%8KE']F!W%0$$EQ;R=8IY2L?LLC>*Z_^3C/[+8EMN>WWG6>K9_C MM.E?RQ6/OLJ2J*J(K>-,GLS*RKLQ(F(^$T0;F2C)W% ;% MDQ0>[Q0>*Q7^Q"*VWM02\OZR:%K6>9C,MTE8LJ@>\4:$O[I3/0J_%623Q[Q ME!DO VD]H'\C]!6./O65N=)5'PGSD3"J_O!-EZSK 65?#PO*AU0J)KM2,8'7 M^ZIU_^6M=;\]VKHK ^L*CX3Y2!B=]'3%U4^GZH-B2B)/=R)/E2(_/"?QLE4Q MXS/LB+$U>=SR9^>D'6+%"\*;\KC\1J*,/TRSLA)_D["2=^!BFG6_5R#>A05_ M:=-T GUSK#MEKG1+ !+F(V&T@4WW2T!'?% X27S3$)-F0UW'PV)%5HS7W&Q; M\IE3/6$J5XS\DO,I.[F=S[-M6O8)J ;K*MC2I*KB'%85'QJ5]D2UO+'A3CH: MH:+*(NTY&Z92)*Y"SB$.KS,=9_\Z61+A%YE*DV+6=G7%,=- G5Q;BH8VV7L;QM!P MNHT4K!Y.MCJ&ZZ,#":C58QXZ*I;K3L;N MN-NK^]# %$H+4#190N'XF&K+I[+1V>];/G@G]*7Z_[>/;/W,\E[G7,W2%A#J MXD!I%$H+4#198^'YF.,+?55B0GT;*,V'TBB4%J!HLN#"SC'_,#_'/,_IN%?G M4%MKJ%D#I04HFJRU<'5,M:WS _/ZZ>&(W.U1$NJY0&D42@M0-'EM@'!H++5# MOLVL^H&RY /@-)EKX[V@8,X-JRQ9UM=&:%+>Z T"J4% M*)HLH_" ++4'=)^$?%1Z6XU+:SF;F8EB&JKFZZB( MLGS"-K+4RU4ZW>LFS,E+F&S9%7FWX2+6S_=^XZ_F:JL(=8V@--K2.E.RPT5] MIZ^3-1).CZ5V>IKV,ZYK&(FV]7?&7)PXBZYVPJ7LM;FBU]!1!] 6:W)0K"UG M;-B.T_U:!1J70FD!BB:+*BP=ZX2E\UWC6N@Z&RC-A])H2]LO8P;N! ML&?L$PMH5,-4\E^B]4V*.I;V)@2HXP.E42@M0-'D,B <']N\T!#6AB[1@=)\ M*(U":0&*)@LN3");;1+I#V%;8*>K=ZVN2Z0.K"TAU"6"T@(4399P;Y^8EDMT M_C"VY9X:W-VKXVLKB=T$AMT%=@FCR!9&D:TVBGY\L-L&D&9=SF1R^*67.B?: MFD)-(2@M0-%D384I9*N7$#UMLK3(VFI8;2]Y87EQ9!-)BY(6?WKFU!B/N^I! M'1XHC4)I 8HFJR<<'OO4AK'OF*G8A]9'OP.O#JXM(]2_@=("%$V643@]]@FG MIY[:W)WOP*MYVJ-9J,,#I5$H+4#19)V%6V1/+C5]@;I$4)H/I5$H+4#19,&% MDV1K.4D:8U^HFP2E^5 :;6DG+=S3U\F'&PA?R3GA*WU/'ZIFZNH#I?E0&FUI M^Z,%;]JWM_*,"V6%A.OCJ-?Y*+M'7>=/'4M;.:@1!*51*"U T>0R((P@Q[I0 MU^E MWA!:3Z41J&T $63!1>VD7,AV\@YTS92Q]=6$FH;06D!BB8KN7=\D-HV M^I#&91PF;WO==WMKE:TT=(D1E.9#:11*"U T66KA)CF76F+D0)<806D^E$:A MM !%DP47!I1S8HE1*_)G7L=K][>L'FW3B.6O.:_VO)I'<5%O@2C(N_BM/>]O MN*&+CZ TWSGTS*RQUS,,IM"X 8HFRRN,*4=M3'W'T6]09PI*\UN:M#_;-(96 M5\'F,O6Y;I/>39G+"K((L_6M3QARI4YTM/VZ@0UE* TWSG< MXV9-3-?JJVU0MPA%DU45;I&C=HM.#93X5)?7P)=JR\1CPK.QKN:ZOX9Y'E:M MJW(X!;63H#0?2J-06H"BR>0$KWFP5UIK1+ -2S@M(HE!:@:')AV3LE^U*>E8L] M.AM[=C;V\&RH9X6BR8(+S\I5>U9GM>;>J1;S7AU%6R_HZB@H+4#19+V$">6J M3:AS6O/FI;/FPNIHVK46ZE!!:11*"U TN10(R\N]U-HI%VIU06D^E$:AM !% MDP47;IBK=L.^8RX,=;F@-!]*HRWMA),=H(+*-[,0]I5WXD"E@S'VCSN9ZI"Z M&D-I/I1&H;0 19.+@C"VO$MMW/.@!A>4YD-I%$H+4#19<.&#>6H?;.^V-$=N M4U*0<'<"U"*,<[(.\R^L;%;Y])8$J#$&I?E0&FUI^S6_QPF25;6C7?6G-^E;+JA#AF4YD-I%$H+4#19:&&F>8='E/>76 M9+4[.I5-,?9N<-C;P6'O!P=UPE T65KAA'F7.DC<@YI>4)H/I5$H+4#19,&% MZ>6IUWG]4;<+5&=+N[A +3,HC9X00'G+0%1.Y,(A##+O__.&X>JQN<*7L\M4@7=6@-!]*HU!:@*+) @OC M;'PIXVP,-Y8DU0L]W8Y /FUNN2G;+DI$"J"",(@[+L35UKQ+7TX"JQ9\$=F+O&>FA+!A[U(5OV=AR M=(\@AU1J"JQ^MC"#/-=,JA_?&U*KU=3 _><7]J0:O!K, @N8L?PODLGUV!I: M*(,E+G-YQW9?H1E0H/E2EHOJ/]K5;4//0FDI)"L:L.I!06C]BY\:(_8 BJ<; MX#4 [QC@OP,8-(#!1Q7\!N!_5"%H ,%' 6$#""OO:[,JIV,L\63$V0YQW5JQ MZ8[F/TZ=?/(ULJ80VWTT;DNA;QWA$9H!M&Y5J@.C]EY&?>T9">]A[OOO%%, M[[-78H-3&%MJ(Q7 MV!-?OO%#9T_NN)P4F[>IUQBDCOPUF^]]8W>/E .*5,K M]%_(D,1/: $4EJ3;VYHJ,'AK%#O7VY-R\S[E$I/<@;=!ZVWP8]ZJ;)?R4E6J MO(T(E:!Z)ZL9KM(YSJ7:%KOL#T[:;^S/N?8')Z=VGW*):70']H>M_:'1_JE* M-%\RDI?ZRP()2$M.M+4(2\G)HI1XD0.2#.TPYRH[J51$*!)KK#K;F8*, M**N04$PC((H&![%LT_9I">R@W@.VW@. MC?&\Q<^%3NDZ>--4I7@.Z$[MBIRD4FV4W^A6%8KWDKZ1^]Q0]DD6#]^L3-?Q MO2@\7IC#4YMMTE.W#J)SV4;G\M1J*XLRQSH4L4IA*9'H[QLH%L#_Z8J'D>W< M>/1)%O=)-N^3+.F)[""^KO-Z2'/^[_VT4=B?ZU'H!EYT])'2M-N?ZZ[G!Y$? M'#:,.PC5RO&"Z'CQ=#&& W]X+)V83?A1D_=.PJ[Y()-C(= 4I:PHE)/JZ)T^ M&M>1F>_Z]Q]OH[5#5[LP)T4G/(K?7VU M>8/YBE"!S#^0J-(PJH8[X+>:OQ=%[K:+R M+YXD%9(8QQ\-Z.Q0LTH\?O^&OJS)"S+? MHH+?9\G7>%T^W\SVUB]9FVVA5EMFF2 MQ0@V<;I_C?YL3L11@L"!$VB30/L)YDB"T208J@EFDV"J)EA-@J6:8#<)MFJ" MTR0XJF?);1)D^#5:%=:)_Y*DM7<1)' MM3JS1^U7\1W\)2L*; MBF%6Q>:K9DAW^R'1D2$9VL:H;^LT9U:@#CN9>G_W>72M,7\O2/42[2R6BZKSYX"J0OU0DJ2#F6JDC#!?( !H:;EF%9/2IA5 TPP-J1@FPXUO-Z7(82HV@:U MCP([2G(.2G)4IQSQDNS65=,?8X.YF[J>;5F]>>1>.H:I>L4$\P$&CJU7_WI3 M(6;5 !.,#2F(6V?+-7MWV:$"U8Z$B-X:;+J2B#29B-9QLBM!L^NN@3^M(_DX MI@H)%[:KK1TOXM8^W%ULH"-;3' M=(_&HU_V&YI[>>7) L)$\T$&Q.B+![-F@(K& 87Y++?%X<@4<,:D0UM94.E MLEGL)YC)PJ%*PI'6GBP<3#0?9# 4#F;- !6- 0Q X4!$1X736MY$[GE+>WGM M;TW9?)77F=KDHZ(M4-%\5+0E*EJ BL90T4(LM*[2VU4$(E]&0''7FAK']]2@ MNR8?RV3]HJX? !Q@?PVU;("*Q@ 2%[#'!M&5>6RD]?6)LK&/[+(1P(LV7*^_ M-GPB=O7SS#2LPW;,,;TTRX%$/E:P/MKZ MHZ(Q@,6(/:% MRNFUODG")W($_S^WRE$P+5-\=%[ZWNVZ4W>U MY'A372U4M 4JFH^*MD1%"U#1&"I:B(76571K_%.Y\?^^[KX![SRHY &-S+U\ M%).5B[H$H$IBB5HV0$5CJB1"A<"NE-JE "I?"GAO;]_ *X@)U=Q'1?-522Q1 MRP:H:$R51*@0V!53Z[93N=M^5F??8':: _U2[[N>\M*3]8-JK@,4! .O+QY4 M9QT5C8$,#*>O'"B*>B.R:2UU*K?4S^WL+37AH-KEJ&@^0 $2#JI7CHK&0 9# MX4!1H\)I77(J=\FEG?V4=6QYGRHW[_^Y]6HZ MM(@O/-VU!W^ 45U]5#0?X&#K!K7[ZXVH50-4- 9PH);IDL%_88,"1=?OD3&1 MM98^E5OZ9RQ7-XCV2?6@6OJH:#[ 58/JJF/BL8 #B/J 0)EZC%:9]]0>YK^ M/#O+&#Z7#3L0\E%,51(JFJ]*8HE:-D!%8ZHD0H7 KI1:K]^0>_WOM;,:> 4Q MH;KZJ&B^*HDE:MD %8VID@@5 KMB:FUV0VZSGV5G&<"3W8 K(2\]63^HWCI M 7 E4&L&J&@,9#!P)<"H,5?".-I01FZIGVEG-:@GA8/JHZ.B^0 %2#BH)CHJ M&@,9#(4#10V$,S_:P6O#\Z=Z^[="J_?CVN]/=#AZV&+N0[VQ6N_X';D*"'"< MD:MPOX%<"[_?S^YCE#_%::$E_%&4TB\=,3OF^RWB]A_*;%OO'_8M*\ML4[]] MYM&:YU6 ^/UCEI5O'ZH"AXWZ;O\/4$L#!!0 ( -> ;E?9R9U*N @ -)A M 9 >&PO=V]R:W-H965TLXO>H]*;6YZ/?3Q9.(>'J>;$2L/WE,9,25 M?BM7_70C!5_N@J)UWQX,QOV(AW%O?KF;=R?GE\E6K<-8W$F2;J.(R^\W8IV\ M7/6LWNN,C^'J264S^O/+#5^)>Z$^;^ZD?M??4Y9A).(T3&(BQ>-5[]JZ8,XX M"]@M\;]0O*0'TR3;E(IV1]'I\+:"] M?[M-EYOS -/Q6VR_BMKWK1'EN*1;]?J8_(2B&*#1AEOD:S3 MW2MYR9>=S'IDL4U5$A7!>@VB,,[_\V_%CC@(T)SF +L(L(\#AB<"G"+ :9MA M6 0,VV88%0&CM@'C(F#<-F!2!$S:!DR+@&G;@%D1,-O)(?_^=E^^RQ6?7\KD MA*;/+%] M(K%#/B2Q>DH)C9=BV1#OFN-GAOB^W@G[/6&_[HD;VPB\%YMSX@S.B#VPG8;U MN6T?;C=MSH]EIS^6W3.'_[E0Y\2:G,SNF\.O-_*<#$8GPP-SN"L6>N6MDRO/ M6F2W\Y6W#$)P]H>$L^,Y70\)\O?O>E'"E(C2_SLBW?"%N.KI M\U(JY+/HS7_ZCS4>_-8D-R3,1<(H$N8A83X2%B!A# 2K"'JX%_301)^[6T%4 MHDN37->;3-=-\LTIXQTE*Y*>Y\Y@9LWT$?U\*$QCLJ[";)>3(G-Z2)B/A 7U MO6$-A[6]P4 Y*V(:[<4T,HKICG_7M:Y*R:>$'+:4H4B;-&6$=6T2D3 WAXT. M]O7@2'2CVK=QM(2'7"$?"0N0, :"5?0VWNMM;-3;O>X'A?'JC*Q$+*2N1'F\ M)'RI2^$P59)G724BONF^7RJ:]#>N?K87],S8 M(O^Y5:G2YV]]/BBNFD;"7"2,(F$>$N8C80$2 MQF8-)=&AT8Y4KSLC(E8;S82JD5FM6>&QXV7:Z\,<.Z"A1* MEJ-92NT*0>E.9#:0&4QE"TJDX/+N%;D.L[!::B@HDUG4VG1]TA<[[. MXFN9ED+3>E":#Z4%4!I#T:KRLTOYV4;Y?=9MI&X?LT)5)E&8IHG\3O[09W%C MG\L,[=Q<(FDNE$:A- ]*\Z&T $IC*%I5UJ4+9+V7#61!?2 HS872*)3F06D^ ME!9 :0Q%JTJ[](,LLR%TDT@=D]6S4;*-5:.&D;[&+93F0FD42O.@--]J,(1& M@WKE'D#3,A2M*L_28;+,%I,K'A1A<:KD-K.:SO2T$CJ1(A]UBWQ&[E7>, NY MT!_S5>/E G..S@*&6D]0&H72/"C-+VBSTQY: $W(4+2J=$NSRC*[5;\G\>K7 M3T)&)!/Q&?%EDC;ZHE;=3+)L9SHE":#Z4%4!I#T:KZ M*RTOZRW/*\T;Q[?[7U#3"TISH30*I7E0F@^E!5 :0]&J4B[-+^N]W"\+:G]! M:2Z41J$T#TKSH;0 2F,H6E7:I0UFF7VP-OTOJ-T%I;E0&H72/"C-M^K.THG^ M%]3/0M&JOX,O?2_;['M!^E_F'%T%#*6Y4!J%TCPHS2]HIOX7-"%#T:K2+:TP MVVR%-=>_Y!]ROWU(Q=>MUBNAS]FKJ38V)^FL7:B;!J51*,V#TGPH+8#2&(I6 ME7EIN=GV.]7&-M1V@])<*(U":1Z4YD-I 93&4+2JM$O;S39Z'VUJ8S.ALX:A M_AJ41J$TKZ =5K-V4S7K0],&4!I#T:KR+*TSVVR=_97(+]G/%Q=\$RJ^)NM$ MM[WDA4O=!K]15$ =-2C-A=(HE.9!:3Z4%D!I#$6K2KNTW>S1>Q454*\-2G.A M- JE>5":#Z4%4!I#T:K2+FTY^RU;CL=DD<3/0NY&Z> K*41V;>.UY6Y4=?U. MKL:+/[?FY)T%VS(MA:;UH#0?2@N@-(:B5;586G2VV:*[DV%^VX-)>I.Z!HY% M!W7MM4;!F36&CY*8U!=3:.:@3 M]G9""DWH06D^E!84-,/=Z R5L*JCTK.RS9[5\6^[7T+U1-K?8FNF=RX1H7X6 ME$:A- ]*\Z&T $IC*%IUS)_2]'(&[]3[<:!.%Y3F0FD42O.@-!]*"Z TAJ)5 MI5V:8H[9%/O OX71-B(/NTNKQ=4KO@BUSFMWWV[*9O[4C;CF;)WU#G7'H#0* MI7E0F@^E!5 :<^IW_#G5'FQ5R:7OY9AO-3N\@?RT/U! CFXX=(;CHWK6G*RS M]-IEI="L'I3F0VE!RSW"4%FKHCH8[N^''228#:?]^%?^P?A7U]7QK_8#%1S\X*5]U\R\ IW% M#36FH#0*I7E0F@^E!5 :0]&JAT!I3#GO94PY4&,*2G.A- JE>5":#Z4%4!I# MT:K2+HTIQVQ,M1VZPVDPA<:CNA5E3M=9HNVR4FA6#TKSH;2@:8_8=6^.H;+F MLNH?C.\>";G:/1P@)8NL7,W'M=[/W3^ X'HW[/[1_!OKXM9JF.]:%S1_O$") MSY]V\('+51BG9"T>=:K!^40?+S)_@$#^1B6;W>CR#XE22;2;?!)\*62V@/[\ M,4G4ZYLLP?XQ#O-_ 5!+ P04 " #7@&Y7J]M?'6 " !1!@ &0 'AL M+W=O!3K?)'PG4(G.&&DG*\9>=/ YF5J.%@048JD9L'IM80:4 M:B(EXW?#:;6?U,#N>,_^:+PK+RLL8,;H#Y+(=&K=6BB!-2ZI?&+5)VC\&($Q MH\(\457G^C<6BDLA6=: E8*,Y/4;[YHZ= #NZ!6 UP"\2P%^ _"-T5J9L37' M$D<3SBK$=;9BTP-3&X-6;DBN=W$IN5HE"B>C!8<"DP1]W*ES(4"@JSE(3*BX M1N_1\W*.KMY>3VRIOJ3S[;AA?:A9O5=8EU ,D>\,D.=X?@]\=AX^AUC!70/W M#N&V\M>:]%J3GN'S+S,Y0+.2<\@E^GF_$I*KH_2KSV--.NHGU==K+ HS O]_Z]\^QM_Y)+DJ.\_A?!?ILUURAX=)-8!N% MCMJ%;=?-:8X7.K=NFW4@<]3*')V5^56FP%'1B(7F1)[56A,&'1U^&-P=B3U- M"ASOKE]KT&H-+BKI\9$:H&],8MJG-3BIV<@+W2.MITF^Z[K.D5B[<^%UL_V" M^49M+J*P5CAG>*-H>-W ZD"RPO2 %9.JHYAAJGH^<)V@UM>,R7V@VTK[%XG^ M E!+ P04 " #7@&Y7;)KMP)(" "@!@ &0 'AL+W=OZZ=+.K6K$*(E\0?]QR?>VQ?C[="WJD"0)/[DE=JXA1:UQ>NJ[(" M2JI.10T5SJR$+*G&KER[JI9 !GQGL%4[;6(R60IQ9SJ?\XGC&4' (=.&@>)O U/@W!"AC-\=I],O:8"[ M[4?VCS9WS&5)%4P%_\%R74R<0=6>#I MR1N<%BLR%65-JX>WBOP-6)&C&6C*N#I&GMO%C!R]/AZ[&K4;!6[6Z;QJ=08O MZ%Q ?4I"[X0$7A .P*>'X3/($.Y;>/ 4[J)CO6U!;UM@^<)_L>V:T27C3#-0 M)V3:2 F5)C\OETI+/+6_AI)O5XN&5S,W^4+5-(.)@U=5@=R D[YYY2?>^R$K M_A/9$V/"WICP$'MZ#6O*\7*B$Y0/9=K"$PLW)6:3QE[DGYE=V>PFL1_GGWD8 M.NKCGNB+>GW107U?=0&2U.VN*;MMT!W4(;4M6;RC(HBCT$^>B=T/\Q-_%(7# M6N->:WQ0ZS>AASV,]ST,1HD7GC^3M1_GGR?):!0\T^7NU ]3N[]0N6:5(AQ6 MB/1.SY!(MO6P[6A1VY*R%!H+E&T6^(2 - $XOQ)"/W9,E>H?I?0/4$L#!!0 M ( -> ;E<;]YU340X ":@ 9 >&PO=V]R:W-H965T+B*1/?\QGG!?DQ3]+\LCYL?9@J?REVDFYF$AOXJ'?KX0/)R4B>9)WQX,3OKS,$Y[5Q?E MMEMQ=9$MBR1.^:T@^7(^#\7S#4^RI\N>U5MO^!(_S JUH7]UL0@?^!TO?EO< M"OFMOZ%,XCE/\SA+B>#3R]ZU]3YP3E2"\*A0B%#^>>1CGB2*)//Q9P7M;6*JA-N?UW1:'KP\F/LPY^,L^19/BMEE M[ZQ')GP:+I/B2_;D\^J ',6+LB0O_R=/U;Z#'HF6>9'-J\0R!_,X7?T-?U0G MXB4)["J!O9/ =@XD&%8)ACL)AJ<'$HRJ!*/="/:!!$Z5P'EI@I,JP'DAP7B4X+^6PNG[EQ7?#(KRZ$-D3$6IO25,?2@65J>4U MCU,E]KM"R%]CF:ZX&F?S>5Q(]18Y^36<+SZ0<986DH\2-2MV_>D3>D3_)9*.396OUIR.K8#/X<%+;OALIGIFZC^7Z3ZU 4-?GCG;@&&O/R2&(L'7,P8YH,AYLR.RQ## ^$^,*3L. 3+,.*7/=EPYEP\\M[5K[]8)X,/39)&PEPDS$/" M*!+&D# ?"0M ,$W0HXV@1R;ZU=>99,ZR9$(67,39A,A.'$FS@A09*92\IUP< MD3#/XX>4R)]D7RDA8?I,LBDI9CP6Z_I7_O84"IE"MF;AM.!"_4RB;+Y(>%E M5@E(G,9%'";D?IG+K.2YVN4^3D.U3U.Y,6:_:[E!PEPDS$/"*!+&S/H9#L@D M?&ZL\Y&Y"$ PK8PXFS+B&(_Q8_@CGB_G)%W.[Z6NI9 G\K8GG>1E81'\(#2_ZC]M*18:C2!AK MS;N/#!> 8)HD3S:2/#%*\@N/LDU3S@]*Q0CN*A4D MS$7"O-.]ZW=N#T?G)SM7D2*#LM.]RJPQJ(\,&H!@F@[/-CH\,^K0W5.?JM-, M\C/RNLH/"7.1, \)HT@8.]O3Z*XZD>&"L_UR>'(RD/\V037AG6^$=VX4WJW( M(LY5;TYD5H)(-9IQ^BB_K ;J#DC1&*&K%)$P%PGSD#"*A+'S M/6W8CG-VZIPZ9SN2W-]SMS4&94P3HS6H1X4'1CG>K>ZG@SQ?\LD1N94BY.16 MML3E#TWB,P.[J@]*N M70O7;KDEEKA<-C1J@:+I8:QO) M,@[J7]VL1[_']>@WN7X0G*MN)OGC(U=#C8U&DIG<6;50*PE*\Z T"J4Q*,V' MT@(43==V[2A9HU?R2"VHV0.EN5":!Z51*(U!:3Z4%J!HNK1K(\AJ<8+BM'2" M/O&"?,M$,2-?^)_+6'61:2949;Z0O>-4WK =ZG(X>XV=HT8P!I;>VHW-&>DL M7B3-@](HE,:@-!]*"U T7;RU9629/2/$.)>U[V78@]6_70%#K1\HS8/2*)3& MH#0?2@M0-%W M5%EF9VJ<1+*'O.UFC$RE[V)O,BB[^:N,M2@@M)<*,V#TBB4 MQJ T'TH+4#1=T;7E99V]5E<9:GY!:2Z4YD%I%$IC4)H/I04HFB[MVE2SS*[: MN*JD2S?CB"Q"01[#9,F/R-L%KV8--LWQO3%S.RL;:J95-,O:'E0]WN^^>]"P M%$IC%>VTY1A\:-2@/:K^7$#ME]EHO\P,[*HP*,VM:-N>^IY?!HU(H33V@OS[ MT(@!BJ;+K_;+;+-?MNJ4WI"JOKMK[92:>9W5!W7'H#0/2J-0&H/2?"@M0-%T M1==&FFV_4J?4AAIJ4)H+I7E0&H72&)3F0VD!BJ9+N[;=;+/M]M.=4C.WL[*A MIEM%:^^40L-2*(U5M-9.*31JT!Y5%UKM@=E&(^+J*Y\O,A&*9Z+\@>+YB$2A M$,]J2D(XSY9I<;1^WBI.J_DV;R?5S)MWAP9?S3$[BQ!JCT%I'I1&H316T5JG M@_O0L &*I@NZ=KYLL_/EW3'OT[J3NQZ(77=SI6#_QH0&<^3.LH8:9U":!Z51 M*(U!:3Z4%J!HNO9KX\P^>:T.,?1A*BC-A=(\*(U":0Q*\Z&T $73I5U;:G:+ MI?;3'>+3%_77QN;XG34+-8'Q3[Q)W*[O!]G MA[HCC7J%^F50F@NE>5 :A=(8E.9#:0&*IJNZ]LOL\]?J9$ -,RC-A=(\*(U" M:0Q*\Z&T $73ETRJ';JAV:'[Z4Y&Q6WM9)CC=]4LE.9!:11*8U":#Z4%*)JN MV=K6&[[$UOL\)=]6RV60SX*4RU$2E^>1B!>'UBMJX?(PFI%L6>1%F$[4<&"U M'(=:F6.Q%-%,#05FLKXO,[ ZH&N2";FO&DTLRPIYJRA')$S)K[^I7;.%TEPHS8/2*)3&H#0?2@M0-%WHM5LZ=%YI,&<(-4.A-!=*\Z T"J4Q M*,V'T@(439=V;88.S4\1_OR-,=0+A=)<*,V#TBB4QEJN;I;R?\S"9%HNHB(K MJO6@@> EO'P]0;FLJ"@O^?]J+,&'GI0 1=.+5&W"#E]DPI9GY4B]!$(M9*,: MBYLPCYN[\&9@.<@4EP]$R%,\T<:;EFE5 :A=(8 ME.9#:0&*IHNZMHE'UBL-](R@CX%":2Z4YD%I%$IC4)H/I04HFB[MVEL=F;W5 MS7K\OVTO_NO&>:2>7VJ4-/3QSXIFV?KLG^%.5\6%1O6@- JE,2C-A]("%$T7 M:VV3CLPV:?=%(,S SF)M\E0'Q_:N5E>[&5=#AV:,0FGL!?GWH1$#%$W7U=;; M\A5 :A=(8E.9#:0&*IDN[=BM'9C]K,RAVG4ZJ43'R>K2IJ>9&X?3S.$[%P"HJ0FE>5 :A=)8BPA,[RB%^H@HFB[V MVD< M[A666NA-J )5MB"J9B%/<3&3.ZBR--1^6L/5S0)/HV9S MT9S3SL4"ZD-":1Z41J$TUJ(7RS&T(E#3$473"T9M.H[,IF-=,#2)J[:DL1&I MUI'?;SJ.?KKM./SB;'/>.Q<5J,L)I7E0&H726$7;G@UA[PT#0;U+%$U__WOM M73HM:\R6@SRK&6J%B!\>E*Q;.E4-?:E*^JHPR#W^1OEXJU[.ER5)*')B?H36 M?&!="PR4YD)I'I1&H33F-+Q%+8OX MD?\_-BCFX^AXV*-"( 8JFEX_:7'7,YFI77T'^ MOIX_<[>\W\RS?^$*>^;,=!8Y]"E7*,V#TBB4QJ T'TH+4#2].-3VK3-\)0?" M@=JX4)H+I7E0&H72&)3F0VD!BJ9+NW:0G18'N:S'5Q,3B+LLISS>EH-"1ZO) M";);4_VJ>D1W,@/R+B,WSD:O0NHO66AZ"9LY;YWU##6+H30*I3$HS8?2 A1- MUW-M%COFA8"[S[1Q]M]YN3MI9&P.VEFH4.L72J-0&H/2?"@M0-%TH=;6KV-V M_4P5[^^KY<>:Z]W&M=>=_1=?6LTOOC1GJ[.4H28NE$:A- :E^5!:@**MI-S/ M9YP7;EB$5Q=S+A[XF">)&J]8IH7J(V]M)8)/U;O6WE_;O?[>=M=Z3ZV&[ ;E?K^EVHV@8 M $ K 9 >&PO=V]R:W-H965T>-!@GE:6]REA^[EI,SL=$Q3]FU)&J3)%0^7K)8;,][ M?F]WX(:OUMH<&$S.,KIBMTS_E5U+^#:H5"*>L%1QD1+)EN>]"__=+ Q-0'[% M%\ZV:N\S,;I.??O!'WB]M MA%R*S0JQXUS,3##WD^!D//3@[VQPWT)F6)$9HF1N3<*1:\D7K U($>Q[>^V> M]OU3ZZ_J0'';1T/[HAG:J@N19Q1*Z9Y"(B M,*N1&[;B2DN:SY"WFFH&,ZXFGP6Y9.3]R*TY&8A=/WZJ+..S0- 1^U\$H6L23+QW$%&,K,Q5T[W7YKW>>U !TW>.)] M[ K4E9I-=*],]O&2)"=4 -.2KU:PXH+KVJ<)'+-BSMSE:RNZHIW1/KHGY-"^ M=";G2,TF%]3D@@,KFZRH; RV5&BB!9"DJ5HR>42H4GP%#,&2@@6HF3I4FWF2LUF M6?L=_P7#(ZDQO&1&32'$87"#K?D,PW<&-L>42H6?,4?^%-KD(A14.S?3RAIO MST>&L5,[XTK-YEH;&A]W--\QC$<'#&.GML:5FHVH-C8^;D1NZC4;,/D:K(J=^ MQY6:S:-V/#YN>6Z:53@41XWRD;SA*8E$'(-ISD_G=5"KORD;:SS?:CZ:P+O4 M&>!K6)R@MC@!;G&NH,Q+-@E4?+OR]=>[R7UAZ\ MW:YKCU.UF2LUFWGM;((#G,WS:T\9;;U/\/K-R1-OHS.1US R06UD MS(N%U] MRL;0 A+O4&=\K^%=@MJ[!+B7>-VU!V\;6WN<^AA7:C;CVL<$N(]QNO;@36%K MCU/?XTK-1EK[G@#W/=VM82F(CVRG-L65FHVHMBG!"^]O&B^]T!77I1^9.E6; MN5*S,=;N)L#=S:%;&W"9S@B=^IM2S;*DX=A[?G=#6'N7\(77,\]D&?F/='[$ MB#?5>7N(4_OB2LW&7-N7\(5W-IWGNU+0*@5]O]]\4XBWVYG2:SB2L'8D(>Y( M ,N]>>1ZT)R':W7.-JC[5QN]W.YW=#U=$>7/_3:=G0-]K8< M)DRN\JV;YE7;)M7%[L/J:+4]]"+?%#FH+R_VEEY1N>*I(C%;0JC7/X'F9;%= ML_BB199O8)P+K462?UPS&C%I+H#S2R'T[HMIH-HT._D?4$L#!!0 ( -> M;E?"UHK)QP0 -&PO=V]R:W-H965T$I\!XE_)GL0*0Z'L<)6+BK*1<7[JN"%<04W&1 MKB%19Y8ICZE4A_S)%6L.=)$GQ9%+/"]P8\H29SK.7[OGTW&ZD1%+X)XCL8EC MRG]<0Y3N)@YV#B\\L*>5S%YPI^,U?8)'D)_7]UP=N:7*@L60")8FB,-RXESA MRQN?9 EYQ!<&.U%YCK*ES-/T.3OXN)@X7E811!#*3(*JARW<0!1E2JJ.?_>B M3GG-++'Z_*#^/E^\6LR<"KA)HZ]L(5<39^B@!2SI)I(/Z>X#[!?4S_3"-!+Y M7[3;QWH."C="IO$^6540LZ1XI-_W1E02<.^%!+)/(,\HX^D*C#: 9 M4+'AH'9+"O1G<6:;GUDQX)2'JQ](=1"*&)VSB$D& L5%S@)1B98Z(=_LPR64 MWTR@-[<@*8O$6R7]^?$6O?G][=B5:BU916ZXK_NZJ)N\4/5@Z6-I+21Y'K^"WK:O'?H2@A0OM%D@>XJ!LT.!BE+ MM.M9U-]IHCVZSCWZ=J84U?3:J\E&_U*L:0@31\VV +X%9_K' M;SCP_FJSRI)8S3B_-,XWJ4]GE#^K=IA'@$3F0>'5"J(%8@GZQ-4$H*LP3#>) M;/.A$ ]R\>R.M9WZQ!_Y_M ;N]OJ&IN!9-CO>T$_&):1M07TR@7TC O06_EM M!O$<>.M^&36Z[IJ,W U]I M]$&Y@(%Q 9]22=6[$^6<)K)ZZV\K=]"H GOJ3MO[N=IFW& 4J+CV4H=EJ<.. M,XG^0_>;><1"]+58@#".JU&^:]=9$JLY,2J=&)W5N(YL&F=)K&8<]C08>?;Z M?:]5;>3>*!AZ/_=[2YP_Z@65*:Y76\$X_ LMS]F62CBNY\T7Z+IWMM3J=F@< MP^?%8]@JD-E2JYNGD0R;F:Q;Y_N-CNY[_5[C3M\2U_.P"GRA\S5_83. W<$6 M(H2K?7\.,[U>:T+ 9T8Z:VH[49KYDYYX\!;=A#6[XO,@-6T4W6VKU M#V,TNQ&+[$:.9+>6.-,L$,UNQ,QNQ2R0[N]@9MW.'P.= ME(Y1.T\T(V8O=LJ=7-TSA'S#C7;1B:2-8^#,TXXS!H;B-F;BN&P?^%N[]1M_.>65*KNZ!Y MD S/J^&MLJ(MM;IYFA6)$:%U+_FT4CFFY'LJ#;O>L\W7[/K M+MI2JSND,=#'9S4"OE5ZM*56-T_3HV\$K&XCL-<*#"-@#"EJ="O?NF<_>9A1 M_L02@2)8JASO8J#FAQ>_(B@.9+K.OXB?IU*F ;E<_WXT/SP( #P( 9 >&PO=V]R:W-H M965T[ZV CU:U> 1AREW.AA][* MF*+O^SI=04[UD2Q X,E"JIP:W*JEKPL%-'.@G/MA$)SX.67"BP=.=JGB@2P- M9P(N%=%EGE-U/P8N-T.OZVT%5VRY,E;@QX."+F$&YKJX5+CS&Y:,Y2 TDX(H M6 R]4;<_[5E]IW##8*-WUL3>9"[EK=V<9T,OL X!A]18!HJ?-4R )L\ HAH0O=9"KP;T7FOA MN :XJ_O5W5W@$FIH/%!R0Y351C:[<-%W:(P7$_:=S(S"4X8X$U]!6BK%Q)*< M4J;(#>4ED N@NE2 S\%H\I&,LHS9K%).SD7U-&V.#Q(PE'%]B"K7LX0?_K$__V?JC8$3-ZX@<7_0,7P**K:DM92>_1G,48:7_;DM[1=QK)[;=KZ\+FL+0P_:F0:W!BS^\ZYX$7]MB_I9D MR5N23=^([%%V>DUV>OO8XX>*[9#O8//29&ND-0H.OC$Z9YR9^\-M36<$*_>A MZ,=4,]TAUT+.K7=TSFVFBQ+K'I6D2!'MJKU#?B@J] *4=L;:4EYY>^*\M?-I M'0<#?[V;QQ#H$W9K5 ;E&PO=V]R:W-H965TQG6RXN)$% M@$)W):ODQ"N4JL\PEED!)9%#7D.EWRRY*(G27;'"LA9 <@LJ&0Y]/\8EH967 M)G9L)M*$-XK1"F8"R:8LB;B_ ,8W$R_PM@/7=%4H,X#3I"8KF(/Z5L^$[N&. M):E >ZVM^P?K7?M94$D3#G[07-53+QW'LIA21JFKOGF$[1^ MQH8OXTS:?[1QM?%[#V6-5+QLP5I!22OW)'=M#CN 8/0((&P!X7,!40N(K%&G MS-JZ)(JDB> ;)$RU9C,-FXU%:S>T,JLX5T*_I1JGTGE!!!2'#63OKA9LU?&Q6 MJ(^N95$/L?^BS_)[*] *(N M@.@0>_IWN=V*#MHG(HTJN*"_(>_S[TC'EM0<%^LT\.TOP>M=:T_7[:D>=:I' MSU5M%G" :B+0FK &!NBX!N%,G/0I=\2G.XK\H=83/!#^9-F>[G&G>_RRM*F4 M37_2XW\2?)CQH8H]E7&G,GZ92GT72$6JG%:K/JGQDU(/53BI>.= ,Y?)%R)6 MM)*(P5)C_.&I!@MW0+N.XK4]XQ9 ;E?++WY%'P0 .P1 9 >&PO=V]R:W-H965T;,G.%P--1DQ_B+B $D^IS05$R=6,KL MUG5%&$."Q37+(%4S:\83+-60;UR1<<"144JH&WC>P$TP29W9Q#Q;\-F$Y9*2 M%!8&5H/6.+9 MA+,=XEI:H>D;$QNCK=B05"_C4G(U2Y2>G"UCS"%F- +^O4 _?CTW<.P*K\;XI>=^TH<_N-AL.&RP!+8"'D$I5&W08?LNED#B-2+K9 M9]BC$#E$2#+TF!)),$65Y!1HP0GC>O8^%\J(BJ9*TQ5)L2X'33&TCHV-8[J: M;6?>=3!QM]70M#K_SM#TR]#T6T-C4^(.A7:W"9L83Y"L@#RGVTLLQ:] M7\GHH._9WU%>OT6R1F%44AA=0B'#'&TQS<&X'C%*L=JJ&7 K\1']5ZFF392L MM6%MDRHG_2,^9\5J9,8EF?$[UH/8.G1F+<:O(GR\!FT2-7=][_"R]M[A,*O4 MTC->%_AM;K>*U/VN-!G^Y:5.Y*M_5#.G2WK&A" K"JHQC"#)=$6_NHB6_SK? M1^-!O]\_)M<@.!RT[ L_.' ,WL#Q'M6:I[9RWHYW:5WK"JW._M#>^)WV-WZG M#4Y7:'7NAQ;';^]QOK:L%_!-U?HX?=\@62=Q:$;\,]U(QX6],'>VLI^7JQ,Z M]!A^ZZO\JXI[ 5V-\V#ON'UH%_SV]PB4U\74/<(+#><$ZAT.OX+K,.W. =P_B]CO($^8;D@I$8:U4O>NAHL'MIP4[ MD"PSI_,5D^JL;VYCP.K$HP74_)HQN1]H ^4'GMG_4$L#!!0 ( -> ;E?] MXU]&PO=V]R:W-H965TE"K)U\4\+6XZ+V6Y_-#K%9,7M8B+ M;K94J;[E.]8IFK>+H>M)CW/,?I]Q9QDG9NK]=?>\AOK[-5.4]2 M]9"38K58Q/FWCVJ>O=UTW,[V"X_)[*6LOM"[O5[&,S56Y:_+AUQ_UMLITV2A MTB+)4I*KYYO.G?M!AD$U8'V/_R3JK=C[F%3?RE.6?:X^D=.;CE-MD9JK25D1 ML?[K5=VK^;R2]'9\J='.;LYJX/['6YVMOWG]S3S%A;K/YK\ET_+EIC/LD*EZ MCE?S\C%[$ZK^AL+*FV3S8OU_\E;?U^F0R:HHLT4]6&_!(DDW?\=?ZW^(O0%N M<&: 5P_P+AW@UP/\PP'AF0%!/2"X=(:P'A!>.J!?#^A?.F!0#QA<.F!8#QA> M.F!4#QBMX[#Y^:U_^%%?9&\NK>6JL^6"=H/5K_S).T"ONXS/6MB1Y7 MWHY73X7ZLE)I2>BK_G]!_DGNIM.D2F(\)S+=_#Y5N?PA4F6-TK]3944F]2SQ=MYO/.S#]AOXZ%G! M7R9EEWC.E?[/\T]LS[U]^$]QVB7N\.SPR#Y\K)9=XI^?G5X^W#LQG%WPO;N# ML[-S^_"[9=XE3GAVN+ /C]1$;[Q[=N/E)3\X;SWEDPR59I M>2K)5K!MDC=8?XU52Z776S=P])_KWNM^1H_OYO4'3C@T[T:1F\:0&$=B HE) M$&:D+]RE+[2F[V'U-$\FI'B)9RSR9*+)4^?D(6JVV M$>P?1=!UNGYXD$'DE!2),23&D9A 8A*$&>D<[-(YL*;S;C;+U2PNE7YQO\MI MO#CW9&S%VL9S3+*LD5>51%J6-:JBF1Z:O^9'V/4U&UVFVC MBL2BT8FH!MZ@?YC7X_L=W(,A-XLC,8'$) @S0N@ZS:Y.QQI#^? +^?V36CRI M_.0.(?OPMDF#:A%4HU"-034.U014DRC-#/#>OGH7NXNS]E")1FH15*-0C4$U M#M4$5),HS4RTUR3: R]<[6#K2".UJ-:L:U?HC RJ<:@FH)JL-6,_H.MTO=T_ MKYG IC5RK3OS;W7D7JO7]@]SO2G5&I3\%N=Y7*U6MVL%\@=Y=^D +9.@6@35 M*%1C4(U#-0'5)$HS8]Z42FX 7CI 2R6H%D$U"M485.-034 UB=+,1#=%E6MO MJKYCZ0 MKZ!:!-4H5&-0C4,U =5DK;G!_B+#[89G%AE-O^7:"Z[[>5P4)'O> MKBU(EI/U<87;W#8W%;O;3NX,LT_4.L-(+8)J%*HQJ,:AFH!JLM:,%R%G\MLT M8*Z] OLU+=1DE:NICFNV2(HBR[^1GS.];+8NBJ%5&%2+H!J%:@RJ<:@FH)I$ M:6:LF];,'8(7Q=#:#*I%4(U"-0;5.%034$VB-#/13='FVINV2#V51*9%F:^J M?1E7A.FYR-W9@Q7L7.M 0]LUJ$:A&H-JW#U1)(;.\4&7 CJM1&GF?9 MZ[BCK,JT5'JBDCS&I;HBXS*NVF']DFZB;XYG)U_3V>=H&V"H%D$U"M485..U M-CK?< OHA!*EF=%MBCC/6HO4K^?NR"1;++*4%&4V^6Q="MN]UC&%%G%0C4(U M!M4X5!-03:(T,]%-$>=YV*6P!^WAH%H$U2A48U"-0S4!U21*,Q/=%'N>O=@; MKQ^4D_7N83)=Y4DZJXXK3[+IU>;8\N**I.IM+0Y=%X*U1A4XU!-0#6)TLSX-H6=9ZU/OJ/>L(.MXPIM[&K->F0$=$8& MU3A4$U!-HC0SJ$T/Y]E[N/MZ#5P_I&[^)MFJ+,HXG>I'W9-9A59Q4"VJM?T' MZJ.H0OLUJ,:AFGC_'T.B)C3SUW1KWB7=VD=2YW#\_FLQ:(4&U2*H1J$:@VH< MJ@FH)E&:F>BF;?,&X-=BT*(-JD50C4(U!M4X5!-03:(T,]%-T>;9ST_[OC4" MM&R#:E&M[3\M]DQ:P8<69E M@FH4JC&HQJ&:@&H2I9F) M;KHUW]ZM?/28"FVPH!J%:@RJ<:@FH)I$:696FZ[+?^?JB'_J0C8UOA_=@3\* M1H>YA;994(U"-0;5.%034$VB-#.W34?FO].1?<_^U]K?<'9V)RWY@V"NV&#?@-;[P:"=&52C4(U! M-0[5!%23*,W\%6@Z,Q]\<.= M!>^?.&'J<%$"[=J@&H5J#*IQJ":@FD1IYOLR-%U;8#]AS;8H>?\,>7VG\3)+ M]0W[7WI4K\GZC:-T]O4O@;[QH3Y&_6[ZO]7FQ:1U'6/?YK:/^E M@FH4JC&H MQJ&:@&H2I9F_-4V?%X O6AE SY6#:A%4HU"-034.U014DRC-3'13^@7VTJ_M M2?9VKG6@H54A5*-0C07'E]/T3IT6SZ'3"J@F49J9U:8%#.PM(.0D>_L.O[Y M$_"#XP;2#8;#XR,[[5O2.KW0!A*J,:C&H9J :A*EF>EM&LC@G0:R]?GW-7AP MK&?H'1Z79)^X=5BA72%48U"-0S4!U21*,\/:=(7!7W!^77!\PM;IXSOLD[<. M++0*A&H,JG&H)J":1&EF8)LJ,/C.D_!VK^U:G-!OGZOU2AA:'$(U"M485.-0 M34 UB=+,M]1NBL,0?))>""WUH%H$U2A48U"-0S4!U21*,Q/=E'JA_22]S8/R M9G%,HLUKNVUQ/:Y7(?=9^JKR;;F]^:Q,GN:*C*NJ/"F3TZ_ZZJGWUR5AWQTY M@\'!NL2^C:US#:WVH!J#:ARJ":@F49J9ZZ;:"]]Y/SK+NH2..?UYNRK9[H#> MNWU[5-/=+%?JW>,V[!O2^B$>6@I"-0K5&%3C4$U -8G2S%^%ICD,??"B!=H2 M0K4(JE&HQJ :AVH"JDF49B:Z*11#>Z%H.?Z4?E7Y)"E4VP-1ZQG-=Z7%&JC.(ROKU>J'RF[M5\7I#U)2]N.M7Z M9?=5DJOGZIU /MQYG=[1UR/W W6KK_<:YO9Z&<_4ISB?)6E!YNI9DTYWH%?8 M>97L[2=EMM11[I"GK"RSQ?K#%Q5/55[=0=_^G&7E]I-J@K[-O_ U!+ M P04 " #7@&Y7FK>("5L# .%@ #0 'AL+W-T>6QE56G-ZLZ!4>:NK%@*-?*3)N39V]=TY(?Q M1]^S2DP>(7G3TA2H; M%)./#Y/?)XY)]Q]+F^&G6L@23S':X"!'>PQAPHG#SV;E_KY2_8Z;?MIF8Y/J MAP?NXMY-Q,2[3FX)'_D3PME4,F!E)&=\ M;<-=",P*7DA/Z8=(IPHA4CU8.+0]>+YJG9R)0IK<-H/]/:V'[P";'AADG#<& MN[X-C("&(\;!AU0\O.*.?.9N+G-K)'YQP/"0;GK_=4ZG8K!WY+4EY2U=J M4TZK#/?JQ/%&_=9.\8 M3,;'8/(H:G)P#":3(S#9?[6WYG-,AL=@LOLF30;U>:UU*'QT)&RB'AR]1_X/ M.,3S;5)ONF1<,5'W%BQ-J7AR,M3RBDSU'[N/]/7XE&9DR=5M X[\;?L[3=DR M3YI1U[ 0]:AM^QM,+XR;<[_.Q41*5S2=U%TYGYJFIQLZ:WT!81>Y,I<;P3@6 M"[7^ QW\ M4$L#!!0 ( -> ;E>7BKL

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 160 197 1 false 35 0 false 7 false false R1.htm 1001 - Document - Cover Page Sheet http://www.esgen-spac.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Balance Sheets Sheet http://www.esgen-spac.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Statements of Operations Sheet http://www.esgen-spac.com/role/CondensedStatementsOfOperations Condensed Statements of Operations Statements 4 false false R5.htm 1005 - Statement - Condensed Statements of Changes in Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit Sheet http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit Condensed Statements of Changes in Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit Statements 5 false false R6.htm 1006 - Statement - Condensed Statements of Cash Flows Sheet http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows Condensed Statements of Cash Flows Statements 6 false false R7.htm 1007 - Disclosure - Organization and Business Operation Sheet http://www.esgen-spac.com/role/OrganizationAndBusinessOperation Organization and Business Operation Notes 7 false false R8.htm 1008 - Disclosure - Significant Accounting Policies Sheet http://www.esgen-spac.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 1009 - Disclosure - Related Party Transactions Sheet http://www.esgen-spac.com/role/RelatedPartyTransactions Related Party Transactions Notes 9 false false R10.htm 1010 - Disclosure - Prepaid Expenses Sheet http://www.esgen-spac.com/role/PrepaidExpenses Prepaid Expenses Notes 10 false false R11.htm 1011 - Disclosure - Accounts Payable and Accrued Expense Sheet http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpense Accounts Payable and Accrued Expense Notes 11 false false R12.htm 1012 - Disclosure - Commitments & Contingencies Sheet http://www.esgen-spac.com/role/CommitmentsContingencies Commitments & Contingencies Notes 12 false false R13.htm 1013 - Disclosure - Warrant Liabilities Sheet http://www.esgen-spac.com/role/WarrantLiabilities Warrant Liabilities Notes 13 false false R14.htm 1014 - Disclosure - Recurring Fair Value Measurements Sheet http://www.esgen-spac.com/role/RecurringFairValueMeasurements Recurring Fair Value Measurements Notes 14 false false R15.htm 1015 - Disclosure - Shareholder's Equity (Deficit) Sheet http://www.esgen-spac.com/role/ShareholderSEquityDeficit Shareholder's Equity (Deficit) Notes 15 false false R16.htm 1016 - Disclosure - Subsequent Events Sheet http://www.esgen-spac.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 1017 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.esgen-spac.com/role/SignificantAccountingPolicies 17 false false R18.htm 1018 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.esgen-spac.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.esgen-spac.com/role/SignificantAccountingPolicies 18 false false R19.htm 1019 - Disclosure - Prepaid Expenses (Tables) Sheet http://www.esgen-spac.com/role/PrepaidExpensesTables Prepaid Expenses (Tables) Tables http://www.esgen-spac.com/role/PrepaidExpenses 19 false false R20.htm 1020 - Disclosure - Accounts Payable and Accrued Expense (Tables) Sheet http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpenseTables Accounts Payable and Accrued Expense (Tables) Tables http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpense 20 false false R21.htm 1021 - Disclosure - Recurring Fair Value Measurements (Tables) Sheet http://www.esgen-spac.com/role/RecurringFairValueMeasurementsTables Recurring Fair Value Measurements (Tables) Tables http://www.esgen-spac.com/role/RecurringFairValueMeasurements 21 false false R22.htm 1022 - Disclosure - Organization and Business Operation (Details) Sheet http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails Organization and Business Operation (Details) Details http://www.esgen-spac.com/role/OrganizationAndBusinessOperation 22 false false R23.htm 1023 - Disclosure - Significant Accounting Policies (Details) Sheet http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://www.esgen-spac.com/role/SignificantAccountingPoliciesTables 23 false false R24.htm 1024 - Disclosure - Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details) Sheet http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details) Details 24 false false R25.htm 1025 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 25 false false R26.htm 1026 - Disclosure - Prepaid Expenses (Details) Sheet http://www.esgen-spac.com/role/PrepaidExpensesDetails Prepaid Expenses (Details) Details http://www.esgen-spac.com/role/PrepaidExpensesTables 26 false false R27.htm 1027 - Disclosure - Accounts Payable and Accrued Expense - Schedule of Company's Accounts Payable and Accrued Expenses (Details) Sheet http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpenseScheduleOfCompanySAccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expense - Schedule of Company's Accounts Payable and Accrued Expenses (Details) Details 27 false false R28.htm 1028 - Disclosure - Commitments & Contingencies (Details) Sheet http://www.esgen-spac.com/role/CommitmentsContingenciesDetails Commitments & Contingencies (Details) Details http://www.esgen-spac.com/role/CommitmentsContingencies 28 false false R29.htm 1029 - Disclosure - Warrant Liabilities (Details) Sheet http://www.esgen-spac.com/role/WarrantLiabilitiesDetails Warrant Liabilities (Details) Details http://www.esgen-spac.com/role/WarrantLiabilities 29 false false R30.htm 1030 - Disclosure - Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details) Sheet http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details) Details 30 false false R31.htm 1031 - Disclosure - Recurring Fair Value Measurements - Additional Information (Details) Sheet http://www.esgen-spac.com/role/RecurringFairValueMeasurementsAdditionalInformationDetails Recurring Fair Value Measurements - Additional Information (Details) Details 31 false false R32.htm 1032 - Disclosure - Shareholder's Equity - Preferred Stock Shares (Details) Sheet http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails Shareholder's Equity - Preferred Stock Shares (Details) Details 32 false false R33.htm 1033 - Disclosure - Shareholder's Equity-Common Stock Shares (Details) Sheet http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails Shareholder's Equity-Common Stock Shares (Details) Details 33 false false R34.htm 1034 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 34 false false All Reports Book All Reports d500566d10q.htm esac-20230930.xsd esac-20230930_cal.xml esac-20230930_def.xml esac-20230930_lab.xml esac-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 52 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d500566d10q.htm": { "nsprefix": "esac", "nsuri": "http://www.esgen-spac.com/20230930", "dts": { "inline": { "local": [ "d500566d10q.htm" ] }, "schema": { "local": [ "esac-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "esac-20230930_cal.xml" ] }, "definitionLink": { "local": [ "esac-20230930_def.xml" ] }, "labelLink": { "local": [ "esac-20230930_lab.xml" ] }, "presentationLink": { "local": [ "esac-20230930_pre.xml" ] } }, "keyStandard": 142, "keyCustom": 55, "axisStandard": 11, "axisCustom": 1, "memberStandard": 17, "memberCustom": 17, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 160, "entityCount": 1, "segmentCount": 35, "elementCount": 299, "unitCount": 7, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 38, "http://fasb.org/us-gaap/2023": 455 }, "report": { "R1": { "role": "http://www.esgen-spac.com/role/CoverPage", "longName": "1001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.esgen-spac.com/role/CondensedBalanceSheets", "longName": "1002 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "longName": "1003 - Statement - Condensed Balance Sheets (Parenthetical)", "shortName": "Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2023_CommonClassAMemberusgaapStatementClassOfStockAxis", "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:TemporaryEquityParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "unique": true } }, "R4": { "role": "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "longName": "1004 - Statement - Condensed Statements of Operations", "shortName": "Condensed Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "P07_01_2023To09_30_2023", "name": "esac:LegalAndProfessionalFees", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P07_01_2023To09_30_2023", "name": "esac:LegalAndProfessionalFees", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "longName": "1005 - Statement - Condensed Statements of Changes in Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit", "shortName": "Condensed Statements of Changes in Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "PAsOn12_31_2021", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2022To03_31_2022", "name": "us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "unique": true } }, "R6": { "role": "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows", "longName": "1006 - Statement - Condensed Statements of Cash Flows", "shortName": "Condensed Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:DvidendsEarnedOnMarketableSecuritiesHeldInTrustAccount", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "unique": true } }, "R7": { "role": "http://www.esgen-spac.com/role/OrganizationAndBusinessOperation", "longName": "1007 - Disclosure - Organization and Business Operation", "shortName": "Organization and Business Operation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.esgen-spac.com/role/SignificantAccountingPolicies", "longName": "1008 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.esgen-spac.com/role/RelatedPartyTransactions", "longName": "1009 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.esgen-spac.com/role/PrepaidExpenses", "longName": "1010 - Disclosure - Prepaid Expenses", "shortName": "Prepaid Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:PrepaidExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:PrepaidExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpense", "longName": "1011 - Disclosure - Accounts Payable and Accrued Expense", "shortName": "Accounts Payable and Accrued Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.esgen-spac.com/role/CommitmentsContingencies", "longName": "1012 - Disclosure - Commitments & Contingencies", "shortName": "Commitments & Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.esgen-spac.com/role/WarrantLiabilities", "longName": "1013 - Disclosure - Warrant Liabilities", "shortName": "Warrant Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:WarrantLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:WarrantLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.esgen-spac.com/role/RecurringFairValueMeasurements", "longName": "1014 - Disclosure - Recurring Fair Value Measurements", "shortName": "Recurring Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.esgen-spac.com/role/ShareholderSEquityDeficit", "longName": "1015 - Disclosure - Shareholder's Equity (Deficit)", "shortName": "Shareholder's Equity (Deficit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.esgen-spac.com/role/SubsequentEvents", "longName": "1016 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies", "longName": "1017 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.esgen-spac.com/role/SignificantAccountingPoliciesTables", "longName": "1018 - Disclosure - Significant Accounting Policies (Tables)", "shortName": "Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.esgen-spac.com/role/PrepaidExpensesTables", "longName": "1019 - Disclosure - Prepaid Expenses (Tables)", "shortName": "Prepaid Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:ScheduleOfPrepaidExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "esac:PrepaidExpensesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:ScheduleOfPrepaidExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "esac:PrepaidExpensesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpenseTables", "longName": "1020 - Disclosure - Accounts Payable and Accrued Expense (Tables)", "shortName": "Accounts Payable and Accrued Expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsTables", "longName": "1021 - Disclosure - Recurring Fair Value Measurements (Tables)", "shortName": "Recurring Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "longName": "1022 - Disclosure - Organization and Business Operation (Details)", "shortName": "Organization and Business Operation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "div", "esac:WarrantLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2023", "name": "esac:NetTangibleAssets", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "unique": true } }, "R23": { "role": "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "longName": "1023 - Disclosure - Significant Accounting Policies (Details)", "shortName": "Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:CashEquivalentsAtCarryingValue", "div", "div", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "div", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "unique": true } }, "R24": { "role": "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "longName": "1024 - Disclosure - Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details)", "shortName": "Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "P07_01_2023To09_30_2023", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis", "name": "esac:AccretionOfTemporaryEquityToRedemptionValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "unique": true } }, "R25": { "role": "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "longName": "1025 - Disclosure - Related Party Transactions - Additional Information (Details)", "shortName": "Related Party Transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:PaymentsToRelatedParties", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "unique": true } }, "R26": { "role": "http://www.esgen-spac.com/role/PrepaidExpensesDetails", "longName": "1026 - Disclosure - Prepaid Expenses (Details)", "shortName": "Prepaid Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:PrepaidInsurance", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "esac:ScheduleOfPrepaidExpensesTableTextBlock", "esac:PrepaidExpensesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:PrepaidInsurance", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "esac:ScheduleOfPrepaidExpensesTableTextBlock", "esac:PrepaidExpensesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpenseScheduleOfCompanySAccountsPayableAndAccruedExpensesDetails", "longName": "1027 - Disclosure - Accounts Payable and Accrued Expense - Schedule of Company's Accounts Payable and Accrued Expenses (Details)", "shortName": "Accounts Payable and Accrued Expense - Schedule of Company's Accounts Payable and Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "longName": "1028 - Disclosure - Commitments & Contingencies (Details)", "shortName": "Commitments & Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "esac:WarrantLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:DeferredUnderwritingFees", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "unique": true } }, "R29": { "role": "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails", "longName": "1029 - Disclosure - Warrant Liabilities (Details)", "shortName": "Warrant Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "PAsOn10_22_2021", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "esac:WarrantLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn10_22_2021", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "esac:WarrantLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "longName": "1030 - Disclosure - Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details)", "shortName": "Recurring Fair Value Measurements - Fair value hierarchy for liabilities measured at fair value on recurring basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:AssetsHeldInTrustNoncurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "name": "us-gaap:AssetsHeldInTrustNoncurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "unique": true } }, "R31": { "role": "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsAdditionalInformationDetails", "longName": "1031 - Disclosure - Recurring Fair Value Measurements - Additional Information (Details)", "shortName": "Recurring Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "P07_01_2023To09_30_2023", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "div", "div", "us-gaap:DerivativesAndFairValueTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P07_01_2023To09_30_2023", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "div", "div", "us-gaap:DerivativesAndFairValueTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails", "longName": "1032 - Disclosure - Shareholder's Equity - Preferred Stock Shares (Details)", "shortName": "Shareholder's Equity - Preferred Stock Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "PAsOn09_30_2023", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails", "longName": "1033 - Disclosure - Shareholder's Equity-Common Stock Shares (Details)", "shortName": "Shareholder's Equity-Common Stock Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:AggregatePercentageOfOutstandingSharesIssuedToInitialShareholdersPriorToBusinessCombination", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To09_30_2023", "name": "esac:AggregatePercentageOfOutstandingSharesIssuedToInitialShareholdersPriorToBusinessCombination", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails", "longName": "1034 - Disclosure - Subsequent Events - Additional Information (Details)", "shortName": "Subsequent Events - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "PAsOn01_18_2023", "name": "us-gaap:AssetsHeldInTrust", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "div", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P10_20_2023To10_20_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis", "name": "us-gaap:PaymentsToAcquireRestrictedInvestments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d500566d10q.htm", "unique": true } } }, "tag": { "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Warrant", "terseLabel": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r415", "r416", "r419", "r420", "r421", "r422" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpense" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Expense", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r8" ] }, "us-gaap_InvestmentIncomeDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeDividend", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Income, Dividend", "terseLabel": "Dividends earned on marketable securities held in Trust Account", "documentation": "Amount of dividend income on nonoperating securities." } } }, "auth_ref": [ "r56" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "presentationGuidance": "Stock issued during period, shares, new issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r5", "r46", "r47", "r68", "r308", "r379", "r388" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2", "terseLabel": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r174", "r201", "r206", "r240", "r269", "r406", "r407", "r411", "r412", "r413" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.esgen-spac.com/role/PrepaidExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid Expense, Current, Total", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r94", "r153", "r154", "r399" ] }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityAccretionToRedemptionValue", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Accretion to Redemption Value", "terseLabel": "Accretion of carrying value to redemption value", "documentation": "Value of accretion of temporary equity to its redemption value during the period." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1", "terseLabel": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r174", "r201", "r206", "r240", "r268", "r411", "r412", "r413" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits accrued for interest and penalties", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r215" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "IPO", "terseLabel": "Initial Public Offering [Member]", "verboseLabel": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by (used) in operating activities:", "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r98", "r213", "r214", "r217", "r218", "r219", "r220", "r307" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r174", "r201", "r202", "r203", "r204", "r205", "r206", "r240", "r270", "r406", "r407", "r411", "r412", "r413" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Related Party Debt", "terseLabel": "Proceeds from note payable-related party", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r19" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Anti-dilutive securities attributable to warrants (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r137" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "definitionGuidance": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/CoverPage", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r83", "r91", "r92", "r93", "r107", "r130", "r131", "r134", "r136", "r140", "r141", "r148", "r157", "r159", "r160", "r161", "r164", "r165", "r184", "r185", "r188", "r191", "r198", "r245", "r308", "r309", "r310", "r311", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r336", "r357", "r379", "r387", "r388", "r389", "r390", "r391", "r432", "r443", "r449" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityIssuePeriodIncreaseOrDecrease", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Carrying Amount, Period Increase (Decrease)", "terseLabel": "Temporary equity, carrying amount, period increase (decrease)", "documentation": "Change in the value of each type or class of stock classified as temporary equity during the period. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r6", "r28" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event", "terseLabel": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r252", "r266" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock", "terseLabel": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r415", "r416", "r417", "r419", "r420", "r421", "r422", "r446", "r447", "r457", "r466", "r467" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r5", "r16", "r32", "r68", "r176" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Class A ordinary shares subject to possible redemption, $0.0001 par value; 2,896,555 and 27,600,000 shares at redemption value as of September 30, 2023 and December 31, 2022, respectively", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r157", "r159", "r160", "r161", "r164", "r165", "r211", "r289" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Private Placement", "terseLabel": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_AssetsHeldInTrust": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsHeldInTrust", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Assets Held-in-trust", "terseLabel": "Cash held outside of the Trust Account", "verboseLabel": "Deposits into the trust account", "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations." } } }, "auth_ref": [ "r442" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_AssetsHeldInTrustNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsHeldInTrustNoncurrent", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Assets Held-in-trust, Noncurrent", "verboseLabel": "Marketable securities held in Trust Account", "terseLabel": "Marketable securities held in Trust Account", "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited." } } }, "auth_ref": [ "r442" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r21", "r89", "r398" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r22" ] }, "us-gaap_TemporaryEquityNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityNetIncome", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Net Income", "terseLabel": "Net income including accretion of temporary equity to redemption value", "documentation": "The portion of net income or loss attributable to temporary equity interest." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r129", "r136" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Ordinary Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r23", "r24" ] }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "negatedLabel": "Accretion of ordinary shares subject to possible redemption", "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrentAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r127", "r136" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "verboseLabel": "Allocation of net income (loss)", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r103", "r116", "r117", "r119", "r120", "r127", "r128", "r133", "r136", "r142", "r143", "r145", "r147", "r403" ] }, "us-gaap_ProceedsFromSaleOfRestrictedInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfRestrictedInvestments", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Restricted Investments", "terseLabel": "Cash withdrawn from Trust Account in connection with redemption", "verboseLabel": "Proceeds from sale of restricted investments", "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period." } } }, "auth_ref": [ "r18" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income (loss)", "definitionGuidance": "Net income (loss)", "terseLabel": "Net (loss) income", "verboseLabel": "Net income (loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r52", "r61", "r76", "r86", "r96", "r97", "r101", "r107", "r114", "r116", "r117", "r119", "r120", "r124", "r125", "r132", "r142", "r143", "r145", "r147", "r148", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r237", "r245", "r292", "r356", "r377", "r378", "r403", "r423", "r455" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r440", "r465" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "esac_FairMarketValuePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "FairMarketValuePrice", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Market Value Price", "documentation": "Price of Fair Market Value" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansPayableCurrent", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Notes and Loans Payable, Current", "terseLabel": "Outstanding amount", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r9" ] }, "esac_TradingDayPriorToDateOnWhichNoticeOfExercise": { "xbrltype": "durationItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "TradingDayPriorToDateOnWhichNoticeOfExercise", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Trading Day Prior To The Date On Which The Notice Of Exercise", "documentation": "Represents Trading Day Prior To The Date On Which The Notice Of Exercise" } } }, "auth_ref": [] }, "esac_ThresholdPeriodForRegistrationStatementToBeEffectiveAfterWhichWarrantsCanBeExercised": { "xbrltype": "durationItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ThresholdPeriodForRegistrationStatementToBeEffectiveAfterWhichWarrantsCanBeExercised", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Threshold Period For Registration Statement To Be Effective After Which Warrants Can Be Exercised", "documentation": "Threshold period for registration statement to be effective after which warrants can be exercised on a cashless basis." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "terseLabel": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r7", "r74", "r182" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital", "terseLabel": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r208", "r209", "r210", "r316", "r446", "r447", "r448", "r457", "r467" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r29", "r30", "r31", "r32", "r33", "r34", "r35", "r66", "r67", "r68", "r91", "r92", "r93", "r140", "r184", "r185", "r186", "r188", "r191", "r196", "r198", "r308", "r309", "r310", "r311", "r410", "r432", "r443" ] }, "esac_PercentageOfGrossProceedsOnTotalEquityProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "PercentageOfGrossProceedsOnTotalEquityProceeds", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Percentage Of Gross Proceeds On Total Equity Proceeds", "documentation": "Represents the percentage of gross proceeds on total equity proceeds." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Redemption of Class A ordinary shares subject to possible redemption", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Sale of Private Placement Warrants (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r199" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r111", "r112", "r113", "r139", "r271", "r306", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r336", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r358", "r359", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r379", "r418" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r3" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.esgen-spac.com/role/ShareholderSEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholder's Equity (Deficit)", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r65", "r106", "r183", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r200", "r233", "r382", "r384", "r392" ] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/PrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.esgen-spac.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance, Current", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r400", "r404", "r453" ] }, "esac_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right Redemption Of Warrants Or Rights Reference Price", "terseLabel": "Stock price trigger for redemption of public warrants", "documentation": "Price of the entity's common stock which would be required to be attained to trigger the redemption of warrants." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r72", "r90", "r107", "r142", "r144", "r146", "r148", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r223", "r225", "r245", "r285", "r348", "r414", "r424", "r455", "r456", "r462" ] }, "esac_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "AgreementDomain", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Agreement [Domain]", "documentation": "Agreement." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r239", "r240", "r243" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Due to related party", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r11", "r414" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r142", "r143", "r145", "r147", "r403" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r252", "r266" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r5", "r17", "r84", "r99", "r100", "r101", "r111", "r112", "r113", "r115", "r123", "r125", "r139", "r149", "r152", "r200", "r208", "r209", "r210", "r221", "r222", "r227", "r228", "r229", "r230", "r231", "r232", "r235", "r246", "r247", "r248", "r249", "r250", "r251", "r256", "r295", "r296", "r297", "r316", "r379" ] }, "esac_BusinessCombinationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "BusinessCombinationAgreementMember", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination Agreement", "terseLabel": "Business Combination Agreement [Member]", "documentation": "Business combination agreement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpenseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of company's accounts payable and accrued expenses", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/CoverPage", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class A Common Stock", "terseLabel": "Class A common stock [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r467" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "terseLabel": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r84", "r111", "r112", "r113", "r115", "r123", "r125", "r149", "r152", "r208", "r209", "r210", "r221", "r222", "r227", "r229", "r230", "r232", "r235", "r295", "r297", "r316", "r467" ] }, "esac_InitialSubscriptionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "InitialSubscriptionAgreementMember", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Initial Subscription Agreement", "terseLabel": "Initial Subscription Agreement [Member]", "documentation": "Initial subscription agreement." } } }, "auth_ref": [] }, "esac_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences": { "xbrltype": "durationItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences", "terseLabel": "Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences", "documentation": "The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r252", "r266" ] }, "esac_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination": { "xbrltype": "durationItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination", "terseLabel": "Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination", "documentation": "The period of time which must elapse after completion of a business combination before the Sponsor can transfer, assign or sell any Founder Shares unless other specified conditions are met." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Reinvestment in marketable securities.", "negatedLabel": "Reinvestment of marketable securities held in Trust Account", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r451" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r252", "r266" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Borrowed amount", "verboseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r38", "r39", "r166", "r253", "r406", "r407" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r25", "r26", "r27", "r78", "r79", "r80", "r81" ] }, "esac_MaximumNumberOfDemandsForRegistrationOfSecurities": { "xbrltype": "integerItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "MaximumNumberOfDemandsForRegistrationOfSecurities", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Maximum Number Of Demands For Registration Of Securities", "terseLabel": "Maximum number of demands for registration of securities", "documentation": "Represents the maximum number of demands for registration of securities." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesRelatedParty", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses, Related Party", "terseLabel": "Operating cost\u2014related party", "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties." } } }, "auth_ref": [ "r53" ] }, "us-gaap_OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Cost and Expense, Operating", "terseLabel": "Other operating costs", "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [ "r54", "r294" ] }, "esac_DeferredUnderwritingDiscount": { "xbrltype": "percentItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "DeferredUnderwritingDiscount", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Underwriting Discount", "documentation": "Represents deferred underwriting discount ." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/CoverPage", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r83", "r91", "r92", "r93", "r107", "r130", "r131", "r134", "r136", "r140", "r141", "r148", "r157", "r159", "r160", "r161", "r164", "r165", "r184", "r185", "r188", "r191", "r198", "r245", "r308", "r309", "r310", "r311", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r336", "r357", "r379", "r387", "r388", "r389", "r390", "r391", "r432", "r443", "r449" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r239", "r240", "r243" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Redeemed or Called During Period, Shares", "negatedLabel": "Redemption\u00a0of\u00a0Class\u00a0A\u00a0ordinary shares subject to possible redemption (in shares)", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r5" ] }, "esac_DeferredUnderwritingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "DeferredUnderwritingFees", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Underwriting Fees", "terseLabel": "Deferred underwriting fees", "documentation": "Deferred underwriting fees." } } }, "auth_ref": [] }, "esac_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days", "terseLabel": "Threshold trading days for redemption of public warrants", "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r252", "r266" ] }, "esac_PrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "PrivatePlacementWarrantsMember", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Private Placement Warrants", "terseLabel": "Private Placement Warrants [Member]", "verboseLabel": "Private Warrants [Member]", "documentation": "Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Public share", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "esac_ClassOfWarrantOrRightDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ClassOfWarrantOrRightDescription", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right Description", "terseLabel": "Class Of Warrant Or Right Description", "documentation": "Class of warrant or right description." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r5", "r84", "r99", "r100", "r101", "r111", "r112", "r113", "r115", "r123", "r125", "r139", "r149", "r152", "r200", "r208", "r209", "r210", "r221", "r222", "r227", "r228", "r229", "r230", "r231", "r232", "r235", "r246", "r247", "r248", "r249", "r250", "r251", "r256", "r295", "r296", "r297", "r316", "r379" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Current", "terseLabel": "Promissory note\u2014related party", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r9" ] }, "esac_ClassOfWarrantOrRightPriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ClassOfWarrantOrRightPriceOfWarrantsOrRights", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Price of Warrants or Rights", "terseLabel": "Price of warrant", "documentation": "Price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [] }, "esac_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days", "terseLabel": "Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination", "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "esac_AccruedOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "AccruedOfferingCosts", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Offering Costs", "verboseLabel": "Accrued Offering Costs And Expenses", "documentation": "Amount of offering costs accrued but not yet paid as of the period date." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 9.0 }, "http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpenseScheduleOfCompanySAccountsPayableAndAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpenseScheduleOfCompanySAccountsPayableAndAccruedExpensesDetails", "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses", "totalLabel": "Total", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r9" ] }, "esac_WarrantsAndRightsOutstandingExercisableTermAfterBusinessCombinations": { "xbrltype": "durationItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "WarrantsAndRightsOutstandingExercisableTermAfterBusinessCombinations", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Warrants And Rights Outstanding Exercisable Term After Business Combinations", "documentation": "Represents Warrants And Rights Outstanding Exercisable Term After Business Combination." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r174", "r201", "r202", "r203", "r204", "r205", "r206", "r268", "r269", "r270", "r406", "r407", "r411", "r412", "r413" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r15", "r42", "r286", "r335" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r55" ] }, "esac_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger": { "xbrltype": "perShareItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Stock Price Trigger", "terseLabel": "Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)", "documentation": "The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' Deficit:" } } }, "auth_ref": [] }, "esac_UnitsIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "UnitsIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Units Issued During Period, Shares, New Issues", "terseLabel": "Sale of Units, net of underwriting discounts (in shares)", "documentation": "Number of new units issued during the period." } } }, "auth_ref": [] }, "esac_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination", "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r91", "r92", "r93", "r140", "r184", "r185", "r186", "r188", "r191", "r196", "r198", "r308", "r309", "r310", "r311", "r410", "r432", "r443" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "esac_ReversalOfOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ReversalOfOfferingCosts", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Reversal Of Offering Costs", "terseLabel": "Reversal of offering costs", "documentation": "Reversal of offering costs." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liabilities", "terseLabel": "Change in fair value of warrant liabilities", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r4" ] }, "us-gaap_DerivativesAndFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesAndFairValueTextBlock", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Derivatives and Fair Value [Text Block]", "terseLabel": "Recurring Fair Value Measurements", "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities." } } }, "auth_ref": [ "r69", "r70" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net", "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net", "documentation": "Amount of transfers of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) into (out of) level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r459" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "esac_ConditionForFutureBusinessCombinationThresholdPercentageOwnership": { "xbrltype": "pureItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ConditionForFutureBusinessCombinationThresholdPercentageOwnership", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Condition for future business combination threshold Percentage Ownership", "documentation": "The threshold percentage of voting interest to be acquired in a future business combination as specified for the use of proceeds from the offering." } } }, "auth_ref": [] }, "esac_NewPubcoCommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "NewPubcoCommonClassAMember", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "New PubCo Common Class A [Member]", "terseLabel": "New PubCo Common Class A [Member]", "documentation": "New pubco common class A." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "esac_RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination": { "xbrltype": "durationItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Redemption of Shares Calculated Based On Number Of Business Days Prior To Consummation Of Business Combination", "terseLabel": "Redemption of shares calculated based on business days prior to consummation of business combination", "documentation": "Represents the redemption of shares calculated based on number of business days prior to consummation of business combination." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r430" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in current assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r87", "r95", "r107", "r148", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r223", "r225", "r245", "r414", "r455", "r456", "r462" ] }, "esac_EsgenCommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "EsgenCommonClassAMember", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "ESGEN Common Class A", "terseLabel": "ESGEN Common Class A [Member]", "documentation": "ESGEN common class A" } } }, "auth_ref": [] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OverAllotmentOptionMember", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Over-allotment option", "terseLabel": "Over-allotment option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "esac_PrivateWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "PrivateWarrantsMember", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Private Warrants", "terseLabel": "Private Warrants [Member]", "documentation": "Represents information pertaining to private warrants." } } }, "auth_ref": [] }, "esac_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrants": { "xbrltype": "durationItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrants", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right, Minimum Threshold Written Notice Period For Redemption Of Warrants", "terseLabel": "Minimum threshold written notice period for redemption of public warrants", "documentation": "The minimum threshold period during which a written notice is required for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r108", "r109", "r260", "r261", "r262", "r263", "r329", "r330", "r331", "r332", "r333", "r353", "r355", "r386" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "esac_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValue": { "xbrltype": "percentItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValue", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right Adjustment Of Exercise Price Of Warrants Or Rights Percent Based On Market Value", "terseLabel": "Adjustment of exercise price of warrants based on market value (as a percent)", "documentation": "Class of Warrant or Right, Adjustment of Exercise Price of Warrants or Rights, Percent, Based On Market Value" } } }, "auth_ref": [] }, "esac_RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "RedemptionOfWarrantPricePerShareEqualsOrExceeds18.00Member", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Redemption Of Warrant Price Per Share Equals Or Exceeds18.00 [Member]", "documentation": "Represents information pertaining to Redemption Of Warrant Price Per Share Equals Or Exceeds18.00." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "esac_RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "RedemptionOfWarrantPricePerShareEqualsOrExceeds10.00Member", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Redemption Of Warrant Price Per Share Equals Or Exceeds10.00", "terseLabel": "Redemption Of Warrant Price Per Share Equals Or Exceeds10.00 [Member]", "documentation": "Represents information pertaining to Redemption Of Warrant Price Per Share Equals Or Exceeds10.00." } } }, "auth_ref": [] }, "esac_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights", "terseLabel": "Redemption price per public warrant (in dollars per share)", "documentation": "Redemption price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireRestrictedInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireRestrictedInvestments", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Restricted Investments", "negatedLabel": "Extension funding of Trust Account", "verboseLabel": "Payments to Acquire Restricted Investments", "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions." } } }, "auth_ref": [ "r58" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r13", "r167" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Public Warrants expiration term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r458" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable", "terseLabel": "Outstanding balance of related party note", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r74", "r464" ] }, "esac_RestatedNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "RestatedNoteMember", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restated Note [Member]", "terseLabel": "Restated Note [Member]", "documentation": "Restated note." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r104" ] }, "us-gaap_MinimumNetWorthRequiredForCompliance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinimumNetWorthRequiredForCompliance", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Banking Regulation, Mortgage Banking, Net Worth, Minimum", "terseLabel": "Minimum Net Worth Required For Compliance", "documentation": "Amount of minimum net worth required for mortgage banking as defined by regulatory framework." } } }, "auth_ref": [ "r393", "r394", "r395", "r396" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r426" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r12", "r88", "r107", "r148", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r224", "r225", "r226", "r245", "r414", "r455", "r462", "r463" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r425" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r104" ] }, "esac_UnsecuredPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "UnsecuredPromissoryNoteMember", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unsecured Promissory Note", "terseLabel": "Unsecured Promissory Note [Member]", "documentation": "Unsecured promissory note." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-current assets:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, shares issued", "verboseLabel": "Common shares, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r47" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r59", "r60", "r61" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r47", "r288", "r414" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments & Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r64", "r155", "r156", "r397", "r454" ] }, "esac_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "AgreementAxis", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Agreement [Axis]", "documentation": "Agreement." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, shares authorized", "verboseLabel": "Common shares, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r47", "r336" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r46", "r287", "r414" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpenseScheduleOfCompanySAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpenseScheduleOfCompanySAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Legal accrual", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r11" ] }, "esac_WaiverOfDeferredUnderwriterFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "WaiverOfDeferredUnderwriterFees", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Waiver of Deferred Underwriter Fees", "terseLabel": "Waiver of deferred underwriters fee", "verboseLabel": "Waiver of deferred underwriter fees", "documentation": "Waiver of deferred underwriter fees." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares, shares outstanding", "verboseLabel": "Common shares, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r47", "r336", "r354", "r467", "r468" ] }, "esac_WorkingCapitalLoansWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "WorkingCapitalLoansWarrantMember", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Working capital loans warrant", "terseLabel": "Working capital loans warrant [Member]", "documentation": "Working capital loans warrant." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityRedemptionPricePerShare", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Redemption Price Per Share", "terseLabel": "Redemption Price Per Share", "verboseLabel": "Redemption price per share", "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r6", "r28" ] }, "esac_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValue": { "xbrltype": "percentItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValue", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right Adjustment Of Redemption Price Of Warrants Or Rights Percent Based On Market Value", "documentation": "Percentage of adjustment of redemption price of stock based on market value." } } }, "auth_ref": [] }, "esac_RecoveryOfOfferingCostsAllocatedToWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "RecoveryOfOfferingCostsAllocatedToWarrants", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Recovery Of Offering Costs Allocated To Warrants", "terseLabel": "Recovery of offering costs related to the IPO allocated to warrants", "negatedLabel": "Recovery of offering costs related to the IPO allocated to warrants", "documentation": "Recovery of offering costs allocated to warrants." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r427" ] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses", "verboseLabel": "Expenses incurred and paid", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "esac_WarrantLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "WarrantLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Liabilities, Fair Value Disclosure", "terseLabel": "Total warrant liabilities", "documentation": "Amount of Warrant Liabilities as on the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/PrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.esgen-spac.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Prepaid Expense, Current", "terseLabel": "Other prepaid expenses, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r441", "r453" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r426" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r207", "r260", "r261", "r329", "r330", "r331", "r332", "r333", "r353", "r355", "r386" ] }, "esac_AggregatePercentageOfOutstandingSharesIssuedToInitialShareholdersPriorToBusinessCombination": { "xbrltype": "percentItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "AggregatePercentageOfOutstandingSharesIssuedToInitialShareholdersPriorToBusinessCombination", "presentation": [ "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Percentage of Outstanding Shares Issued to Initial Shareholders Prior to Business Combination", "documentation": "Represents Aggregate Percentage of Outstanding Shares Issued to Initial Shareholders Prior to Business Combination." } } }, "auth_ref": [] }, "esac_ImpactOfWaiverOfDeferredCommissionByUnderwriters": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ImpactOfWaiverOfDeferredCommissionByUnderwriters", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Impact Of Waiver Of Deferred Commission By Underwriters", "terseLabel": "Impact of the waiver of deferred underwriters fee", "documentation": "Impact of waiver of deferred commission by underwriters." } } }, "auth_ref": [] }, "esac_ConvertibleStockConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ConvertibleStockConversionRatio", "presentation": [ "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "ConvertibleStockConversionRatio", "terseLabel": "Ratio to be applied to the stock in the conversion", "documentation": "The ratio to be applied to the stock in a conversion of convertible stock." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "esac_ChangeInValuationOfClassAOdinarySharesSubjectToPossibleRedemption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ChangeInValuationOfClassAOdinarySharesSubjectToPossibleRedemption", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Change In Valuation Of Class A Odinary Shares Subject To Possible Redemption", "terseLabel": "Change in value of Class\u00a0A ordinary shares subject to possible redemption", "documentation": "Change in valuation of class a odinary shares subject to possible redemption." } } }, "auth_ref": [] }, "esac_DvidendsEarnedOnMarketableSecuritiesHeldInTrustAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "DvidendsEarnedOnMarketableSecuritiesHeldInTrustAccount", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Dvidends Earned On Marketable Securities Held In Trust Account", "negatedLabel": "Dividends earned on marketable securities held in Trust Account", "documentation": "Dividends earned on marketable securities held in trust account." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r2" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r260", "r261", "r461" ] }, "esac_WarrantAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "WarrantAgreementMember", "presentation": [ "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Agreement", "terseLabel": "Warrant Agreement [Member]", "documentation": "Warrant agreement." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "esac_PrepaidExpensesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "PrepaidExpensesTextBlock", "presentation": [ "http://www.esgen-spac.com/role/PrepaidExpenses" ], "lang": { "en-us": { "role": { "label": "Prepaid Expenses [Text Block]", "terseLabel": "Prepaid Expenses", "documentation": "Represents prepaid expenses text block." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r14", "r110", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r253", "r405", "r406", "r407", "r408", "r409", "r444" ] }, "esac_WarrantLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "WarrantLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.esgen-spac.com/role/WarrantLiabilities" ], "lang": { "en-us": { "role": { "label": "Warrant Liabilities Disclosure [Text Block]", "terseLabel": "Warrant Liabilities", "documentation": "The entire disclosure for Warrant Liabilities" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total shareholders' deficit", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r47", "r49", "r50", "r63", "r338", "r354", "r380", "r381", "r414", "r424", "r445", "r452", "r460", "r467" ] }, "esac_WarrantLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "WarrantLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Warrant Liabilities", "documentation": "n/a" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "esac_CommonStockSubjectToPossibleRedemptionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "CommonStockSubjectToPossibleRedemptionPolicyTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Common Stock Subject to Possible Redemption [Policy Text Block]", "terseLabel": "Class A Ordinary Shares Subject to Possible Redemption", "documentation": "Represents the accounting policy on common stock subject to possible redemption." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income (loss) per share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r102", "r116", "r117", "r119", "r120", "r122", "r130", "r134", "r135", "r136", "r138", "r236", "r237", "r284", "r293", "r401" ] }, "esac_DerivativeFinancialInstrumentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "DerivativeFinancialInstrumentsPolicyTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments [Policy Text Block]", "terseLabel": "Derivative Financial Instruments", "documentation": "The disclosure of Derivative Financial Instruments" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r426" ] }, "esac_EmergingGrowthCompanyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "EmergingGrowthCompanyPolicyTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Emerging Growth Company [Policy Text Block]", "terseLabel": "Emerging Growth Company Status", "documentation": "Represents the accounting policy on Emerging Growth Company." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "definitionGuidance": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r199" ] }, "esac_AssetsHeldInTrustAccountPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "AssetsHeldInTrustAccountPolicyPolicyTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Assets Held In Trust Account, Policy [Policy Text Block]", "terseLabel": "Marketable Securities Held in Trust Account", "documentation": "The disclosure of accounting policy for assets held in trust." } } }, "auth_ref": [] }, "esac_WarrantLiabilitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "WarrantLiabilitiesPolicyTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Warrant Liabilities [Policy Text Block]", "terseLabel": "Warrant Liabilities", "documentation": "The disclosure of warrant liabilities" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r429" ] }, "esac_NetTangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "NetTangibleAssets", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Net Tangible Assets", "terseLabel": "Net tangible assets", "documentation": "This elements represents net tangible assets." } } }, "auth_ref": [] }, "esac_PercentageOfBusinessCombinationsAggregateFairMarketValue": { "xbrltype": "percentItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "PercentageOfBusinessCombinationsAggregateFairMarketValue", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Percentage Of Business Combinations Aggregate Fair Market Value", "terseLabel": "Percentage of business combinations aggregate fair market value", "documentation": "This elements represents percentage of business combinations aggregate fair market value." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r57" ] }, "esac_SponsorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "SponsorMember", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sponsor", "terseLabel": "Sponsor [Member]", "documentation": "This member stands for sponsor." } } }, "auth_ref": [] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Redeemed or Called During Period, Value", "negatedLabel": "Redemption\u00a0of\u00a0Class\u00a0A\u00a0ordinary shares subject to possible redemption", "terseLabel": "Aggregate redemption amount", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r5" ] }, "esac_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ConditionForFutureBusinessCombinationThresholdNetTangibleAssets", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Condition for future business combination threshold Net Tangible Assets", "documentation": "The threshold net tangible assets which the reporting entity must maintain in order to proceed with a business combination utilizing the proceeds of the offering." } } }, "auth_ref": [] }, "esac_AccretionOfTemporaryEquityToRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "AccretionOfTemporaryEquityToRedemptionValue", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Accretion of temporary equity to redemption value", "negatedTerseLabel": "Accretion of temporary equity to redemption value", "documentation": "Accretion of temporary equity to redemption value." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r7", "r43", "r44", "r73", "r74", "r110", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r253", "r405", "r406", "r407", "r408", "r409", "r444" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income (loss) per share", "verboseLabel": "Basic net income (loss) per share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r102", "r116", "r117", "r119", "r120", "r122", "r127", "r130", "r134", "r135", "r136", "r138", "r236", "r237", "r284", "r293", "r401" ] }, "esac_PromissoryNoteWithRelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "PromissoryNoteWithRelatedPartyMember", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Promissory Note with Related Party", "terseLabel": "Promissory Note with Related Party [Member]", "documentation": "This member stands for promissory note with related party." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r428" ] }, "esac_PaymentsToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "PaymentsToRelatedParties", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments To Related Parties", "terseLabel": "Payments To Related Parties", "documentation": "Payments to related parties." } } }, "auth_ref": [] }, "esac_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "MaximumBorrowingCapacityOfRelatedPartyPromissoryNote", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum Borrowing Capacity of Related Party Promissory Note", "terseLabel": "Maximum borrowing capacity of related party promissory note", "documentation": "Amount of maximum borrowing capacity of related party promissory note." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r207", "r260", "r261", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r329", "r330", "r331", "r332", "r333", "r353", "r355", "r386", "r461" ] }, "esac_WorkingCapitalLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "WorkingCapitalLoan", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Working Capital Loan", "documentation": "Amount of working capital loans." } } }, "auth_ref": [] }, "esac_MaximumLoansConvertibleIntoWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "MaximumLoansConvertibleIntoWarrants", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "maximum Loans Convertible Into Warrants", "terseLabel": "Loan conversion agreement warrant", "documentation": "The maximum amount which a potential loan could have repaid through issuance of warrants." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r212", "r216" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r85", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r123", "r124", "r125", "r126", "r138", "r150", "r151", "r222", "r234", "r235", "r236", "r237", "r254", "r255", "r256", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/CoverPage", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class B Common Stock", "terseLabel": "Class B Common Stock [Member]", "verboseLabel": "Class B common stock [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r467" ] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Temporary equity, par value, (per share)", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r6", "r28" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r85", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r123", "r124", "r125", "r126", "r138", "r150", "r151", "r222", "r234", "r235", "r236", "r237", "r254", "r255", "r256", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit", "http://www.esgen-spac.com/role/CondensedStatementsOfOperations", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesDetails", "http://www.esgen-spac.com/role/SignificantAccountingPoliciesReconciliationOfNetLossPerCommonShareDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r111", "r112", "r113", "r139", "r271", "r306", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r336", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r358", "r359", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r379", "r418" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r40", "r41", "r360", "r361", "r364" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "us-gaap_GeneralInsuranceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralInsuranceExpense", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General Insurance Expense", "terseLabel": "Insurance", "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)." } } }, "auth_ref": [ "r55" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r265", "r267" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r426" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.esgen-spac.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r257", "r258", "r259", "r261", "r264", "r313", "r314", "r315", "r362", "r363", "r364", "r383", "r385" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r36" ] }, "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Due to Related Parties, Current", "terseLabel": "Due to related party", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r3" ] }, "us-gaap_DerivativeInstrumentDetailAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentDetailAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instrument Detail [Abstract]", "terseLabel": "Recurring Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDeferredLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredLiabilities", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Liabilities", "terseLabel": "Decrease in deferred underwriting liability", "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle." } } }, "auth_ref": [ "r3" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r10", "r107", "r148", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r224", "r225", "r226", "r245", "r334", "r402", "r424", "r455", "r462", "r463" ] }, "esac_PublicWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "PublicWarrantsMember", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Public Warrants", "terseLabel": "Public Warrants [Member]", "documentation": "Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r360", "r361", "r364" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r426" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Preferred shares, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r46", "r184" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails", "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common shares, par value, (per share)", "verboseLabel": "Common shares, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r47" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r426" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "esac_SponsorShareConverted": { "xbrltype": "sharesItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "SponsorShareConverted", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Sponsor Share Converted", "terseLabel": "Sponsor share conversion", "documentation": "Sponsor share converted." } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails", "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.esgen-spac.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails", "http://www.esgen-spac.com/role/WarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred shares, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r46", "r336" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r426" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "verboseLabel": "Preferred shares, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r46", "r336", "r354", "r467", "r468" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpenseScheduleOfCompanySAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.esgen-spac.com/role/AccountsPayableAndAccruedExpenseScheduleOfCompanySAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other payables and expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r11" ] }, "esac_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination": { "xbrltype": "percentItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Percentage Obligation To Redeem Public Shares If Entity Does Not Complete A Business Combination", "terseLabel": "Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)", "documentation": "Represents the percentage of shares which the reporting entity is obligated to redeem if a business combination is not consummated using the offering proceeds within a specified period." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityCommonStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "Temporary equity, shares outstanding", "terseLabel": "Class A common stock subject to possible redemption, outstanding (in shares)", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r45" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total Liabilities, Redeemable Ordinary Shares and Shareholders' Deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r51", "r75", "r291", "r414", "r445", "r452", "r460" ] }, "us-gaap_CommonStockConversionBasis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockConversionBasis", "presentation": [ "http://www.esgen-spac.com/role/CommitmentsContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Conversion Basis", "terseLabel": "Common Stock, Conversion Basis", "documentation": "Description of basis for conversion of convertible common stock." } } }, "auth_ref": [ "r93" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Redeemable Ordinary Shares and Shareholders' Deficit" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Recurring", "terseLabel": "Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r238", "r244" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheetsParenthetical", "http://www.esgen-spac.com/role/ShareholdersEquityPreferredStockSharesDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value, (per share)", "verboseLabel": "Preferred stock, par value, (per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r46", "r184" ] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAdjustmentMember", "presentation": [ "http://www.esgen-spac.com/role/SubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "auth_ref": [ "r111", "r112", "r113", "r122", "r123", "r138", "r235", "r236", "r433", "r434", "r435", "r436", "r437", "r438", "r439" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r174", "r201", "r202", "r203", "r204", "r205", "r206", "r240", "r268", "r269", "r270", "r406", "r407", "r411", "r412", "r413" ] }, "esac_ScheduleOfPrepaidExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "ScheduleOfPrepaidExpensesTableTextBlock", "presentation": [ "http://www.esgen-spac.com/role/PrepaidExpensesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Prepaid expenses", "documentation": "Tabular disclosure of the carrying amounts of Prepaid Expenses. This disclosure includes other current and other noncurrent expenses." } } }, "auth_ref": [] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperation" ], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Business Operation", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r77", "r82" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://www.esgen-spac.com/role/OrganizationAndBusinessOperationDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r48", "r68", "r290", "r299", "r304", "r312", "r337", "r414" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.esgen-spac.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of compute basic and diluted net income per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r450" ] }, "esac_WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50", "terseLabel": "Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50[Member]", "documentation": "Warrants Each Whole Warrant Exercisable For One Share Of Class Common Stock At Exercise Price." } } }, "auth_ref": [] }, "esac_UnitsEachConsistingOfOneShareOfClassCommonStockAndOneHalfOfOneWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "UnitsEachConsistingOfOneShareOfClassCommonStockAndOneHalfOfOneWarrantMember", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Units Each Consisting Of One Share Of Class Common Stock And One Half Of One Warrant [Member]", "terseLabel": "Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant [Member]", "documentation": "Units Each Consisting Of One Share Of Class Common Stock And One Half Of One Warrant ." } } }, "auth_ref": [] }, "esac_Warrantliabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "Warrantliabilities", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "WarrantLiabilities", "terseLabel": "Warrant Liabilities", "documentation": "no definition available" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r59" ] }, "esac_LegalAndProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "LegalAndProfessionalFees", "crdr": "debit", "calculation": { "http://www.esgen-spac.com/role/CondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Legal And Professional Fees", "terseLabel": "Legal and professional fees", "documentation": "Legal and professional fees." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value hierarchy for liabilities measured at fair value on recurring basis", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": [ "r37", "r71" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfChangesInOrdinarySharesSubjectToPossibleRedemptionAndShareholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Shares, Issued", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r5" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.esgen-spac.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.esgen-spac.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of the period", "periodStartLabel": "Cash, beginning of the period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r21", "r59", "r105" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.esgen-spac.com/role/RecurringFairValueMeasurementsFairValueHierarchyForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r239", "r240", "r241", "r242", "r244" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "esac_DeferredUnderwriterSDiscountNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.esgen-spac.com/20230930", "localname": "DeferredUnderwriterSDiscountNoncurrent", "crdr": "credit", "calculation": { "http://www.esgen-spac.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.esgen-spac.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Underwriter's Discount, Noncurrent", "terseLabel": "Deferred underwriters fee", "documentation": "The carrying value as of balance sheet date of deferred underwriting discount, classified as noncurrent." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(27)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//820/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481586/948-10-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481586/948-10-50-5" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481586/948-10-50-5" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481586/948-10-50-5" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r402": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r403": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r404": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r405": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r406": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r407": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r408": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r409": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r410": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r424": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r425": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r432": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 53 0001193125-23-277097-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-277097-xbrl.zip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end